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Abstract
Schizophrenia (Sz) is a debilitating neurodevelopmental disorder with no curative
treatment to date. Common approaches to studying Sz include post-mortem tissue studies,
neuroimaging studies, genetic screening, animal models, pharmacological models and
recently, induced pluripotent stem cells (iPSC). While the studies have yielded valuable
data in the field, each model provides a snapshot of Sz at different stages of its
development; urging for a model that could better represent most, if not all, of Sz
pathophysiology. Other than the development of a new Sz model, advance in the field
includes enhancing existing models such as developing a 3-dimensional (3D) cell culture
environment and interfacing cell culture with biomaterials and electrical stimuli.
Electrical stimulation (ES) therapy for Sz is increasingly being recognised. Nevertheless,
ES mechanism of action in ameliorating Sz symptoms at the molecular level is still
obscure.
The aim of this thesis was to develop and compare different in vitro Sz models for the
application of electrical stimuli via a conductive polymer (CP) platform in the effort of
uncovering ES mechanism of action in attenuating molecular deficits induced by the
disorder and to elucidate the role of ES in iPSC development. The work described in this
thesis employed a hypothalamic cell line for a drug-induced Sz model, primary cells
isolated from Sz mouse models, and patient-derived iPSC. The development of a druginduced Sz cell line model interfaced with a CP platform has revealed possible
interactions of drug molecules with the CP platform, necessitating further investigations
into this occurrence as it could have an impact on the use of biomaterials in drug delivery.
The effect of ES on a hypothalamic neuronal cell line, which has not been reported in the
literature to date; is described herein. ES of primary neurons isolated from Sz mouse
models uncovered a potential connection between ES signalling pathways with some of
i

the Sz candidate genes, namely nicotinic acetylcholine receptor subunit 7, N-methyl-Daspartate receptor, dopamine and tyrosine hydroxylase. The proof-of-concept study using
iPSC derived from a healthy donor and Sz patient has generated an optimised iPSC
culture, demonstrating successful differentiation into neural progenitor cells expressing
neural progenitor, neuronal and glial markers. Preliminary ES experiment in
differentiating iPSC suggested minor enhancement of neural progenitor and neuronal
markers, supporting future studies into the ES of patient-derived iPSC via the CP
platform.
In conclusion, the thesis has investigated various Sz models interfaced with CP with or
without ES, laying the groundwork for future studies. Some of which includes the
interaction of drug molecules with biomaterials and the resulting effects on cells,
signalling pathways induced by ES which could further support its use in Sz therapy, and
the development of patient-derived iPSC incorporating electrical stimuli to mimic the
human microenvironment.
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Chapter 1: Introduction

1.1 Schizophrenia symptoms and risk factors
Schizophrenia (Sz) is a devastating psychiatric disorder as evidenced by its high mortality
rate and rank among the world’s top 20 most debilitating diseases [1-3]. Among the most
disabling symptoms experienced by Sz patients are cognitive deficits, such as impairment
of working memory, attention, and executive function [4]. Sz patients also suffer from
positive symptoms characterized by hallucinations, thought disorganization, and bizarre
behaviour; and negative symptoms presented as lack of emotion and apathy [5]. The age
of onset of Sz symptoms is typically late-adolescence to early adulthood, whereas
prodromal refers to those at a clinical high-risk of developing Sz [6].
Sz is established as a complex neurodevelopmental disorder where causal factors interact
pre-, peri- and post-natal long before the onset of symptoms [7, 8]. Although the exact
aetiology remains unclear, the genetic component of the disease is supported by family,
twin and adoption studies, with its heritability being as high as 80% [9]. Another
significant component in the development of Sz is environmental risk factors, such as
stressors. While Sz is highly heritable, most cases are essentially sporadic [10]. It is
hypothesized that sporadic cases arise from de novo mutations acting with environmental
risk factors [11, 12]. Described as the “Two-Hit Hypothesis”, the interaction of
environmental factors with genetic predisposition would place a person at a higher risk
compared to the factors acting independently [13]. While there have been a few studies
of environmental stressors in mouse modelling (discussed in section 1.3.4), gene x
environment (GxE) interaction in Sz has largely been understudied [14, 15].
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1.2 Schizophrenia treatments
There is no curative treatment for Sz to date, whereby current pharmacological and nonpharmacological interventions only serve to manage the symptoms. Challenges
associated with the treatments, e.g. severe adverse effects and lack of efficacy in a
subgroup of patients; indicate a need for better therapeutic strategies.
1.2.1

Pharmacotherapy

Antipsychotic medications, classified as first-generation antipsychotic (FGA, or typical
antipsychotic) or second-generation antipsychotic (SGA, or atypical antipsychotic), are
the mainstay treatment for Sz. While the medications have been shown to attenuate some
of the positive, negative, and cognitive symptoms in a portion of Sz patients, they also
induce negative effects on the central nervous system (extrapyramidal symptoms such as
dystonia, akathisia, and tardive dyskinesia), endocrine system (weight gain and increased
risk for diabetes mellitus) and cardiovascular system (increased risk for cardiovascularrelated mortality) [16].
An early consensus in the field was that SGAs had superior efficacy and fewer adverse
effects in comparison to the FGAs; however, recent studies demonstrated negligible
differences between the two classes [17, 18]. For instance, no difference in cognitive
improvement was observed in a study between SGAs (quetiapine, risperidone and
ziprasidone) vs perphenazine (FGA) and another study failed to show greater efficacy of
the same SGAs over perphenazine in alleviating negative and cognitive symptoms [18,
19]. As demonstrated in Table 1.1, each class confers varying risks for adverse effects. In
general, FGAs posed greater risks for extrapyramidal symptoms whereas SGAs showed
a higher risk for weight gain; both had similar cardiac mortality risks [16]. Nonetheless,
SGAs such as clozapine, olanzapine, and risperidone were deemed to be superior to other
drugs of either class [20].
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Table 1.1: Risks for adverse effects associated with first-generation antipsychotic (FGA)
and second-generation antipsychotic (SGA) drugs. The table outlines the drugs with the
greatest or lowest risks for developing diabetes mellitus, extrapyramidal symptoms, and
seizure [21-25].
Adverse Effects

Greatest Risk

Lowest Risk

Olanzapine (SGA)
Diabetes mellitus

Risperidone (SGA)
Quetiapine (SGA)

Aripiprazole (SGA)
Extrapyrimidal
symptoms

Quetiapine (SGA)
Clozapine (SGA)

Thioridazine (FGA)
Seizure

Clozapine (SGA)

Risperidone (SGA)

Chlorpromazine (FGA)

Haloperidol (FGA)
Fluphenazine (FGA)

Despite a degree of drug efficacy in a subgroup of Sz patients, approximately 30% of Sz
patients are categorised as treatment-resistant schizophrenia (TRS), meaning their
symptoms have not improved after at least two trials of antipsychotic medications [26].
Although clozapine has been shown to be the most effective in TRS patients, 45-70% of
these still respond poorly to clozapine [27, 28]. Even when the drugs are effective in
alleviating some of the Sz-related symptoms, over one-third of Sz patients per year adhere
poorly to the antipsychotic medication regime, in part due to the adverse effects
associated with the treatment [29]. To manage the issues surrounding pharmacotherapy,
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non-pharmacological interventions are increasingly being used in conjunction with
pharmacotherapy to increase treatment effectiveness and adherence, both in Sz and TRS
patients.
1.2.2

Non-pharmacological interventions

Psychotherapy is utilised in Sz treatment to treat residual symptoms from
pharmacotherapy and increase adherence to medications. Comprehensive reviews of the
treatment have been discussed by Jones et al. [30] and Rector and Beck [31], and are
beyond the scope of this thesis. Other non-pharmacological interventions include
electroconvulsive therapy (ECT), transcranial direct current stimulation (tDCS), deep
brain stimulation (DBSt), and transcranial magnetic stimulation (TMS).
ECT, which involves delivering extremely high current levels (up to 900 mA) to the brain
for up to 6 seconds, was introduced in the 1930s but its use declined with the emergence
of antipsychotic medications and the social stigma surrounding ECT [32-34]. In the early
1980s, the revival of ECT in Sz has led to its utilisation as an augmentation therapy,
largely in TRS and clozapine-resistant patients, with reported response rate of 47%-77%
[35, 36]. The resurgence of electrical stimulation (ES) therapy has also resulted in tDCS
and DBSt being introduced into Sz treatment.
tDCS is a non-invasive procedure where a low direct current (0.5 to 2 mA) is delivered
to the brain regions of interest for up to 30 minutes, via electrodes placed on the scalp
[37]. It has been shown to reduce auditory hallucinations and improve cognitive deficits
in Sz patients [37, 38]. DBSt on the other hand, is an invasive technique necessitating
surgeries for electrodes placement in the brain. While DBSt has been explored more
extensively in other disorders, its use in Sz treatment is still in its infancy. Bikovsky et al.
[39] has reported improved behavioural Sz-like deficits in a rat model through DBSt of
medial prefrontal cortex and nucleus accumbens (NAc); located at the basal forebrain. A
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pilot study by Salgado et al. [40] showed improvement in auditory hallucinations and
symptoms related to social isolation in 5 TRS patients through DBSt of NAc or the
subgenual area in the medial prefrontal cortex. In addition, a recent phase I clinical trial
for DBSt in TRS patients, targeting NAc; has demonstrated 62% reduction in positive
symptoms and 33% improvement of negative symptoms in a TRS patient [41]. Another
DBSt phase I clinical trial (NCT02377505) that targets substantia nigra pars reticulata of
the midbrain in TRS patients, is currently underway [42]. TMS is another non-invasive
neurostimulation technique where alternating magnetic fields are used to induce electric
currents in the brain, and has been shown to reduce auditory hallucinations and negative
symptoms in Sz [43]. The efficacy of TMS treatment in Sz has been reviewed by Cole et
al. [43] and is beyond the scope of this thesis.
As pharmacological and non-pharmacological interventions principally ameliorate only
some of the symptoms, more efforts are needed to better understand Sz aetiology and
development, in the hope of finding better treatments. Despite progress in the field, a
comprehensive model for studying the disorder is yet to be developed.

1.3 Schizophrenia models
In the past few decades, common approaches to studying Sz include the use of postmortem tissue, neuroimaging, genetic screening, pharmacological interventions and
animal studies. While these conventional methods have yielded the majority of findings
to date, for the most part they have provided a snap-shot of the advanced phases of the
disorder rather than the full-spectrum of changes pre- to post-onset of clinical
symptomatology. The use of stem cells is an emerging technology in Sz research,
progressing towards complementing existing models. Although each model has its own
advantages and limitations, combining data from different models could eventually
provide a more complete picture of the disorder. An overview of the Sz models is
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depicted in Figure 1.1.

Figure 1.1: Models for studying Sz neurobiology. Animal modelling, pharmacological
studies, neuroimaging, and post-mortem tissue studies have for the most part provided
insight into the disease progression after the onset of symptoms, which may in some cases
be confounded by unrelated variables. Patient-specific stem cells retain an individual’s
genetic signature, providing insights into genetic risk potentially underlying the
developmental defects of derivative neurons and supporting cells underlying symptoms.
1.3.1

Post-mortem tissue studies

Post-mortem tissue studies provide an insight into the anatomical cytoarchitecture of the
brain, revealing neuropathological and neurochemical changes in the brain [44]. This
method complements other methods operating on the macroscopic level by revealing
microscopic changes. For example, while neuroimaging studies demonstrated a total loss
of grey matter volume in the cortical brains of Sz patients, it lacks information in regards
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to what the reduction represents [45]. Post-mortem tissue studies have further linked
neuroinflammation and deficits in pyramidal cell spine density in the superior temporal
gyrus and dorsolateral prefrontal cortex, to the loss of grey matter in Sz patients [46-48].
Findings from post-mortem tissue studies are also used to derive or validate findings from
animal models [49, 50]. For instance, a study by Takahashi et al. [51] showed that a
protein tyrosine phosphatase, receptor type A (PTPRA) null allele mouse model was able
to mimic Sz neuropsychological and gene expression abnormalities. The model was
further validated by the same author through the finding of a reduction in PTPRA
expression levels in the prefrontal cortex from post-mortem tissue samples of Sz patients.
As post-mortem captures the end-point of the disorder, the findings may be confounded
by other variables such as perimortem changes and medications. The cause of death and
hypoxia can alter the neurochemical and molecular targets of interest [44]. Further,
antipsychotic medications are known to induce changes in the neurons, synapses, and
neurotransmitters targeted by the drugs. These in turn may obscure the deficits induced
by the disorder itself [44].
1.3.2

Neuroimaging

Some of the neuroimaging techniques used in Sz research are the conventional
structural magnetic resonance imaging (MRI), functional MRI (fMRI), functional
magnetic resonance spectroscopy (fMRS), positive emission tomography (PET) and
single-photon emission computed tomography (SPECT). These techniques have the
capacity to highlight alterations in the brain structure, connectivity, and neurotransmitter
levels (Table 1.2)
PET and SPECT imaging can be used as a proof-of-mechanism of pharmacotherapies
and non-pharmacotherapies (e.g. ECT)( Table 1.2). By measuring the binding level of
drug molecules to their target receptors along with the induced drug response in
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patients, the doses required for the desired level of receptor occupancy can be
determined [52]. In addition, data from neuroimaging can be translated into nonpharmacological interventions. fMRI studies have reported activation of speech
generation and perception areas during auditory hallucinations [53]. Accordingly,
interventions that modulate brain activity in these regions, such as tDCS, should be able
to target and alleviate the symptom [54].
Due to limited resources, each neuroimaging study typically involves a small sample size,
an indication that most neuroimaging Sz studies lack power, which could inevitably lead
to false-positives [55]. A larger sample size could be obtained through multicentre
studies; however, variations in imaging acquisition techniques, investigators’ expertise
and patient population across studies, can give rise to other problems [55]. Notably, poor
imaging reliability across neuroimaging scanners has resulted in poor study replications
[56]. Notwithstanding findings with significant group differences, there is still a large
overlap between Sz patients and healthy populations; thus, concrete Sz diagnosis cannot
be inferred and the definition of a “healthy control” is ambiguous [57].
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Table 1.2: Sz pathophysiology uncovered by neuroimaging. Neuroimaging techniques
used in Sz include structural magnetic resonance imaging (MRI), functional MRI (fMRI),
functional magnetic resonance spectroscopy (fMRS), positive emission tomography
(PET) and single-photon emission computed tomography (SPECT).
Neuroimaging
techniques

Findings in Sz patients compared to healthy controls

References

Structural
MRI

Altered structural integrity of white matter in frontal and

[58-61]

temporal brain regions and tracts
Loss of total and regional grey matter volumes
Reduced cortical thickness in the inferior frontal gyrus
fMRI

Altered local functional connectivity in bilateral orbital frontal

[62-65]

cortex, left putamen primary sensory cortices, right supplemental
motor area and bilateral thalami
Emotional regulation deficits in prefrontal cortex
Less ventral striatal activation during reward anticipation
Abnormal global connectivity in sensory, subcortical regions and
frontal and parietal areas
fMRS

Increased GABA in perisylvian structures

[66, 67]

Reduced N-acetyl-aspartate/creatine

PET

Microglia activation

[68-70]

Neuroinflammation in the hippocampus
Link between excitement symptom severity and dopamine
receptors availability in the insula
SPECT

Uptake of dopamine-related radioligand in the left caudate

[71-73]

nucleus after ECT treatment
5-HT2A receptor blockade by clozapine and risperidone
High striatal DRD2 blockade by chlorpromazine associated with
depressive symptoms
ECT, electroconvulsive therapy; GABA, gamma-aminobutyric acid; DRD2, dopamine receptor
D2; 5-HT2A, 5-hydroxytryptamine 2A.
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1.3.3

Genetic association studies

A candidate gene approach is a targeted approach that explores the association between
potential susceptibility genes and the disorder. Although some of the common candidate
genes for Sz (disrupted-in-schizophrenia 1 (DISC1), catechol-O-methyltransferase
(COMT), neuregulin 1 (NRG1), dystrobrevin binding protein 1(DTNBP1), and dopamine
receptor D2 (DRD2)) have been identified through association studies and gene ranking,
the studies frequently lack statistical power [74, 75]. As such, the role of these candidate
genes as Sz risk factors have been re-evaluated in other association and empirical studies,
yielding contradictory outcomes [76-80].
In contrast to the candidate gene approach, genome-wide association studies (GWAS)
interrogate the genome without relying on any a priori selected candidate genes for
associations between common genomic variants or loci and the disorder. To date, over
50,000 samples have been genotyped in the last 5 years and more than 100 risk loci related
to Sz have been discovered [81]. A large GWAS study identified several loci consisting
of genes relevant to major hypotheses of Sz aetiology, such as DRD2, genes involved in
glutamatergic neurotransmission and synaptic plasticity; as well as immune functions
[82]. Needless to say, the findings from association studies still require validation through
other studies, e.g. animal models; to confirm the association with the disease aetiology
and study the functions of the identified genes.
1.3.4

Animal model

Animal models for Sz include rodents, primates, zebrafish, and fruit fly [83]. While
zebrafish and fruit fly are the least-expensive models with high throughputs, they are not
suitable for modelling complex human behaviours [84]. Rodent models are relatively
cost-effective and less onerous to produce. Additionally, they can provide insights at the
molecular, cellular and behavioural levels [84]. Sz animal models generally comprise of
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genetic models, developmental disruption models and pharmacological intervention
models.
Genetic animal models can be developed through gene knock-outs or knock-ins via
targeted mutations or transgenesis, as well as large scale mutagenesis. In knock-out and
knock-in mouse models, mutations are created through homologous recombination in
embryonic stem cells, which are then transmitted through the germ line to create loss-offunction or gain-of-function models [85, 86]. Large scale mutagenesis is performed via
radiations, e.g. X-rays to induce large deletion and translocation mutations involving
multiple genes; or via mutagen N-ethyl-N-nitrosourea treatment to induce point mutations
at a high locus-specific rate, relevant to the disorder [85, 87].
Mutations of dopamine transporter (DAT), N-methyl-D-aspartate receptor 1 (NMDAR1),
22q11.2, calceurin, DISC1 and NRG1 have been described in Sz animal models [88-90].
Other candidate gene mutations are also being explored as Sz models, for instance
targeting the cholinergic system, 5-hydroxytryptamine (5-HT) receptors and neural cell
adhesion molecule (NCAM)-180.
Developmental disruption models are used to study the progression of Sz and gene x
environment (GxE) interactions relevant to Sz pathophysiology. In neurodevelopmental
model, neonatal or perinatal insults have been introduced to produce abnormal behaviours
in adult rodents that correspond to the Sz behavioural symptoms presented in humans.
This may be achieved by inducing neonatal lesions in the ventral hippocampus, prenatal
administration of mitotoxin methylazoxymethanol acetate, and prenatal/neonatal immune
activation through maternal infections via bacterial or viral exposure [91-94]. Early-life
stress is simulated through maternal deprivation by isolating rodent pups from mothers
for a single period, or through the post-weaning social isolation method (rearing rodents
in persistent isolation from weaning day to late-adolescence or adulthood) [95, 96]. GxE
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studies utilising DISC1 and NRG1 mutant mouse models are shown in Table 1.3. Another
environmental stressor prominent in Sz is drug abuse, which is modelled through
pharmacological interventions.

Table 1.3: A list of gene x environment (GxE) interaction studies in DISC1 and NRG1
mutant mouse models. The phenotypes observed in the adult mouse developmental
models were induced by genetic risk factors interacting with pre- or post-natal
environmental stressors. Prenatal immune challenge refers to administration of
polyinosinic:polycytidylic acid (poly I:C) in pregnant dams at gestational day 9.

Genotype

Environmental
Stressor

Phenotype

References

DISC1 point

Prenatal immune

PPI and LI deficits

[97]

mutation (L100P)

challenge

Impaired working memory and
sociability

Mutant human

Prenatal immune

Anxiety and depressive-like behaviours

DISC1

challenge

Altered social behaviour

DISC1 dominant-

Poly I:C treatment at

Anxiety-like behaviour

negative mutant

postnatal day 2-6

Impairment of object recognition

[98]

[99]

memory and social behaviour
Hippocampus glutamate-release deficits
DISC1 dominant-

Mouse pup exposure

Sex-dependent hyperactivity

negative mutant

to toxin lead (Pb2+)

Disruption of PPI

[100]

Lateral ventricles enlargement
DISC1 point

Mouse pup isolation

Social memory impairment

mutation (L100P)

from age 5-8 weeks

Exacerbated neurogenesis deficits in

[101]

hippocampus
TM-NRG1

Prenatal immune

Deficits in social behaviour and spatial

deletion

challenge

working memory

[102]

PPI, prepulse inhibition; LI, latent inhibition; TM-NRG1 deletion, heterozygous deletion of the
transmembrane domain of NRG1.
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1.3.5

Pharmacological model

In Sz, pharmacological models have been used as an indirect tool to uncover potential
neurochemical mechanisms implicated in the disorder, with the potential to identify novel
therapeutic targets. Pharmacological findings have led to the formation of the most
common neurochemical hypothesis of Sz, namely dopamine, glutamatergic, and
serotonin. The proposal that dopamine pathways are hyperactive in Sz originates from the
observation that amphetamine and other dopamine-mimetic drugs increased psychotic
symptoms; whereas neuroleptic drugs (e.g. chlorpromazine and haloperidol) that
primarily block DRD2, has been shown to reduce Sz-related psychomotor and positive
symptoms [103, 104].
The glutamatergic hypothesis stemmed from findings that NMDA (a subtype of glutamate
receptor) antagonists, the likes of phencyclidine (PCP) and ketamine; exacerbated
symptoms in Sz patients and induced Sz-like symptoms in healthy individuals [105]. The
discovery of metabotropic glutamate receptor 2 (mGluR2) agonists with anti-psychotic
potentials in rodent models and Sz patients further supports the hypothesis [106].
Similarly, the serotonin hypothesis is derived, in part, from observations that 5-HT2A
receptor agonists, such as the hallucinogenic lysergic acid diethylamide (LSD); induced
Sz-like positive symptoms, while antipsychotic medications (clozapine, olanzapine, and
risperidone) with high affinities for these receptors are antagonists of these receptors
[107].
Pharmacological interventions have been integrated with other models, e.g. animal
models and as described in section 1.3.2, neuroimaging. Pharmacological screening in
animal models include investigating the efficacy of antipsychotic medications in
alleviating Sz-like symptoms in lesion-induced neurodevelopmental rodent models
(Table 1.4). A few of the studies failed to show symptomatic improvements and even
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reported symptoms exacerbation in the models with haloperidol and clozapine treatments,
questioning the model’s validity (Table 1.4).
The impacts of common drug abuse, such as PCP and cannabis; have been studied in
lesion-induced developmental disruption models and genetic models (Table 1.4). PCP
and its analogues are also used to induce Sz cognitive and behavioural symptoms in
animal models, as well as for drug screening of antipsychotic medications [108-111]. The
mechanism of action of these drugs in Sz aetiology can also be studied through the
administration of PCP on primary cells ex vivo [112].
One of the challenges in animal models is potential misdiagnosis of Sz. Rodent DISC1
mutations may have demonstrated neurobiological deficits corresponding to Sz postmortem tissue samples or neuroimaging studies; however, the resulting behavioural
deficits may vary. For instance, mice with DISC1 Q31L point mutations presented more
depression-related behaviours whereas mice with DISC1 L100P point mutations
demonstrated more Sz-like behaviours [113]. Moreover, interpreting disordered mouse
behaviours as complex Sz phenotypes, e.g. paranoia; is challenging, rendering other
positive symptoms, e.g. hallucinations; difficult to study in animal models [84]. Questions
remain whether Sz symptoms are sufficiently recapitulated in these models.
As for pharmacological model limitations, drug-induced models may not fully represent
Sz as it is a neurodevelopmental disorder with various interplays of GxE risk factors
[112]. Furthermore, in humans, Sz-like symptoms can be induced after prolonged
administration of drugs (PCP or amphetamine); which may not be fully replicated in the
laboratory due to ethical issues, practicality, and increased risk of adverse effects [112].
Thus, the attenuation of symptoms by antipsychotic medications in drug-induced animal
models may not all be relevant to the neurobiology of Sz. Given the current shortfalls in
Sz research, there is an urgent need for new pre- and post-clinical methods to advance the
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understanding of relevant cellular and molecular biology that can fully recapitulate Sz
patients’ genotype and phenotype.
1.3.6

Stem cell modelling

Since the first report of bone fide embryonic stem cell lines by Thomson et al. [120] in
1998 and the emergence of studies demonstrating the feasibility of reprogramming
somatic cells to pluripotent stem cells, much attention has been directed to using
pluripotent stem cells as a source of progenitor and lineage specific cells for disease
modelling [121-123]. Due to their relative ease of derivation and acceptance for research,
human induced pluripotent stem cells (iPSC) in particular are increasingly being used and
are especially valuable for previously “difficult to model” disorders such as
neuropsychiatric disorders where viable primary patient neuronal cells are difficult to
obtain. For example, iPSC have the capacity to generate neural cells that in many ways
mimic cells of the human central nervous system, including retainment of the donor
patients’ genetic background. iPSC may, therefore, be used as in vitro tools for studying
complex disorders such as Sz to validate current hypotheses and explore new hypotheses
on disease biology and therapeutics. The use of iPSC technology may serve to
complement other models by capturing underlying cellular and subcellular aspects of Sz
previously overlooked. Over the last decade, several studies have integrated targeted-gene
approaches, large-scale genomic/proteomic analyses and pharmacological interventions
to reveal genetic, protein, and phenotypical deficits, as well as drug efficacies, in Sz
patient-specific stem cells (Table 1.5).
Heterogeneity and reproducibility issues, stemming from methodological limitations and
source differences, are part of the challenge of stem cell modelling. While early Sz stem
cell models generated immature fetal-like neurons, limiting their capacity to model later
developmental stages of Sz, recent advances in the field are progressing towards
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developing mature brain organoids [143].
As each model has its own advantages and challenges, efforts have been made into
enhancing existing models. For example, the conventional 2-dimensional (2D) cell
culture system can be improved by incorporating biomaterials and using their biological,
chemical, physical, or electrical properties to develop a 2D, or even 3D; environment
optimal for cell proliferation, differentiation, function, and to better represent human body
microenvironment [144-147].
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Table 1.4: Pharmacological intervention studies in Sz developmental disruption and
genetic models. Developmental disruption models are developed by inducing rat neonatal
ventral hippocampal (NVH) lesion and the genetic models include disrupted-inschizophrenia 1 (DISC1) and neuregulin 1 (NRG1) mutant mouse models.
Model

Drugs

Findings

References

Rat NVH lesion

Clozapine, olanzapine,

Clozapine, olanzapine, and risperidone

[114]

risperidone and

but not haloperidol reversed PPI deficits

haloperidol
Rat NVH lesion

Clozapine, risperidone

Low clozapine and risperidone dose

[115]

attenuated PPI deficits
No significant effect on SI deficits
Higher dose of clozapine potentiated
deficits
Rat NVH lesion

Clozapine

Clozapine induced sex-dependent

[116]

memory impairment and potentiated
hippocampal lesion-induced deficits
Rat NVH lesion

PCP

PCP exacerbated lesion-induced

[117]

attentional deficits
Mouse DISC1

THC

Cannabis worsened adult emotional

dominant-negative

memory impairment in adult mutant

mutant

mice

TM-NRG1 deletion

CP55,940

NRG1 mutation increased tolerance to
the locomotor suppressant and
anxiogenic effects of drug

PPI, prepulse inhibition; SI, social interaction; PCP, phencyclidine; THC, delta-9tetrahydrocannabinoid; TM-NRG1 deletion, heterozygous deletion of the transmembrane
domain of NRG1; CP55,940, a synthetic cannabinoid.
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[118]

[119]

Table 1.5: Studies conducted using Sz patient-specific stem cells. Genomic and proteomic
analyses have been utilised to reveal neuronal deficits and validate candidate genes
related to Sz pathophysiology. Treatment of the stem cells with various
pharmacotherapeutic drugs have shown variable efficacies.
Type of Analyses

Cell Type Generated

Findings

References

NPC

Adherens junctions and

[124]

Targeted-gene:

15q11.2del
mutation

apical
polarity deficits

22q11.2del

Glutamatergic neurons

Delayed reduction of

mutation

[125]

NANOG and OCT4 during
neural differentiation
Heterogeneous neurons

45 differentially expressed

[126]

miRNA
Heterogeneous neurons

~2-fold reduction in

[127]

expression of almost all
genes in the 22q11.2
region in Sz
NPC and

Significant reduction of

heterogeneous neurons

neurosphere size, neural

[128]

differentiation effciency,
neurite outgrowth and
cellular migration
4 basepair deletion

iPSC

Established iPSC lines

in DISC1-

from Sz patients with

frameshift

DISC1 mutation
Glutamatergic neurons

Reduced SV2 density and
sEPSC frequency
Increased mRNA
expression of presynaptic
proteins
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[129]

[130]

CTNAP2

NPC

Changes in CTNAP2

heterozygous

expression, reduced

deletion

neurosphere migration

[131]

Large scale genomic and proteomic:

Abnormal

NPC

Abnormal expression of

expressions

[132]

cAMP, WNT, NOTCH,
SLIT/ROBO axon
guidance and
transcriptional silencing
pathways
NPC, glutamatergic

Altered gene expression

neurons

and protein levels involved

[125, 133]

in cytoskeletal
remodelling, chromatinmodifying enzymes,
oxidative stress, adhesion,
synaptogenesis
iPSC and NPC

228 genes related to neural

[134]

development and plasticity
altered during neuronal
differentiation, ARMC8,
BCL11A, CDO1 and
FOXG1 disrupted during
differentiation
NPC

Perturbed levels of global

[135]

protein synthesis
NPC

Perturbations in WNT

[136]

signalling
Heterogeneous neurons

Reduction of activity-

[137]

dependent gene expression
NPC

miR-9 significantly

[138]

downregulated
Validation of

NPC, glutamatergic

8/12 migration associated

Candidate Genes

neurons

candidate genes
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[125, 133]

NPC

ANK3, ZNF804A,

[132]

GABRB1, ERBB4,
PDE4B
CNV Analysis

NPC

Increased burden in Sz

[132]

neurons
Neural phenotype:

Hippocampal dentate

Impaired differentiation of

gyrus granule neurons

NPC to DG hippocampal

[139]

granule neuron
Dopaminergic and

Aberrant induction of

glutamatergic neurons

dopaminergic neuron and

[140]

maturation of
glutamatergic cells
NPC, Hippocampal

Attenuation of neuronal

dentate gyrus granule

connectivity

[132, 139]

neurons
Heterogeneous

Synaptic dysregulation

[140, 141]

NPC

Migration impairment

[133]

NPC, dopaminergic

Aberrant mitochondrial

[133, 140]

and glutamatergic

morphology, network

neurons

structure and connectivity

neurons, glutamatergic
neurons and
dopaminergic neurons

Metabolism:

Mitochondrial dysfunction
- Impaired respiration and
increased oxidative stress
Drug screening:

Loxapine

NPC

Amelioration of impaired
neuronal connectivity and
aberrant RNA expression
of NRGI, GRIK1,
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[132]

ADCY8, PRKCA,
WNT7A and TCF4

NPC

Impaired migration and

[132]

reduced neural adhesion
genes
VPA

NPC

Normalized generation of

[133, 142]

ROS and levels of zinc and
potassium
NPC

No significant effect on

[133]

migration
Thioridazine,

NPC

No significant effect on

clozapine,

[132]

neuronal connectivity

olanzapine,
risperidone
NPC, neural progenitor cells; iPSC, induced pluripotent stem cells; SV2, synaptic vesicle protein
2; DG, dentate gyrus; ROS, reactive oxygen species; CNV, copy number variant; sEPSC,
spontaneous excitatory postsynaptic currents; miR-9, microRNA-9; CTNAP2, contactinassociated protein-like 2; cAMP, cyclic adenosine monophosphate; ARMC8, armadillo repeat
containing 8; BCL11A, B cell CLL/lymphoma 11A; CDO1, cysteine dioxygenase type 1;
FOXG1, forkhead box protein G1; ANK3, ankyrin 3; ZNF804A, zinc finger protein 804A;
GABRB1, gamma-aminobutyric acid type A receptor subunit Beta1; ERBB4, Erb-B2 receptor
tyrosine kinase 4; PDE4B, phosphodiesterase 4B; NRGI, neuregulin 1; GRIK1, glutamate
receptor ionotropic receptor kainate 1; ADCY8, adenylate cyclase 8; PRKCA, protein kinase C
alpha type; TCF4, transcription factor 4.
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1.4 Biomaterials and electrical stimulation in schizophrenia research
Biomaterials have been used in biomedical applications, such as tissue engineering, drug
delivery, and biosensors. The advance in tissue engineering includes developing 3D
organoids using biomaterial matrices, e.g. hydrogels, chitosan, and gelatine [145]. Several
studies have reported improved neuronal cultures (increased neurite lengths and network
connectivity, guided neurite outgrowth directionality and cell migration, and enhanced
neuronal differentiation) through the manipulation of biomaterials’ stiffness,
topographical, and electrical properties [148-155]. To highlight the latter, ES is
increasingly recognised as important for excitable and non-excitable cell support, being
important for in vivo tissue development and healing following trauma. By using
conductive biomaterials for the delivery of ES in cell culture, the culture can reap the
benefits of ES and biomaterials within one system.
1.4.1

Conductive polymers

There are over 25 conductive polymers (CPs), the most commonly used CPs include
polypyrrole (Ppy), polyaniline, poly(3,4-ethylenedioxythiophene, polyacetylene) and
polythiophene (Figure 1.2) [156-158]. CPs have a high conductivity to weight ratio, allow
spatiotemporal control of electrical stimulus, and they can be made biocompatible,
biodegradable and porous [156]. The unique mechanical, electrical and chemical
properties of CPs, which can be further modified according to their application; make
these materials attractive for biomedical applications. For instance, through ES, ultrasonic
irradiation, or the incorporation of biomolecules (e.g. nerve growth factors, fibronectin,
etc.) or nanoparticles; the CP can be utilised for drug delivery, biosensing, or as an
enhanced platform for cells- promoting cell adhesion, growth and neurite extension [159165].
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Figure 1.2: Chemical structures of polymers. Image obtained from Ravichandran et al.
[158].

CPs possess a conjugated backbone; whereby single and double bonds alternate between
the carbon atoms (Figure 1.3). A localised sigma (σ) bond, which forms a strong chemical
bond, could be found in both single and double bonds, whereas a double bond consists of
an additional bond called the pi (π) bond (Figure 1.3)[158]. The π bond is less strongly
localised, thereby allowing electrons to delocalise and move between the atoms with ease
[156]. The ease of electrons jumping within and between the polymer chains gives rise to
the conductivity of the polymers [156]. Another key to conductivity is the doping process.
Polymers are synthesised in their oxidised, conducting form, and only when the dopant
molecule (a negative charge/anion) is present can the backbone be stabilised, and the
charge be neutralised [156]. The dopant introduces a charge carrier into this system by
adding or removing electrons to/from the polymer chain, then re-localising them as
loosely held, localised electrons surrounded by a crystal lattice distortion, also known as
polarons or bipolarons [156]. When an electrical potential is applied, the dopants move
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in or out of the polymer, disrupting the stable backbone and allowing charge to be passed
through a polymer in the form of polarons and bipolarons [156]. Figure 1.4 illustrates the
formation of polaron and bipolaron in a Ppy chain.

Figure 1.3: A schematic of a conjugated backbone in polymers. The backbone consists of
a series of alternating single and double bonds. The localised sigma (σ) bond, present in
single and double bonds, forms strong chemical bond within the chain; whereas the less
strongly localised pi (π) bond, present in double bonds, allows electrons to delocalise and
move freely within the chain. Carbon and hydrogen atoms are denoted as C and H.
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Figure 1.4: The formation of polaron and bipolaron in a polypyrrole chain. Image
obtained from Camurlu [166].

The two main methods for CP synthesis are chemical and electrochemical synthesis.
Chemical synthesis produces a powder or a thick film of the polymer. While this method
allows easy bulk production, the conductivity of the polymer is frequently lower when
compared to a CP produced via electrochemical synthesis [167]. In electrochemical
synthesis, electrical current or potential is applied through electrodes placed in a solution
containing the monomer, doping agent and the solvent (Figure 1.5) [168, 169]. The
potential applied between the electrodes, or electrical current passing through the
electrodes results in the deposition and oxidisation of the monomer onto the positively
charged working electrode, generating insoluble polymer chains [170]. Electrochemical
synthesis can be performed via galvanostatic, potentiostatic, or potentiodynamic
techniques. In galvanostatic polymerisation, the electrical current is controlled while the
potential between the electrodes varies, which generates a steady rate of polymer
deposition [171]. In potentiostatic polymerisation, the potential is controlled instead of
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the current. This can protect the integrity of the component to be coated, typically
essential for biosensors [171]. In potentiodynamic deposition, polymers are deposited in
layers, as the polymerising potential is swept between a low and high potential limit in
cycles [172].

Figure 1.5: A schematic of the electrochemical synthesis set-up. Electrical current or
potential is applied between two electrodes, connected via a galvanostat or potentiostat;
and placed in the polymer solution (monomer solution, doping agent and solvent).

Ppy has been selected as the focus of this thesis as it is the most extensively studied CP
[173]. In addition to good biocompatibility, Ppy has a high conductivity and good
chemical stability [156]. Biocompatibility of Ppy has been demonstrated in many in vitro
and in vivo studies. For instance, Ppy and its composites have been shown to confer
minimal tissue response after 4 weeks of implantation in rats and only minor
inflammation during 6 months of implantation in rats [174, 175]. Ramanaviciene et al.
26

[176] demonstrated neither allergic response nor inflammation in mice, 6 weeks after
intraperitoneal injection of chemically synthesised Ppy particles. However, adverse
effects have also been reported. For instance, Kim et al. [177] showed reduced viability
of human lung fibroblast and mouse alveolar macrophage cell lines when treated with
Ppy nanoparticles. Human mesenchymal stem cells (hMSC) isolated from healthy
volunteers showed reduced growth on silk fibroin mats coated with Ppy compared to
hMSC on non-coated silk fibroin mats [178]. A number of factors could have led to the
reduced biocompatibility, such as insufficient preparatory steps to remove impurities (e.g.
rinsing, extraction methods, incubation in biological buffer, etc.), ageing, and synthesis
conditions [156, 179].
PC12 neuronal cells have been the most common cell line used to investigate neuronal
compatibility with Ppy in vitro [180]. Advances in the field have led to the use of primary
neurons and neurons derived from stem cells to investigate the molecular effects of ES
delivered through Ppy-based scaffolds. ES-induced enhancements in neurite outgrowth,
adhesion, differentiation, and maturation have been reported (Table 1.6). It should be
noted that the described ES studies employed variable ES parameters, derived from
independent optimisation studies.
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Table 1.6: Electrical stimulation (ES) studies using neurons. The effects of ES delivered
via polypyrrole (Ppy)-based scaffolds have been studied in the PC12 neuronal cell line,
as well as in primary neurons isolated from rodents or derived from stem cells.
Cell type

Scaffold

Effects of ES

ES Parameter

References

PC12 cells

ECM-coated

Enhanced neurite

100 mV/cm for 14 days,

[181]

Ppy/PLA fibers

adhesion, alignment

2h per day

and elongation
PC12 cells

Ppy/collagen

Enhanced neurite

± 1 mA, 0.1 ms pulses,

complex

outgrowth and

250 Hz biphasic pulsed

scaffold

orientation

current, 2h

Primary PFC

Ppy(DBS)

Improved neurite

± 0.25mA/ cm2 biphasic

neurons from

coated gold-

outgrowth

current, 100 µs pulses with

DISC1-LI and

mylar

[182]

[183]

20 µs interphase potential,

NRG1-KO

250 Hz frequency, 8

mouse pups

hours/day over 3 days in
7-day culture

Primary PFC

Cells

Improved neurite

1 ± 0.25 mA/ cm2 using a

neurons from

encapsulated in

ourgrowth and

biphasic waveform of 100

NRG1-KO and

collagen,

synaptogenesis in

µs pulses with 20 µs

WT mouse

Ppy(DBS)

WT and NRG1-KO

interphase open circuit

pups

coated

neurons

potential and a 3.78 ms

interdigitated

[184]

short circuit (250 Hz)

Ti6Al4V alloy
electrodes
Primary

Ppy-coated 3D

Accelerate neuron

100 Hz pulsed electrical

cerebral cortical polyacrylonitrile maturation

field of 100 mV cm-1, 4 hr

neurons from

daily for one week

nanofibres

[185]

rat pups
hNSCs ReNcell

Ppy(DBS)

Promotes hNSCs

± 0.25mA/cm2 biphasic

CX

coated gold-

differentiation

current, 100 µs pulses with

mylar

20 µs interphase, 250 Hz
frequency, 8 hrs/day, D1D3 in 6-day differentiation
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[186]

Neuron-like

Ppy/chitosan

Enhanced expression

1000 mV/cm, 10 Hz, 1h

cells derived

membrane

of neural

for 3 days

from ASCs

[187]

differentiation
markers

ECM, extracellular matrix; DBS, dodecylbenzenesulfonic acid; PLA, poly(lactide acid);
PDDLA/CL, poly (D,L-lactide-co-epsilon-caprolactone); PFC, prefrontal cortical; hNSC,
human neural stem cell; ASC, adipose stem cell; WT, wild-type; DISC1-LI, disrupted-inschizophrenia-1 locus impaired; NRG1-KO, neuregulin 1-knockout.

1.4.2

Polypyrrole-based scaffolds in schizophrenia models

In Sz models, biomaterials with and without ES have been utilised to investigate their
capability in ameliorating Sz phenotypes. Zhang et al. [183, 184] have shown increased
neurite outgrowths in primary neurons isolated from Sz DISC1 and NRG1 mutant mouse
models in 2D and 3D cultures, when Ppy-mediated ES was applied. An increase in neurite
branching of primary neurons, isolated from Sz NRG1 mutant mouse model; when
cultured on Ppy platforms without ES, has been reported by Stewart et al. [188]
Other than ameliorating phenotype deficits, Ppy-based scaffolds have been used for drug
delivery and as a sensor. A controlled drug release system may address treatment noncompliance in Sz patients and maintain drug concentrations at a therapeutically desired
level in the body. Saha et al. [189] and Svirskis et al. [190, 191] have investigated the use
of Ppy composites for ES-controlled release of antipsychotic risperidone to HepG2 and
C6 glioma cell lines, as well as into a phosphate buffered saline (PBS)-filled vessel.
Shahrokhian [192] employed carbon electrode doped with Ppy to detect antipsychotic
olanzapine in human plasma samples, which could be useful in the clinical settings when
determining the amount of olanzapine circulating in the bloodstream of patients. Despite
the great value that CP offer, only a few studies have investigated the potentials of CP in
Sz research.
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1.5 Summary and aims
Sz is a debilitating neurodevelopmental disorder with no curative treatment to date. While
current pharmacological and non-pharmacological interventions confer a degree of
efficacy in managing some of the symptoms, there is still a great need for more effective
treatments that can target all the symptoms and produce less severe adverse effects. The
lack of an effective treatment is, in part, due to the obscurity of the disease
pathophysiology and aetiology. Theories have suggested interactions of genetic risk
factors with environmental stressors; nevertheless, the polygenic and heterogeneous
nature of Sz underpinning the complexity of the disease makes research difficult. Despite
better understanding of the disorder achieved through existing models; limitations,
methodological issues and widespread discrepancies in findings within and across
different models create urgency for a better model.
Model augmentations can be achieved through integrations with conductive biomaterials,
providing electrical currents, topographies, chemical, mechanical, or 3D spatial
arrangements optimal for cell culture. Studies have supported the relevance of Ppymediated ES in Sz models and as potential therapeutic strategies. While ES therapies such
as ECT, tDCS and DBSt for Sz patients have been reported in the literature, the focus had
largely been on the attenuation of Sz symptoms. Thus, the mechanism of ES at the
molecular level remains elusive, highlighting an area that requires more attention.
This thesis aimed to compare existing and new models for studying the efficacy of ES
mediated by Ppy-based platforms on ameliorating Sz neuronal phenotype deficits in vitro.
Chapter 2 describes the development of a Sz pharmacological model from a hypothalamic
neuronal cell line via PCP treatment, with the aim to attenuate PCP-induced deficits
through ES. Chapter 3 utilises existing DISC1 and NRG1 mutant Sz mouse models to
identify Sz-related genes that are affected by ES, to reveal additional mechanisms of
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action of ES. Since the study employed models that have already been established, it
allowed the author to explore different Ppy dopants to enhance Ppy properties and
compatibility with the models. Chapter 4 focuses on the development and characterisation
of iPSC isolated from a healthy control and a Sz patient and includes preliminary ES
experiments during differentiation of the iPSC into NPC. Overall conclusions and future
directions are discussed in the final chapter.
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Chapter 2: Development of a phencyclidine-induced
schizophrenia model for electrical stimulation studies
2.1 Introduction
The hypothalamus lies at the base of the brain; directly above the pituitary gland. It
regulates the pituitary function and maintains homeostasis in the body. Some of the major
cell groups that can be found within the periventricular and lateral zones of the
hypothalamus are paraventricular nucleus (PVN), suprachiasmatic nucleus (SCN),
mammillary body (MB) nucleus, arcuate nucleus, and supraoptic nucleus (Figure 2.1)
[193]. Supraoptic nucleus and PVN are the sites of synthesis for neuropeptides oxytocin
and vasopressin, along with their carrier, neurophysin [194].

Figure 2.1: Anatomy of the hypothalamus. Some of the major cell groups are
paraventricular nucleus (PVN), suprachiasmatic nucleus (SCN), mammillary bodies
(MB) nucleus, arcuate nucleus, and supraoptic nucleus.
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The hypothalamus has been associated with psychiatric disorders such as depression,
bipolar disorder, posttraumatic stress disorder, and borderline personality disorder [195200]. In Sz, the hypothalamus was considered to be marginally affected by the disorder;
however, the role of the hypothalamus in Sz pathophysiology is increasingly being
recognised due to recent findings [201]. Moreover, a recent functional analysis of 608
recognised Sz candidate genes has identified 181 Sz-related genes within the
hypothalamus, placing the hypothalamus among the top five brain regions with the
highest expression of Sz-related genes [202].
In post-mortem studies, the cell density of nitric oxide synthase (NOS)-positive PVN,
neurophysin immunoreactivity in PVN, endorphinoceptive PVN cells, beta-endorphincontaining arcuate nucleus, and the total number of MB neurons were all reduced in Sz
patients compared to the healthy controls [203-206]. The involvement of the
hypothalamic-pituitary-adrenal (HPA) axis in Sz pathophysiology has also been reported,
whereby the HPA axis dysfunction resulted in increased risk for psychosis, poor physical
health, and premature mortality in Sz patients [207, 208]. In addition, HPA axis has been
linked to neuroimmune disturbances associated with Sz [201].
The development of deep brain stimulation (DBSt) techniques has revived interests in the
hypothalamus as a therapeutic target for various disorders [209]. Some of the disorders
currently being explored with hypothalamic DBSt are Parkinson’s Disease (PD),
epilepsy, and psychopathological symptoms, such as obesity and aggressive behaviours
[209-211]. DBSt of posterior hypothalamic (PH) nucleus has been shown to reverse
catalepsy/akinesia and restored motor behaviours in PD rat models [212, 213].
Furthermore, in rat pentylenetetrazol seizure models, DBSt of the PH exerted antiepileptic effects [211]. On the other hand, DBSt targeting lateral hypothalamic nucleus
demonstrated a reduction in food intake and subsequently weight-loss in rat obesity
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models [214]. The reduction of aggressiveness was also observed in patients with mental
retardation when DBSt was applied to the posteromedial hypothalamus [209].
Akinesia, seizures, obesity, and aggression are also symptoms associated with Sz [215218]; thus, results from the hypothalamic DBSt described earlier may be relevant to Sz.
Nevertheless, to the best of author’s knowledge, DBSt of the hypothalamus region has
not been documented for Sz treatment. In parallel with the recently increased recognition
of the hypothalamus involvement in Sz, this study aimed to elucidate the therapeutic
effects of electrical stimulation (ES) in a hypothalamus Sz model, developed via
phencyclidine (PCP) treatment.
PCP (Figure 2.2) induces psychosis in humans and has been a substantial tool in
modelling Sz due to its capacity in mirroring Sz positive, negative, and cognitive
symptoms [219]. The PCP-induced Sz models in the literature range from in vivo PCP
treatment of rodents and non-human primates, to ex vivo PCP treatment of mouse primary
cells [219-222]. The drug is most commonly known as a non-competitive N-methyl-Daspartate (NMDA) receptor antagonist; however, its interactions with the sigma receptor,
ion channels (voltage-dependent sodium and potassium channels), and nicotinic
acetylcholine receptor have also been reported [219, 223]. The effects of PCP observed
in previous Sz models include cognitive dysfunctions, behavioural deficits, changes in
neurochemicals (ie. dopamine, serotonin, glutamate, gamma-aminobutyric acid (GABA),
glucose, calcium/calmodulin-dependent protein kinase II (CaMKII), extracellular-signalregulated kinase (ERK), and brain-derived neurotrophic factor (BDNF)), and anatomical
alterations of the prefrontal cortex, hippocampus, entorhinal cortex, cingulate, and
retrospinal cortex [220, 224-231]. PCP-induced deficits in neurite outgrowth, dendritic
spine synapses, axonal myelination, and axon outgrowth have also been established [220,
222, 226, 232, 233].
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PCP is metabolised in the body, mainly through hydroxylation on piperidine and
cyclohexane rings, into 1-(1-phenylcyclohexyl)-4- hydroxypiperidine (PCHP), cis, transisomer of 4-phenyl-4-piperidino-cyclohexanol (c-PPC and tPPC) and cis, trans-isomer of
1-phenyl-1-(4’-hydroxypiperidino)-4-cyclohexanol (c-PCPdiol and t-PCPdiol) (Figure
2.2) [234, 235]. Since PCP is also ingested through smoking, investigations into pyrolyis
products of PCP have been conducted, where 1-phenyl-1-cyclohexene (PC), piperidine,
and N-acetylpiperidine were identified (Figure 2.2) [236]. Due to technical limitations,
there are still unidentified PCP by-products [236].

Figure 2.2: Chemical structures of PCP and its by-products. Each structure was obtained
from the ChemSpider (CS) database [237] with the following CSIDs: Phencyclidine
(PCP): 6224; 1-(1-phenylcyclohexyl)-4- hydroxypiperidine (PCHP): 89272; 4-phenyl-4piperidino-cyclohexanol

(PPC):142418;

cyclohexanol

143027;

(PCPdiol):

1-phenyl-1-(4’-hydroxypiperidino)-4-

1-phenyl-1-cyclohexene

(PC):

12501;

N-

acetylpiperidine: 11561; and piperidine: 7791. All structures were accessed on 16th
August 2018.
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To date, the development of a PCP-induced Sz model using a hypothalamic cell line has
not been reported. Since PCP has been shown to induce neurite defects (determined by
the mRNA expression of neuronal marker microtubule-associated protein 2 (MAP2) and
MAP2-immunostained neurons); and the modulation of neurite outgrowth via ES has
been reported in several studies [183, 184, 222, 238-244], the aims of this chapter were
to develop a PCP-induced Sz model using an immortalised mouse hypothalamus cell line,
mHypoA-59

in

order

to

investigate

the

effects

of

ES

on

the

model.

2.2 Materials and methods
2.2.1
2.2.1.1

Cell culture
2-dimensional monolayer cell culture

The adult mouse hypothalamus cell line mHypoA-59, obtained from BioScientific, was
kindly donated by Professor Xu-Feng Huang (Illawarra Health Medical Research
Institute, University of Wollongong). The cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM; Life Technologies) containing 10% foetal bovine serum (FBS;
Life Technologies) and 1% penicillin-streptomycin (P/S) (referred to as culture medium
thereafter) and passaged every 3-4 days.
2.2.1.2

3-dimensional cell culture

A 3-dimensional (3D) Collagen Culture Kit (Millipore) was used for the 3D culture. The
collagen solution was prepared according to the manufacturer’s instructions on ice by
adding 20% of 5x DMEM to the Collagen Solution (Millipore), then 2.5% Neutralisation
Solution (Millipore) was added to the mixture and mixed well. For cell preparation, 2.5 x
105 cells were centrifuged, and the cell pellet was resuspended in the culture medium
(<10% of the final volume of collagen solution), then the cell suspension was mixed with
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the chilled collagen solution with a ratio of 1:10 before transferring the gel containing the
cells to a 24-well tissue culture plate. The plate was incubated at 37oC in a humidified 5%
CO2 incubator for 20-30 mins until the gel turned cloudy. After the collagen gel was
formed, the culture medium was added to the wells before returning the plate to the
incubator.
2.2.2

Preparation of conductive polymer films

Polypyrrole (Ppy) and dodecylbenzene sulfonic acid (DBS) were used in this study as
Ppy is the most extensively studied conductive polymer, as described in Chapter 1; and
enhancements of Ppy when doped with DBS have been established [183, 186, 188].
Polymer films (Figure 2.3A) were prepared by galvanostatic polymerisation of aqueous
pyrrole solution (0.2 M), with DBS (0.05 M) as the dopant, using an eDAQ EA161
potentiostat at a current density of 0.25 mA/cm2 for 2 mins. Pyrrole and DBS were
obtained from Merck Millipore and Sigma-Aldrich, respectively. All pyrrole and dopant
solutions were prepared with Milli-Q water. The deposition of polymer onto gold-coated
mylar (Solutia Performance Films) was performed in a standard three-electrode
electrochemical cell with gold-coated mylar as the working electrode, platinum wire mesh
as the counter electrode, and Ag/AgCl as the reference electrode. After polymerisation,
the films were rinsed with dH2O then dried with N2.
2.2.3

mHypoA-59 culture in Ppy/DBS-based chamber and electrical stimulation
(ES)

Custom cell culture chamber and stimulation module were prepared by gluing clear
bottomless polystyrene chambers onto Ppy/DBS film using silicon adhesive followed by
overnight curing at RT (Figure 2.3B). The Ppy/DBS-based chambers were sterilised with
70% ethanol (EtOH) for 20 mins and air-dried in a Biosafety Cabinet (BSC). To reduce
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toxicity from the glue and for sterility testing, 1 mL/well of culture medium was added to
the chambers, which were then covered with a plastic lid. The chambers were contained
within a deep petri dish (25 x 100 mm; Figure 2.3C) and left overnight at 37oC in a
humidified 5% CO2 incubator. Prior to cell seeding, the medium was removed from the
chambers, followed by rinsing with sterile phosphate buffered solution (PBS). The cells
were seeded at either 2.5 x 103 or 1.0 x 103 cells/well then left overnight at 37oC in a
humidified 5% CO2 incubator to attach.
For electrical stimulation (ES), the plastic lid on the chamber was replaced with a lid
incorporating platinum mesh electrodes for each well (Figure 2.4A), then connected to a
DS8000 8-Channel Digital Simulator (World Precision Instruments) and placed at 37 oC
in a humidified 5% CO2 incubator (Figure 2.4B). ES was conducted through a twoelectrode setup with an auxiliary platinum mesh electrode contacting the medium and the
gold-coated mylar coated with Ppy/DBS as the working electrode (Figure 2.4C). Based
on established stimulation protocols [184, 186, 245-247], the cells were stimulated using
biphasic current at a current density of 1 mA/cm2, 100 μs pulses with 20 μs interphase
open circuit potential gap, and 3.78 ms short circuit (250 Hz) for 8 hrs/day on day D1
(D1), D2 and D3 of culture (Figure 2.4D). Cells were fixed or collected for experiments
on D4.
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Figure 2.3: Preparation of a polypyrrole/dodecylbenzene sulfonic acid (Ppy/DBS)
chamber. (A) A gold-coated mylar film coated with Ppy/DBS via galvanostatic
polymerisation. (B) A clear bottomless polystyrene 4-well/chamber glued to the Ppy/DBS
film. (C) Ppy/DBS chamber covered with a plastic lid and contained within a 25 x 100
mm petri dish for incubation at 37oC.
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Figure 2.4: Electrical stimulation setup. (A) Ppy/DBS chamber with a platinum mesh
electrode lid. (B) Ppy/DBS chambers at 37oC in a humidified 5% CO2 incubator
connected to DS8000 Digital Simulator. (C) Illustration of the two-electrode electrical
stimulation setup. (D) The biphasic waveform had a current density of 1 mA/cm2, 100
μs pulses with 20 μs interphase gap.
2.2.4

Phencyclidine treatment

Phencyclidine (PCP) was obtained as a gift from Professor Xu-Feng Huang. The cells
were seeded in either tissue culture plates or Ppy/DBS-based chambers, then left
overnight at 37oC in a humidified 5% CO2 incubator. On D1, the culture medium was
replaced with fresh culture medium containing 25 µM PCP. The PCP dose was chosen
based on optimisation studies with mHypoA-59 conducted within the group at Illawarra
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Health Medical Research Institute, University of Wollongong. For non-treated controls,
the culture medium was replaced with fresh medium without PCP on D1. The cells were
returned to the incubator until D4, then samples were collected for assays.
2.2.5

Immunocytochemistry

Cells were fixed with 3.7% paraformaldehyde (PFA, Fluka) in PBS at RT for 20 mins,
then blocked and permeabilised with Blocking Buffer (BB: 5% goat serum (SigmaAldrich) and 0.3% Triton-x-100 (Sigma-Aldrich) in PBS) at RT for 1 hr. The cells were
then incubated with rabbit anti-MAP2 (Cell Signalling Technology) diluted at 1:200 in
5% goat serum/PBS overnight at 4oC. After incubation, cells were washed 3 times for 5
mins with Washing Buffer (WB: 0.1% Triton-x-100 in PBS), then incubated with
AlexaFluor® goat 488 anti-rabbit (Invitrogen) and nuclear stain DAPI (ThermoFisher
Scientific), diluted at 1:1000; in BB for 2 hrs at RT. The wash step was repeated, then the
Ppy/DBS films were carefully peeled off the chamber and cut into approximately 1x1 cm2
squares. Each Ppy/DBS square or coverslip was mounted onto glass slides with
ProLong® Gold antifade reagent (Invitrogen). Imaging was performed with an Axio
Imager fluorescence microscope (Carl Zeiss).
Image analysis was conducted with the Simple Neurite Tracer (FIJI) plugin in ImageJ
1.52d (NIH, USA). Figure 2.5 illustrates an example of the neurite traces performed on
an image of electrically stimulated mHypoA-59 immunostained with MAP2. The
software automatically calculated the lengths in µm for each path traced. The Hessianbased analysis feature was enabled to improve accuracy and efficiency of path-finding.
Traces that were at least 15 µm long were included for analysis, whereas those shorter
than 15 µm were excluded as they may not be considered as neurites [248, 249].
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Figure 2.5: Example of neurite lengths measurement of mHypoA-59 cells using FIJI
Simple Neurite Tracer based on a MAP2-immunostained 8-bit image. Paths in purple
were ≥15µm (included for analysis), and the paths in green were <15µm (excluded from
analysis).

2.2.6

Flow cytometry

Cells were dissociated using 0.05% Trypsin-EDTA (Life Technologies) for 2 mins at
37oC, then centrifuged at 300 x g for 5 mins. The supernatant was removed, and the cells
were fixed with 3.7% PFA in PBS on ice for 10 mins. Next, the cells were washed with
Washing Buffer (WB: 0.1% Triton-x-100 in PBS), then centrifuged at 300 x g for 5 mins.
The cells were then blocked and permeabilized with Blocking Buffer (BB: 5% goat serum
and 0.3% Triton-x-100 in PBS) for 30 mins on ice. The cells within each sample were
then distributed into two microcentrifuge tubes, one tube was stained with mouse antiMAP2 (Life Technologies) diluted at 1:250 in 5% goat serum/PBS and the other tube was
incubated with 5% goat serum/PBS without primary antibodies, serving as the negative
control. The cells were incubated on ice for 30 mins. After washing, the cells were
incubated with secondary antibodies Alexa Fluor® 488 (1:1000; Invitrogen) or Alexa
Fluor® 647 (1:1000; Invitrogen) in the dark for 30 mins on ice. The wash protocol was
repeated and cells were resuspended in 2% FBS:PBS before running the samples through
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BD Accuri™ C6 Flow Cytometer (Becton Dickinson (BD) Biosciences) for analysis.
Each flow cytometry graph presented in the results section corresponds to one
experiment. The step-by-step analysis performed using the BD Accuri C6 Software is
demonstrated in Figure 2.6. Figure 2.6A shows forward-scattered light (FSC) vs sidescattered light (SSC) density plot of a negative control. FSC is proportional to the size or
surface area of the cell, whereas SSC is proportional to the cell granularity or internal
complexity. To exclude debris from the analysis, a gate was drawn around the population
of interest on the plot. Debris emits low FSC and SSC levels, thus usually signified by
the population in the bottom left corner. Figure 2.6B shows a histogram representing the
entire sample through the FL1 fluorescence detector (488 nm laser) on the x-axis and the
number of cells on the y-axis, whereas Figure 2.6C shows the corresponding histogram
of the gated population, without the debris.
To quantify the number of cells expressing MAP2, the same gate was applied to the
MAP2-immunostained sample, then a histogram of the MAP2-immunostained sample
was overlayed with the negative control sample (Figure 2.6D). A marker was then placed
across each peak where M1 signified the MAP2-negative cell population whereas the
region to the right of M1 (marked as M2), was considered positive for MAP2. The
software then automatically generated statistical percentages corresponding to the
markers.
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Figure 2.6: Step-by-step analysis performed using BD Accuri C6 Software. (A) Density
plot of forward-scattered light vs side-scattered light of a negative control. The red line
indicates the gate drawn around the population of interest. (B) A histogram of
fluorescence vs cell count corresponding to the ungated population. (C) A histogram of
fluorescence vs cell count corresponding to the gated population. (D) Overlayed
histograms of MAP2-AlexaFluor488-immunostained sample (blue peak) and negative
control sample (black peak). The region within marker M1 was considered negative for
MAP2 and the region within M2 was deemed positive for MAP2.
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2.2.7
2.2.7.1

Quantitative real-time polymerase chain reaction (qRT-PCR)
RNA isolation

On D4, the cells were collected for RNA isolation using PureLink® RNA Mini Kit (Life
Technologies). The cells in culture plates or chambers were collected into 1.5 mL RNasefree tubes using a Lysis Buffer (Life Technologies) containing 1% 2-mercaptoethanol
(Bio-Rad). For collagen gel culture, the cells were incubated in the Lysis Buffer for 10
mins prior to collection. Each lysate was passed through a 21-gauge needle attached to a
1 mL syringe, 5-10 times. 70% EtOH was added to each cell homogenate at 1:1, then
vortexed to disperse any precipitates. The samples were transferred to separate spin
cartridges attached to collection tubes, then centrifuged at 12,000 x g for 15 secs at RT.
The flow-through was discarded and 700 µL Wash Buffer I (Life Technologies) was
added to each spin cartridge before centrifuging at 12,000 x g for 15 secs at RT. The flowthrough was discarded, then 500 µL Wash Buffer II (Life Technologies) diluted with
EtOH was added to each spin cartridge and the centrifugation step was repeated. The
wash with Wash Buffer II was repeated once more, then an additional spin at 12,000 x g
for 2 mins at RT was executed to dry the membranes with attached RNA. The spin
cartridge was inserted into a recovery tube, then 15-30 µL of RNase-free water was added
to the centre of each spin cartridge and incubated for 1 min at RT. To elute the RNA from
each membrane, the spin cartridges were centrifuged at 12,000 x g for 2 mins at RT.
The isolated RNA was treated with RQ1 RNase-free DNase (Promega). Briefly, each
RNA sample was mixed with the Reaction Buffer (Promega) and RQ1 RNase-free DNase
(Promega) diluted in nuclease-free water, in a 20 µL reaction. The mixture was incubated
at 37oC for 30 mins, then 1 µL of RQ1 DNase Stop Solution (Promega) was added to
terminate the reaction. Finally, the samples were incubated at 65oC in a C1000 Touch
Thermal Cycler (Bio-Rad) for 10 mins to inactivate the DNase.
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2.2.7.2

Complementary DNA (cDNA) synthesis

The RNA concentration was measured using Thermo Scientific™ NanoDrop 2000
spectrophotometer (ThermoFisher Scientific), then 0.2 to 1 μg of RNA was used to
synthesise cDNA using Tetro™ cDNA Synthesis Kit (Bioline) in a 20 μL reaction.
Briefly, the priming premix consisting of random hexamers (40 µM), 10 mM
deoxynucleotide (dNTP) mix, 5x Reaction Buffer (Bioline), RiboSafe RNase inhibitor
(Bioline), and Tetro reverse transcriptase (Bioline), was prepared on ice. Then the premix
was mixed with each sample in an 8-strip tube (ThermoFisher Scientific), then incubated
in a C1000 Touch Thermal Cycler at 25oC for 10 mins, 45oC for 30 mins, and 85oC for 5
mins.
2.2.7.3

RT-PCR

The cDNA samples were diluted to 5 ng/2 μL volume with autoclaved distilled water.
Primer mix was prepared by mixing SYBR® Select master mix for CFX (Life
Technologies) with primers to obtain a final primer concentration of 400 nM. Primers
listed in Table 2.7 were obtained from Sigma-Aldrich. 2 μL of diluted cDNA was
aliquoted into each well of a 96-well plate then 18 μL of primer mix was added to
respective wells in triplicates. The plate was run on CFX96™ Real-Time PCR detection
system (Bio-Rad) with the conditions listed in Table 2.8. The melting curve (65oC to 95oC
with 0.5oC increment for 5 secs) was incorporated at the end of the cycle.
Experiments were run three times unless otherwise stated. For analysis, 2-ΔΔCq formula
was used [250]. Briefly, the quantification cycle (Cq) values from each sample were
normalised to their respective GAPDH levels. The samples were then normalised to the
control for each experiment to determine the relative expression.
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Table 2.7: List of primer sequences used for mHypoA-59 quantitative real-time
polymerase chain reaction.
Forward (5’-3’)

Name

Reverse (5’-3’)

MAP2

GAAGAAACAGCTAATCTGCC

CTCTTGCTTATTCCATCAGTG

Sigma receptor

GCTGCAGTGGGTATTTGTGA

ACTTTTCGTGGTGCCCTCTT

GAPDH

GGCAAGTTCAACGGCACAGTC TGGTGGTGAAGACGCCAGTAG

Table 2.8: The thermal cycling conditions used for mHypoA-59 quantitative real-time
polymerase chain reaction (qRT-PCR).
Step

Temperature (oC)

Duration Cycles

UDG activation

50

2 min

AmpliTaq® DNA

95

2 min

Denature

95

15 sec

Anneal

58

15 sec

Extend

72

1 min

Hold

Hold

polymerase activation
40

UDG, Uracil-DNA-glycosylase.

2.2.8

Quartz crystal microbalance with dissipation monitoring

Quartz crystal microbalance with dissipation monitoring (QCM-D) was used to study the
adsorption of PCP onto the Ppy/DBS polymer films. QCM-D sensors were first cleaned
with piranha solution (3:1 concentrated sulfuric acid/30% hydrogen peroxide) for 3 mins,
and then rinsed with deionised water. The quartz sensor crystals were electropolymerised
with 0.2M distilled aqueous pyrrole solution (Merck Millipore) and 0.05M DBS at 0.25
mA/cm2 for 2 mins using the QSense® electrochemistry module connected to a
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potentiostat, model EA161 (eDAQ), then placed into QSense® flow modules QFM 401
(Biolin Scientific) and equilibrated by running baseline solution (DMEM) at 60 µL/min
flow rate for 30 mins at 22oC. Once equilibrated, PCP solutions (3 µM or 25 µM) diluted
in either DMEM containing 10% FBS or DMEM without FBS were introduced to the
flow modules at a flow rate of 10 µL/min. The samples were removed after 1h 20 mins
and the rinse with baseline solution was commenced.
The quartz crystal oscillates at a specific frequency when voltage is applied to it. The
changes in frequency of the oscillating crystal provides the changes in mass on the quartz
surface through the Sauerbrey relationship [251]. When the driving voltage to the crystal
is isolated, the energy from the oscillating crystal dissipates from the system [251]. For
analysis, the QCM-D frequency and dissipation measurement parameters were studied,
and the Sauerbrey model was used to quantify the mass adsorbed to the QCM-D sensor
surface [251].
2.2.9

Gas chromatography-mass spectrometry analysis

2.2.9.1

Sample preparation

25 µM PCP diluted in Milli-Q water was incubated in a 12-well tissue culture plate with
or without Ppy/DBS substrate, at 37oC in a humidified 5% CO2 incubator. The aqueous
PCP solutions were then collected for analysis at D4. The extraction and gas
chromatography-mass spectrometry (GC-MS) procedures described below were
performed by Dr. Patricia Hayes (Intelligent Polymer Research Institute, University of
Wollongong).
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2.2.9.2

Extraction

The extraction of PCP solution was performed with dichloromethane (2x2 mL). The
organic layer was then collected, dried over magnesium sulfate (MgSO4), filtered, and
transferred into a vial for analysis.
2.2.9.3

GC-MS Procedures

For analysis, 2 µL was injected into an Agilent 7890A GC/5975C mass selective detector
(MSD) system (Agilent Technologies). An Agilent non-polar HP-5MS capillary column
(30 m x 0.25 mm i.d, 0.25 µM film thickness) was used under the following conditions:
pulsed splitless injection (injection pulse pressure of 35psi until 0.5 min and purge flow
to split vent of 50 ml/min at 0.75min); gas carrier helium at a flow rate of 1 mL/min;
injection port, 200oC; column oven programming; starting at 120oC and held for 2 mins,
then raised to 300oC at 15oC/min, held for 35 mins. The MSD transfer line, MS source
and MS quadrupole temperatures were 270oC, 230oC, and 150oC, respectively. The total
analysis time was 59 mins.
2.2.10 Liquid chromatography-mass spectrometry analysis
The samples prepared in section 2.2.9 were also analysed using liquid chromatographymass spectrometry (LC-MS). The analysis was performed by Dr. Patricia Hayes using a
LCMS-2020 liquid chromatography mass spectrometer (Shimadzu), equipped with an
electrospray ionisation (ESI) probe. The analytes were scanned in positive and negative
ion mode. LC-MS-grade acetonitrile was used as the mobile phase at a flow rate of 0.2
mL/min. The operating parameters were as follows: 1 µL injection volume, detector
voltage, 1 kV; nebulising gas flow, 1.5 L/min; desolvation line (DL) temperature, 250oC;
and heat block temperature, 200oC.
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2.2.11 Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics version 23. All values are
presented as mean ± standard error of the mean (SEM). The mean differences of neurite
lengths and MAP2 mRNA expression between mHypoA-59 control vs ES-mHypoA59
were analysed with Student’s t-test. Student’s t-test was also used to analyse the mean
differences of MAP2 mRNA expression between mHypoA-59 control and PCP-treated
mHypoA59 on tissue culture plastic (TCP) and Ppy/DBS platforms. Levene’s test was
used to test for homogeneity of variance and when significant (p<0.05), the output derived
from calculations with “equal variances not assumed” was selected for the report. The
mean differences of sigma receptor and MAP2 mRNA expressions in mHypoA-59
control and PCP-treated mHypoA-59 on TCP vs Ppy/DBS platforms, 2D vs 3D platforms,
and non-treated control vs treatments (PCP, ES, and ES+PCP); were assessed with oneway ANOVA analysis with Tukey Honest Significance Difference (HSD) post-hoc test.
When Levene’s test was significant (p<0.05), Welch and Brown-Forsythe tests were
additionally performed to confirm the statistical significance.

2.3 Results
2.3.1

Compatibility of Ppy/DBS with mHypoA-59

mHypoA-59 cells were first cultured on Ppy/DBS films for compatibility testing with the
polymer. The cells cultured in Ppy/DBS chambers exhibited morphologies comparable to
the cultures on tissue culture plastic (TCP) and expressed the neuronal marker, MAP2
(Figure 2.7), indicating the Ppy/DBS films were compatible with the mHypoA-59 cells.
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The optimum cell seeding density to achieve ~90% confluency by D4, was 2.5 x 103
cells/well of the Ppy/DBS chamber. For immunocytochemistry, the seeding density was
reduced to 1.0 x 103 cells/well to minimise cells growing on top of each other, for easier
image analysis.

Figure 2.7: mHypoA-59 cell culture on Ppy/DBS film and tissue culture plastic (TCP).
(A) Bright field image of mHypoA-59 cells cultured on a Ppy/DBS film. (B)
Immunofluorescent co-staining of mHypoA-59 cells cultured on Ppy/DBS film. MAP2
expression is displayed in green and DAPI is shown in blue. (C) Bright field image of
mHypoA-59 cells cultured on TCP. Scale bars represent 200 µm for (A) and (C); 50 µm
for (B).
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2.3.2
2.3.2.1

Electrical stimulation enhanced neurite outgrowth of mhypoa-59 cells
Neurite length analysis

Prior to developing a PCP-induced Sz model, the mHypoA-59 cells were electrically
stimulated to assess whether the cells respond to ES mediated by Ppy/DBS, as it has not
been reported in the literature to date. Qualitative analysis based on MAP2immunostained cells showed longer neurite lengths and branching of electrically
stimulated mHypoA-59 (ES-mHypoA59) compared to the non-stimulated control (Figure
2.8).

Figure 2.8: Immunofluorescent co-staining of MAP2 (green) and DAPI (blue) in
mHypoA-59 cells on day 4. Images show (A) mHypoA-59 non-stimulated control and
(B) electrically stimulated mHypoA-59. Scale bars represent 50 µm.

For quantitative analysis, neurite lengths of MAP2-stained cells were measured. Overall,
36 traces of ≥15 µM from each sample were obtained from over 5 images and over 20
neurons for analysis. The average neurite length of ES-mHypoA59 was significantly
greater (p<0.01) than the average neurite length of the unstimulated control (59.8±6.65
vs 37.2±2.85; Figure 2.9).
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Figure 2.9: Neurite length analysis between mHypoA-59 unstimulated control and ESmHypoA59. Neurite lengths were measured with Simple Neurite Tracer (FIJI) through
MAP2-stained 8-bit images. Values are presented as the mean neurite lengths (μm) ±
SEM (n =36). **p<0.01, by Student’s t-test.

2.3.2.2

Flow cytometry analysis of MAP2 expression

Flow cytometry was performed to quantify the number of MAP2-expressing cells within
each cell population. The assay of ES-mHypoA59 vs non-electrically stimulated control
indicated 95.5% of the ES-mHypoA59 population expressed MAP2, whereas in the nonelectrically stimulated control population, there were 46.7% of cells expressing MAP2
(Figure 2.10). This suggests an increase in cells expressing MAP2 when the cells were
electrically stimulated.
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Figure 2.10: Flow cytometry analysis of MAP2 expression in mHypoA-59 control and
ES-mHypoA59. The negative control is represented by the black peak and the red peak
designates the MAP2-stained sample. (A) mHypoA-59 cell population consisted of
46.7% of MAP2-expressing cells, whereas (B) 95.5% of cells expressed MAP2 in the
ES-mHypoA59 cell population.

Note that few studies have reported flow cytometry as the method with a higher
detection sensitivity when compared to immunofluorescence assays [252-254]. The
positive signal from immunofluorescence microscopy in this study was achieved
through the subjective adjustment of exposure time, yielding a 100% of cells expressing
MAP2 in comparison to the quantitative flow cytometry showing only 46.6% of cells
expressing MAP2 in non-electrically stimulated mHypoA-59 cultured on Ppy/DBS.
Additional quantification assay, namely qRT-PCR analysis was carried out to
complement this data.
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2.3.2.3

qRT-PCR analysis of MAP2 mRNA expression

mRNA of each sample was collected on D4 and the MAP2 mRNA expression was
analysed using qRT-PCR. The MAP2 mRNA expression was higher (p<0.05) in ESmHypoA59 (1.43±0.069) compared to the non-electrically stimulated control (Figure
2.11).

Figure 2.11: MAP2 mRNA expression in mHypoA-59 control and ES-mHypoA59,
analysed with quantitative real-time polymerase chain reaction. Values are presented as
the mean of mRNA expression relative to control ± SEM (n=3). *p<0.05; by Student’s
t-test.

Taken together, ES increased the neurite length, along with MAP2 mRNA and protein
levels in mHypoA-59 cells, when compared to the non-electrically stimulated control.
This result confirmed the cells’ response towards electrical stimuli. The next step was to
investigate the capability of ES in ameliorating possible PCP-induced defects in the cells.
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2.3.3

The effects of phencyclidine treatment on mHypoA-59 cells

The effects of PCP treatment on mHypoA-59 cells were first investigated on TCP.
Observations under the microscope did not show apparent morphological difference
between PCP-treated cells and non-treated cells on D4 (Figure 2.12). The proliferation
and survival rates of the cells also did not seem to be affected when observed under the
microscope at D4. Flow cytometry assays did not show a significant difference in the
number of cells expressing MAP2 where PCP-treated cell population consisted of 97.2%
of MAP2-expressing cells, and 98.6% of cells expressed MAP2 in the non-treated control
population (Figure 2.13). qRT-PCR analysis however, showed a reduction of MAP2
mRNA expression in the PCP-treated cells (0.450±0.008, p<0.001) compared to the nontreated control (Figure 2.14A).

Figure 2.12: Bright field microscopy of mHypoA-59 cells cultured on tissue culture
plastic (TCP). Images show (A) non-treated control and (B) cells treated with
phencyclidine on day 4 (D4).
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Figure 2.13: Flow cytometry analysis of MAP2 expression in mHypoA-59 control and
PCP-treated mHypoA-59 cultured on tissue culture plastics (TCP). The negative control
is represented by the black peak and the blue peak designates the MAP2-stained sample.
(A) The mHypoA-59 control cell population consisted of 98.6% of MAP2-expressing
cells, whereas (B) 97.2% of MAP2-expressing cells were detected in the PCP-treated
mHypoA59 cell population.

The results indicate that while the number of cells expressing MAP2 in PCP-treated
population was comparable to the non-treated control population, and no apparent
difference was observed in the cell morphology with PCP treatment, the overall mRNA
expression in PCP-treated samples were significantly reduced compared to the nontreated control. Since the effect of PCP was established at the mRNA level in cells
cultured on TCP, the experiment was then transitioned to the Ppy/DBS platform, as the
electrical currents would be delivered via the platform.
The experiments conducted on TCP were repeated in cells cultured on Ppy/DBS. The
Ppy/DBS platform was anticipated to mirror the PCP-induced reduction of MAP2 mRNA
expression in cells cultured on the TCP platform. Interestingly, the effect was reversed
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on Ppy/DBS, whereby the MAP2 mRNA expression was increased in the PCP-treated
cells (1.44±0.025, p<0.01) compared to the non-treated control (Figure 2.14B). Similarly,
the flow cytometry assay also showed an increase in the percentage of MAP2-expressing
cells, from 48.1% in non-treated control cell population, to 94.9% in PCP-treated cell
population (Figure 2.15).

Figure 2.14: MAP2 mRNA expression in mHypoA-59 control and PCP-treated mHypoA59, analysed with quantitative real-time polymerase chain reaction. Graphs show MAP2
mRNA expression between mHypoA-59 control and PCP-treated mHypoA-59 cultured
on (A) TCP and (B) Ppy/DBS. Values are presented as the mean of mRNA expression
relative to control ± SEM (n = 3). **p<0.01, ***p<0.001; by Student’s t-test.
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Figure 2.15: Flow cytometry analysis of MAP2 expression in mHypoA-59 control and
PCP-treated mHypoA-59 cultured on Ppy/DBS. Negative control is represented by the
black peak and the red peak designates the MAP2-stained sample. (A) mHypoA-59
control cell population consisted of 48.1% of MAP2-expressing cells, whereas (B)
94.9% of MAP2-expressing cells were detected in the PCP-treated mHypoA59 cell
population.

A further investigation was warranted for the discrepancy between the two platforms:
TCP and Ppy/DBS. It was inferred that the interaction between PCP molecules and
Ppy/DBS may have altered the effects of PCP on the cells, or the interaction between
Ppy/DBS and the cells may have modified the cells’ response to PCP.
2.3.4

Quartz crystal microbalance with dissipation monitoring analysis

One of the proposed interactions between Ppy/DBS and PCP was the adsorption of PCP
molecules onto the Ppy/DBS substrate. Quartz crystal microbalance with dissipation
monitoring (QCM-D) was used to explore this interaction. The adsorption mass from 25
µM PCP diluted in culture medium onto Ppy/DBS, calculated using the Sauerbrey model;
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was 46.1 ng/cm2, whereas the adsorption mass of a lower concentration of PCP (3 µM)
was negligible (Figure 2.16).

Figure 2.16: Mass adsorption from PCP diluted in culture medium onto Ppy/DBS film,
calculated using the Sauerbrey model. Adsorption from 3 µM PCP was negligible,
whereas the adsorption mass from 25 µM PCP onto Ppy/DBS was 46.1 ng/cm2.

Since the adsorption of bovine serum albumin (BSA; a major component of FBS) onto
Ppy substrates has been reported in the literature [255-258], QCM-D analysis was also
run on 25 µM PCP diluted in either culture medium (DMEM containing FBS) or DMEM
only to investigate the influence of FBS on the adsorption of PCP. Interestingly, the
adsorption recorded for PCP diluted in DMEM without FBS onto Ppy/DBS was higher
(205.2 ng/cm2) than the adsorption for PCP diluted in culture medium (46.1 ng/cm2;
Figure 2.17), suggesting an involvement of FBS in this interaction.
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Figure 2.17: Mass adsorption from 25 µM PCP onto Ppy/DBS film, calculated with
Sauerbrey model. The adsorption mass for PCP diluted in culture medium (DMEM +
FBS) or DMEM only was 46.1 ng/cm2 and 205.2 ng/cm2, respectively.

These data indicated an adsorption of 25 µM PCP onto Ppy/DBS, suggesting the level of
PCP available to the cells may be different between the Ppy/DBS and TCP platforms as
distinct topographies of Ppy/DBS and TCP would have resulted in varying degrees of
PCP adsorption. However, this does not necessarily explain the increase of MAP2 mRNA
expression, as a lack of PCP molecules acting on the cells was expected to have a
negligible effect on the MAP2 mRNA expression.
2.3.5

Gas chromatography/liquid chromatography-mass spectrometry analyses

Another proposed mechanism was the decomposition, or a structural modification of the
PCP molecules induced by Ppy/DBS substrates, subsequently altering its effects on the
cells. To investigate this, PCP solution incubated in either TCP (referred to as PCP-TCP
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thereafter) or in TCP with Ppy/DBS substrates (PCP-Ppy/DBS), were analysed on gas
chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass
spectrometry (LC-MS) to identify possible by-products of PCP.
Figure 2.18 shows a chromatogram of the samples ran through the GC. The retention time
(min) on the x-axis was the time it took from the injection of samples to the detection of
the isolated volatile compounds eluted from the capillary column. The abundance on the
y-axis represents the intensity of the signal. The greater the concentration of the
compound in the sample, the greater the signal. The PCP compound was detected in PCPTCP at 10.052 with a signal intensity of approximately 3.8 x 106 and at 10.074 min in
PCP-Ppy/DBS with a signal intensity of approximately 1.1 x 106 (Figure 2.18).

Figure 2.18: GC/MS chromatogram of the volatile compounds detected in (A) PCP-TCP
and (B) PCP-Ppy/DBS samples. The signal was detected at (A) 10.052 min with a signal
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intensity of approximately 3,800,000, and at (B) 10.074 min with a signal intensity of
approximately 1,100,000.

After eluting from the GC column, the PCP compound entered the electron ionisation
mass spectrometry detector and was broken into fragments - usually small or large pieces
of the original molecule. The fragments were then detected and recorded on mass spectra
graph (Figure 2.19). The fragments were charged ions with a specific mass; thus, the xaxis on Figure 2.19 represents the mass to charge ratio (m/z), which is equivalent to the
molecular weight of the fragment. The y-axis (abundance) represents the signal intensity
of each of the fragments.
The recorded mass spectrum was then compared against the mass spectra library in the
GC-MS computer. The output was a list of likely compound identifications with the
statistical probability of the match. The peak at m/z 242.2 was identified as PCP (Figure
2.19).
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Figure 2.19: GC-MS mass spectrum of volatile compounds in (A) PCP-TCP and (B) PCPPpy/DBS. The compound of m/z 242.2 was identified as PCP using the mass spectra
library. The signal intensity of PCP was ~300,000 in (A) and ~20,000 in (B).

If the interaction of Ppy/DBS and PCP had resulted in a decomposition or structural
change of the PCP molecules, the mass spectra of PCP-Ppy/DBS was expected to
generate peaks different to that in PCP-TCP. However, there was no difference observed
between the mass spectra of both samples. LC-MS was then performed for further
validation since LC-MS, compared to GC-MS, can detect a broader range of organic
compounds, as well as detecting more polar and volatile compounds. Polarity and thermal
stability issues can also be avoided using LC-MS [259]. In GC-MS, the components from
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GC are introduced directly to the mass spectrometers as they are readily in the gas phase.
In the LC-MS system, the liquid mobile phase needs to be processed to generate suitable
ions. This can be achieved with electrospray ionisation (ESI) through a process of
ionisation and evaporation. The ions generated by ESI are protonated molecules (positive
mode) and deprotonated molecules (negative mode).
In this study, the signal for PCP upon protonation is at m/z 244.3 (Figure 2.20). Similar
to GC-MS, the LC-MS mass spectrum in the positive ion mode showed no difference
between PCP-TCP and PCP-Ppy/DBS (Figure 2.20).

Figure 2.20: LC-MS (ESI) mass spectrum of PCP compounds in the positive ion mode.
The signal for protonated PCP was at m/z 244.3. (A) The signal intensity for PCP-TCP
was ~920,000. (B) The signal intensity for PCP-Ppy/DBS was ~620,000.
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In the negative ion mode however, the mass spectrum of PCP-Ppy/DBS had identified
compounds with m/z 297.1, 311.2, 325.0, and 339.2; which were absent in PCP-TCP
(Figure 2.21). A separate experiment analysing DBS solution only, conducted by Dr. Paul
Molino (Intelligent Polymer Research Institute, University of Wollongong), also yielded
compounds with m/z 297.1, 311.2, 325.0 and 339.2 (unpublished data), which indicates
the compounds were most likely fragments of DBS, rather than from PCP (Figure 2.22).

Figure 2.21: LC-ESI MS mass spectrum of PCP compounds in the negative ion mode.
The profiles show deprotonated molecule fragments in (A) PCP-TCP, and (B) PCPPpy/DBS. Additional compounds with m/z 297.1, 311.2, 325.0, and 339.2 were detected
in (B).
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Figure 2.22: LC-ESI MS mass spectrum of DBS in the negative ion mode. The DBS
solution analysed by Dr. Paul Molino consisted of fragments with m/z 297.1, 311.1,
325.0, and 339.2.

Taken together with the GC-MS analysis, these results implied that the likelihood of the
PCP molecules being fragmented or altered by Ppy/DBS substrates was low. It is worth
noting however, that the abundance of PCP molecules in PCP-Ppy/DBS (20,000) were
significantly lower than in PCP-TCP (300,000; Figure 2.19). Since the solution collected
from the PCP-Ppy/DBS incubation contained a lower amount of PCP than in PCP-TCP,
this further supports the previous QCM-D data highlighting the adsorption of PCP onto
Ppy/DBS.
2.3.6

Expression of PCP receptors on cells incubated on TCP and Ppy/DBS
platforms

As the interaction of polymer substrates with cell receptors have been established [260],
the expression of receptors for PCP were investigated. mRNA samples were collected
from mHypoA-59 cultured on TCP on D4. The expression of common PCP receptors, Nmethyl-D-aspartic acid receptor (NMDAR) subunits 1 (NR1), 2A (NR2A), and 2B
(NR2B) were assayed via qRT-PCR; however, the primer targets were not amplified in
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the qRT-PCR runs. This could either be due to the primer sequences not targeting the
specific transcript variants expressed by mHypoA-59, or that mHypoA-59 cell line did
not express the receptors.
Another established PCP receptor which has also been associated with Sz
pathophysiology, is sigma receptor (σ) [223], thus the mRNA expression of the receptor
was investigated in this study. One-way ANOVA analysis with a Tukey HSD post hoc
test showed no significant difference (p>0.05) between the mRNA expression of σ
receptor between PCP-treated cells and non-treated control on either TCP or Ppy/DBS
platforms (Figure 2.23). The mRNA expression of σ receptor in cells cultured on
Ppy/DBS, both with or without PCP treatment; were significantly lower (p<0.001) than
the cells cultured on TCP (Figure 2.23).
To investigate whether the σ mRNA expression had an influence on MAP2, the MAP2
mRNA expression for TCP against Ppy/DBS platforms were run in parallel with the σ
receptor analysis. The reduction of MAP2 mRNA expression in PCP-treated cells
(0.661±0.094, p<0.05) compared to the non-treated control on TCP, and the increase in
MAP2 mRNA expression in PCP-treated cells on Ppy/DBS (0.409±0.039 vs
0.116±0.015, p<0.05) were recapitulated in this experiment (Figure 2.23). Additionally,
the cell culture on Ppy/DBS platform expressed lower MAP2 mRNA expression
compared to the cell culture on TCP (Figure 2.23).
The data suggests PCP had no significant effect on the mRNA level of σ receptor.
However, lower expression of σ receptor in cells on Ppy/DBS compared to the cells on
TCP may imply there were fewer receptors for PCP to convey its effects in the Ppy/DBS
system, hence the observation of a more potent effect of PCP on cells in TCP compared
to Ppy/DBS. Nevertheless, it still does not explain the increase of MAP2 mRNA
expression with PCP treatment.
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Figure 2.23: mRNA expression of sigma receptor and MAP2 on day 4 in mHypoA-59
control and PCP-treated mHypoA59 cells cultured on TCP or Ppy/DBS, analysed with
quantitative real-time polymerase chain reaction. Values are presented as the mean of
mRNA expression relative to TCP control ± SEM (n = 3). *p<0.05, **p<0.01,
***p<0.001 vs TCP control, $p<0.05 PpyDBS vs TCP PCP, #p<0.05 PpyDBS PCP vs
PpyDBS control; by one-way ANOVA analysis with Tukey HSD post-hoc test.
2.3.7

Phencyclidine treatment in a 3-dimensional collagen gel cultures

Since the Ppy/DBS substrates in a 2-dimensional (2D) ES setting seemed to interfere with
the development of the PCP-induced Sz model, another ES system was explored. A 3D
ES system recently developed within the group by Zhang et al. [184] was tested in this
study. The system involves culturing cells in a collagen gel to achieve a 3-dimensional
distribution of cells, which is then seeded onto Ppy/DBS-coated interdigitated electrodes
for the ES application (depicted in Appendix 1).
Before interfacing the cells with electrodes, cell culture of mHypoA-59 was first tested
in the collagen gel for viability. The cells were encapsulated within the gel in culture

69

medium and maintained until D4. Bright field microscopy images showed increased
numbers of neurite processes, albeit not necessarily increased neurite lengths, of the cells
in the gel compared to the cells cultured in a 2D system (Figure 2.24).
The cells were then immunostained with MAP2 using the standard staining protocol,
along with the immunostaining of cells in the 2D platform in parallel; however, no MAP2
was detected in the 3D culture. Various staining protocols were trialled, including higher
volume of staining solutions (from 200 µL to 300 µL) and the addition of 0.3% Triton-x100 to the primary antibody dilution solution for permeabilization; which generated
similar results. Optimisation of the immunostaining protocol is still required for the
mHypoA-59 cells within the collagen gel; however, due to time constraints, it was not
carried out for this thesis.

Figure 2.24: Bright field images of mHypoA-59 cells cultured on TCP. Images show
cell culture in (A) 3-dimensional (3D) collagen gel and (B) 2D monolayer. Scale bars
represent 100 µm.

mRNA was extracted from the cells cultured in 2D and 3D systems on D4, then qRTPCR analysis was performed for σ receptor and MAP2 markers. A trend similar to the 2D
Ppy/DBS culture was observed in the 3D culture, whereby PCP-treated cells showed
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significantly higher (p<0.01) MAP2 mRNA expression compared to the non-treated
control (1.40±0.162 vs 0.453±0.107, Figure 2.25). In addition, the mRNA expression of
MAP2 was significantly lower in the non-treated 3D culture (0.453±0.107, p<0.05)
compared to the non-treated 2D control on TCP (Figure 2.25).
In contrast to the trend observed in the 2D Ppy/DBS vs TCP platforms, the σ receptor
mRNA expression was higher in the 3D culture, either in PCP-treated cells (1.56±0.046)
or non-treated control (1.30±0.111), compared to the PCP-treated (0.819±0.039) and nontreated control in the 2D culture (Figure 2.25).
Thus, the previous theory of PCP exerting a more potent effect on cells expressing higher
σ receptor mRNA expression may not be valid in this experiment. The expression of
MAP2 may therefore be independent of the σ receptor expression. Due to time
constraints, this observation of MAP2 elevation with PCP treatment was not explored
further.

Figure 2.25: mRNA expression of sigma receptor and MAP2 in mHypoA-59 control
and PCP-treated mHypoA59 cells cultured in 2D and 3D systems, analysed using
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quantitative real-time polymerase chain reaction. Values are presented as the mean of
mRNA expression relative to 2D control ± SEM (n = 3). *p<0.05, **p<0.01 vs 2D
control, $$$p<0.01, $$$p<0.001 3D vs 2D PCP, ##P<0.01 3D PCP vs 3D control; by
one-way ANOVA analysis with Tukey HSD post-hoc test.
2.3.8

The effect of electrical stimulation on phencyclidine-treated cells

While the development of a PCP-induced Sz model was not successful with the mHypoA59 cells on the Ppy/DBS platform, preliminary ES experiments were performed to assess
the impact of ES on PCP-treated cells. Cells were treated with 25 µM PCP from D1 to
D4, ES from D1 to D3, or a combination of both. Cells without any treatment were used
as a control. Cells were collected on D4 for qRT-PCR assay.
All the three treatments significantly increased MAP2 mRNA expression compared to the
non-treated control (PCP: 1.58±0.058, p<0.01; PCP+ES:1.58±0.052, p<0.01; and
ES:1.53±0.095; p<0.05)(Figure 2.26). There was no significant difference in the MAP2
mRNA levels between the PCP-treated, PCP+ES-treated, and ES-treated cells.
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Figure 2.26: mRNA expression of MAP2 in mHypoA-59 cells with PCP and ES
treatments on the Ppy/DBS platform, analysed using quantitative real-time polymerase
chain reaction. The treatments were as follows, PCP: 25 µM PCP from D1 to D4, PCP +
ES: 25 µM PCP from D1 to D4 + 8 hrs/day ES from D1 to D3, or ES: 8 hrs/day ES from
D1 to D3. Values are presented as the mean mRNA expression relative to non-treated
control ± SEM (n = 3). *p<0.05, **p<0.01 vs non-treated control; by one-way ANOVA
analysis with Tukey HSD post-hoc test.

2.4 Discussion
This chapter explores the use of mHypoA-59 hypothalamic cell line in developing a PCPinduced Sz model to investigate the capacity of ES in attenuating the effects of PCP.
Complex interactions between PCP and the conductive polymer platforms however, has
hindered the development of the model.
2.4.1

The effects of PCP on mHypoA-59 cultured on TCP

In the present study, 25 µM PCP did not show an effect on cell survival, which coincides
with another study demonstrating no effect on cell viability with PCP treatment despite
demonstrating impaired synaptic connectivity in PCP-treated neurons [243]. While the
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number of cells expressing MAP2 in the cell population treated with PCP and in nontreated control population were similar in this study, the level of MAP2 mRNA expressed
in PCP-treated cells was significantly lower than in the non-treated controls. The finding
of MAP2 mRNA expression reduction by PCP treatment in this study is in line with a
study by Martin et al. [244] that found reduced gene expression of MAP2 in neurons
treated with PCP.
The discrepancy between the level of MAP2 mRNA and the percentage of cells
expressing MAP2 protein may be explained by the processes involved in protein
synthesis. Essentially, a protein is synthesised in a cell’s ribosome from an mRNA
sequence, through a process called translation. Although protein abundance is directly
proportional to the level of mRNA in typical instances, several studies have reported poor,
or varying degree of correlations between the level of mRNA and protein concentration
in the cells [261-265]. These studies implied that the correlations are contingent on the
type of gene, protein, cells, and the conditions the cells are in. For instance, not all mRNA
is efficiently translated into a protein, hence resulting in a detection of high mRNA levels
and low protein concentration.
Another factor that should be taken into consideration is the cells’ regulation of protein
synthesis/degradation, which varies in different conditions [266, 267]. The varying
protein turnover rates may lead to an accumulation of proteins with a higher half-life,
even after a downregulation of mRNA levels and protein synthesis in the cells. This is
illustrated in Figure 2.27. In this study, PCP treatment may have reduced the MAP2
mRNA expression on or by D4 however, the reduction of protein concentration resulting
from lower protein synthesis and protein degradation; may only be observed after D4.
The results from qRT-PCR may be further validated by extending the culture period
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beyond D4 and measuring the protein concentration of MAP2 with assays such as flow
cytometry or western blot, at different timepoints.

Figure 2.27: Different degree of correlations between the level of mRNA and the protein
concentration. (A) The protein abundance correlates with the level of mRNA. (B) mRNA
and protein synthesis are downregulated, but the previously synthesised proteins in the
cells have not undergone degradation and accumulates in the cells, thus leading to poor
correlation between the mRNA and protein levels. (C) After protein degradation, the
number of synthesised proteins correlates with the current level of mRNA.

2.4.2

The complex interactions on a Ppy/DBS platform

It is noted that the number of mHypoA-59 cells expressing MAP2 was higher in the cell
population cultured on TCP (98.6%) than those cultured on Ppy/DBS (average: 47.4%).
Similarly, in cells cultured on Ppy/DBS, the MAP2 mRNA expression was lower than
the cells cultured on TCP, while the PCP treatment increased the MAP2 mRNA
expression in cells cultured on Ppy/DBS. QCM-D, GC-MS, and LC-MS analyses in the
present study have suggested the adsorption of PCP molecules onto Ppy/DBS. QCM-D
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analysis further demonstrated a higher mass adsorption for PCP diluted in DMEM
compared to PCP diluted in DMEM containing FBS, implicating the involvement of FBS
in the interaction between PCP and Ppy/DBS. FBS is commonly added to cell culture
medium as a source of growth factors, hormones, and nutrients. BSA is the most abundant
protein in FBS and acts as a carrier of proteins and other ligands essential for cell growth
[268]. Several studies have reported the adsorption of BSA onto polymer substrates; thus,
the reduced expression of MAP2 in cells cultured on Ppy/DBS may have been the result
of BSA adsorbing onto Ppy/DBS, limiting the availability of proteins and nutriments
within FBS to the cells [255-258].
While several studies have reported increased neurite outgrowth and proliferation with
Ppy as described in Chapter 1, it should be noted that the lack of reports on unfavourable
effects of Ppy and its composites on cells may be because negative results are often not
published. Few studies have shown that cultures on Ppy platforms were not always
superior to non-Ppy platforms. In a study investigating the proliferation of rat neuronal
cell lines on surfaces coated with different polymers, Ppy-coated surface demonstrated
higher cell proliferation than a non-coated glass surface at 24 hrs; however, at 72 hrs, the
cell proliferation on the non-coated glass was greater than the Ppy-coated surface [269].
Similarly, Castano et al. [270] showed increased adhesion of mesenchymal stem cells to
TCP coated with 20 mm Ppy, but the cell adhesion was significantly reduced on 35 – 50
mm Ppy-coated TCP compared to cells cultured on non-coated TCP. Another study found
that in the absence of electrical stimuli, the adhesion and neurite extension of PC12 cells
and primary chicken sciatic nerve explants cultured on Ppy doped with poly(styrene
sulfonate) were equal to that cultured on TCP [271]. These variations in cell response to
Ppy substrates could be due to a number of factors such as Ppy synthesis conditions,
preparatory steps prior to culture, choice of dopants, type of cells used, to name a few
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[173]. It may be that the mHypoA-59 cells did not respond favourably to the Ppy/DBS
films synthesised in this study. Future studies could assess cell death on the Ppy/DBS
platform by running cell viability assays or labelling the cells with propidium iodide for
flow cytometry assays.
A proposed mechanism for the lack of PCP effects on the Ppy/DBS platform is the
diminishing of PCP-induced neurotoxic effects on the cells by Ppy/DBS substrates. PCP
damages cells through the induction of oxidative stress, a condition that has been
associated with the pathophysiology of Sz [272-274]. Ppy is known for its antioxidant
properties, hence in this study, the Ppy/DBS platform may have also counteracted the
oxidative stress effects induced by the PCP molecules [275, 276].
The complex interactions between protein-Ppy/DBS, cell-Ppy/DBS, proteins-PCP and
PCP-Ppy/DBS may have all contributed to the increase in MAP2 mRNA expression in
PCP-treated cells cultured on Ppy/DBS. As QCM-D analysis is a bulk measurement, it
does not differentiate the molecules that adsorb onto the polymer surface, making it
difficult to elucidate the specific interactions that occurred in the system. A sequential
competitive adsorption that involves displacements of proteins from the surface, which
relies on several factors including, but not limited to, affinity, reversibility, molecular
weight, and pH; could have also played a role [277-280]. These complex interactions have
not been comprehensively studied in the field to date and are beyond the scope of this
thesis.
2.4.3

The effects of PCP in 3-dimensional collagen gel

The theories proposed in the previous section may be relevant in a system with polymer
substrates; however, a similar pattern was observed in mHypoA-59 cells cultured in a
3D collagen gel. Two contrasting theories were formed surrounding this observation.
First, the 3D collagen gel environment may have hampered the effects of PCP on the
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cells. A study has shown a diminished effect of PCP in neuronal nitric oxide synthase
(nNOS) knockout mice, suggesting an intact nNOS system is vital for PCP-induced
effects [281]. Gorska et al. [282] found that the expression of nNOS was significantly
reduced in cells cultured in a 3D collagen matrix. If the nNOS system was impaired in
mHypoA-59 cells within the 3D collagen gel, then the neurotoxicity of PCP may have
not been thoroughly conveyed.
The second theory is that the increase in MAP2 mRNA expression was the cells’ response
mechanism to oxidative stress. A hypoxic environment due to irregular gas penetration
and limited nutrition diffusion, have been reported in 3D scaffolds [282-284] . This may
explain the reduction of MAP2 mRNA expression in the 3D collagen gel culture, as cells
have been reported to self-regulate by limiting growths in a 3D environment due to
insufficient surface area for the exchange of catabolite and nutrients [284]. The
introduction of additional oxidative stress instigator, such as PCP, to an already
compromised system may then initiate signalling pathways related to cell differentiation
and survival, hence the upregulation of MAP2 mRNA expression with the administration
of PCP, as a way of adapting to the new environment. MAPs are known to be involved
in neuroprotection against oxidative stress and other unfavourable stimuli [285, 286]. The
involvement of MAP4 and MAP1B in neuroprotective mechanisms have been reported;
however, literature on the direct involvement of MAP2 is still scarce [287]. Further
research could be conducted to investigate the relationship between MAP2 and
neuroprotective mechanisms. Since the aim of the chapter was to develop a PCP-induced
Sz model on an electroactive platform, further investigative work into the cell’s response
in a 3D collagen gel is beyond the aim of this chapter.
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2.4.4

PCP receptors

While common receptors of PCP have been cited as NMDAR and σ receptor in the
literature, the present study showed that σ receptor may not be involved in the modulation
of PCP [219, 223, 288, 289]. In line with this, Mattson et al. [233] has demonstrated that
the degeneration of cortical neurons resulting from PCP treatment were not mediated by
NMDAR nor σ receptor. These findings suggest that the mechanism of PCP may not be
as straightforward, adding to the complexity of the model.
2.4.5

The effects of electrical stimulation on mHypoa-59 cells

ES increased the neurite lengths along with MAP2 mRNA and protein expression in
mHypoA-59. It is reasonable to question whether this observation is an augmentation of
cells or a stress response towards ES, as the effects were comparable to PCP treatments.
Therefore, measures could be taken in future studies to differentiate between favourable
and adverse responses. This could be achieved by investigating the levels of stress and
inflammatory markers along with neuronal markers in response to ES.
2.4.6

Technical limitations

The results obtained in the 3D collagen gel culture may be due to the culture not being
optimised yet. Optimising the cell density within the gel and medium replenishments
protocol could ensure sufficient gas and nutrients available to the cells, potentially leading
to an enhanced culture in future studies.
The mHypoA-59 cell line is yet to be fully characterised. It is a relatively new cell line
and to date, has only been published in two papers investigating neuropeptides related to
metabolism [290, 291]. Moreover, the cell line screening profile is not provided by the
manufacturer; therefore, the full profile of genes and proteins expressed by the cells are
still not established.
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2.4.7

Conclusions and future directions

The aim of this chapter was to investigate the effects of ES on a PCP-induced Sz model,
using the mHypoA-59 cell line. This study has suggested favourable effects of ES on the
mHypoA-59 cell line, which have not been reported in the literature. The development of
a PCP-induced Sz model on a conductive platform however, has not produced the desired
outcome.
This study has identified several areas that could be explored in future studies, some of
which include investigating the interaction of drug molecules with polymer substrates and
serum albumin, as these may have an effect on drug delivery systems utilising polymers.
Stress markers in ES experiments and in the 3D collagen gel environment could also be
investigated to clarify cell response.
To further validate the use of mHypoA-59 as a Sz model, the effects of PCP on other Szrelated markers that have been associated with the drug, as described in section 3.1; could
also be assessed. This includes nicotinic acetylcholine receptor, dopamine, serotonin,
GABA and glutamate. Neuronal markers other than MAP2, such as NeuN, could also be
explored. In addition, a Sz cell line model that would be more suitable for polymer-based
ES studies could be developed by inducing a gene knockdown with small interference
RNA as opposed to using drugs that may interact with the polymer platforms.
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Chapter 3: The effects of electrical stimulation on
schizophrenia candidate genes in DISC1-locus impaired and
NRG1-knockout mouse models

3.1 Introduction
This chapter employed models that are more established than the cell line model used in
Chapter 2 to progress towards investigating the effects of ES on an Sz model. Mice have
been a valuable tool in modelling human diseases as their genome highly resembles that
of humans [89]. Due to factors such as ethical considerations, a mouse model is typically
used after investigating and deriving preliminary information from other simpler models,
such as disease cell lines [292].
Previous studies involving Disruped-In-Schizophrenia-1 (DISC1) mutations or mutant
DISC1 mouse models have found neural circuits malfunctioning within hippocampus and
prefrontal cortex, as well as abnormal interneuron development, synaptic transmission
and plasticity, in both hippocampal and frontal cortical network [293-298]. The axonal
and dendritic morphogenesis, and dendritic spine development in hippocampal and
cortical neurons were also affected in the DISC1-mutant. For instance, the frontal cortical
neurons had shorter dendrites, decreased surface area and spine density compared to their
wild-type (WT) counterparts [299, 300]. Moreover, DISC1 mutants exhibited aberrant
progenitor cell proliferation, neurogenesis, and cell migration, as well as altered neuronal
distribution [299, 301, 302]. In neuregulin 1 (NRG1) mutant mice, defects in cortical
dendrite development as well as glutamatergic and dopaminergic neurotransmissions
have been reported [303, 304]. Further, NRG1 mutations have led to impaired latent
inhibition and reduced basal serum levels of inflammatory cytokines [305, 306].
Zhang et al. [183] have demonstrated increased levels of synaptic markers (post-synaptic
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density protein 95 (PSD-95) and synaptophysin) and growth factor brain-derived
neurotrophic factor (BDNF) modulated by polypyrrole/dodecylbenzene sulfonic acid
(Ppy/DBS)-mediated ES in primary prefrontal cortical (PFC) neurons isolated from WT,
DISC1-locus impaired (LI), and NRG1-knockout (KO). Image-based analysis of
neuronal marker microtubule-associated protein 2 (MAP2) also showed greater neurite
outgrowths in the electrically stimulated WT, DISC1-LI, and NRG1-KO PFC neurons
compared to the non-stimulated controls [183]. The aim of this chapter was to investigate
additional effects of ES on these PFC neurons, focusing on Sz candidate genes that have
been linked to DISC1 and NRG1. This study maintained the focus of the study by Zhang
et al. [183] within the prefrontal cortex region due to the high association of prefrontal
cortex with Sz pathophysiology, and because this brain region is a typical target for noninvasive neuronal stimulation such as transcranial direct current stimulation (tDCS) in Sz
patients [307].
Another component of this chapter is the exploration of different types of dopants for
Ppy-mediated ES, as dopants are known to affect the chemical, physical and
electromechanical properties of Ppy [308]. Dopants toluene-4-sulfonic acid (pTS) and
poly(sodium 4-styrene sulfonate) (PSS) were selected for a comparison against DBS, as
these are among the dopants commonly used with Ppy [186, 188, 308, 309]. Schmidt et
al. [271] have shown that PC12 cells cultured on Ppy/PSS had attached and differentiated
as well as cells cultured on tissue culture plastic (TCP) and that Ppy/PSS-mediated ES
had increased neurite length of PC12 cells compared to the controls cultured on TCP.
Other studies with Ppy/PSS include implants in rat cerebral cortex and Ppy/PSSdeposited-electrodes on neural probes in the cerebellum of guinea pigs [310, 311]. As for
Ppy/pTS, the polymer has been incorporated into electrodes for cochlear implants
exploring neurite outgrowth in auditory neurons as well as charge and neurotrophin
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delivery [312, 313]. Furthermore, Evans et al. [314] have investigated Ppy/pTS in
promoting neurite outgrowth of spiral ganglion neuron explants.
To summarise, this chapter explores (i) the compatibility of PFC neurons on different
types of Ppy films, and (ii) the impact of ES on selected Sz candidate genes associated
with DISC1 or NRG1 mutants.

3.2 Materials and methods
3.2.1

Preparation of polymer films and chambers

Polymer films were prepared via galvanostatic polymerisation of aqueous pyrrole
solution (0.2 M), using an eDAQ EA161 potentiostat at a current density of 0.25 mA/cm2
for 2 mins. Pyrrole monomer was obtained from Merck Millipore and all dopants were
obtained from Sigma-Aldrich. The dopants used were: 0.05 M dodecylbenzene sulfonic
acid (DBS), 0.05 M toluene-4-sulfonic acid (pTS) and 0.05 M poly (sodium 4-styrene
sulfonate) (PSS). All pyrrole and dopant solutions were prepared with Milli-Q water. The
deposition of polymer onto gold-coated mylar (Solutia Performance Films) was
performed in a standard three-electrode electrochemical cell with gold-coated mylar as
the working electrode, platinum wire mesh as the counter electrode, and Ag/AgCl as the
reference electrode. After polymerisation, the films were rinsed with dH 2O then dried
with N2.
Custom cell culture chamber and stimulation module were prepared by gluing clear
bottomless polystyrene chambers onto polymer films using silicon adhesive followed by
overnight curing at RT. The chambers were then sterilised with 70% ethanol (EtOH) for
20 mins then air-dried in a Biosafety Cabinet (BSC). To reduce toxicity from the glue and
for sterility testing, 1 mL/well of culture medium was added to the chambers which were
then covered with a plastic lid. The chambers were contained within a deep petri dish (25
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x 100 mm) and left overnight at 37oC in a humidified 5% CO2 incubator. Prior to coating
with poly-D-lysine (PDL; Sigma-Aldrich), the medium was removed from the chambers,
followed by a rinse with sterile phosphate buffered solution (PBS). Images of the film
and chambers were presented in Chapter 2, Figure 2.3.
3.2.2

Atomic force microscopy

Atomic force microscopy (AFM) was used to analyse the roughness of the polymer films.
Imaging was performed by Alex Nagle (PhD candidate, University of Wollongong) using
AFM XE Bio (Park Systems). For AFM imaging, the polymer films were washed with
dH2O and dried with N2. AFM images were captured over a 10 µm area using NP-010
silicon nitride cantilever tips (Bruker) in tapping mode. The mean roughness (Ra) and root
mean square roughness (Rq) values were calculated using Gwyddion software. Ra is the
arithmetic mean of the absolute profile of heights, with no distinction of peaks and
valleys, whereas Rq is the mean of squared absolute values of surface roughness profile
[315]. As the amplitude is squared in Rq calculation, it is more sensitive to peaks and
valleys than Ra.
3.2.3

Source of prefrontal cortical neurons

All mice were purchased from Australian BioResources (ABR), New South Wales and
housed at the University of Wollongong animal facility. The development of
heterozygous DISC1-LI and NRG1-KO mice were previously described [316, 317]. The
deletion in DISC1-LI mutation encompassed the region prior to exon 1 up to exon 3 and
a base pair deletion in exon 6, whereas NRG1-KO involves a mutation in most of exon
11 encoding the transmembrane domain and some of the intermediate downstream intron.
Wild-type (WT) C57BL/6J female mice were housed with one to two mice per cage,
whereas the heterozygous DISC1-LI or NRG1-KO male mice were kept separately with
one mouse per cage. To obtain pups with either WT or heterozygous DISC1-LI or NRG184

KO genotypes, the female WT mice were placed with either the male heterozygous
DISC1-LI or NRG1-KO mice for one week to encourage mating. All experimental
procedures were approved by the Animal Ethics Committee, University of Wollongong,
under AE16/05 and AE16/06, and complied with the “Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes”.
3.2.4

Genotyping mouse pups

On postnatal Day 0 to 3 (PN0-3), genotypes of the pups were determined via tail biopsy
and polymerase chain reaction (PCR). The DNA was extracted and amplified from the
tail tissue using REDExtract-N-Amp™ Tissue PCR Kit (Sigma-Aldrich). Briefly, an
extraction solution was prepared by mixing the Extraction Solution (Sigma-Aldrich) with
the Preparation Solution (Sigma-Aldrich) in a microcentrifuge tube. At the animal
facility, the tip (0.5-1 cm) of each pup’s tail was cut with scissors sterilised with 70%
ethanol (EtOH), then the tip was cut into 3-5 mm pieces and mixed with the extraction
solution prepared earlier. The tissue samples were incubated at RT for 15-20 mins before
incubating at 95oC for 5 mins. The Neutralization Solution B (Sigma-Aldrich) was added
to the tissue samples, then the solution from each sample was mixed with respective
primer mix prepared with Red Extract N-Amp PCR Ready Mix (Sigma-Aldrich) for a 20
µL PCR reaction. All primers were obtained from Sigma-Aldrich (Table 3.1). The
extracts were amplified using Mastercycler® Pro (Eppendorf) with the conditions listed
in Table 3.2.
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Table 3.1: List of primer sequences for pup genotyping procedure.
Name
Wild-type DISC1

Forward (5’ to 3’)
TTCCCTTTCTCACCCACACAGG

Reverse (5’ to 3’)
CTGGGTGTAGCTAATGGATCCG

DISC1-LI

TTCCCTTTCTCACCCACACAGG

TCCAGATAACTGCCGTCACTCC

Wild-type NRG1

AACAGCCTGACTGTTAACACC

TGCTGTCCATCTGCACGAGACTA

NRG1-KO

ATGAACTGCAGGACGAGGCA

GCCACAGTCGATGAATCCAG

Table 3.2: The thermal cycling conditions used for the amplification of mouse pup tail
extracts.

Step
Initial denaturation

Temperature
(oC)
Duration Cycles
94
3 min
Hold

Denaturation

94

1 min

Annealing

65

1 min

Extension

72

2 min

Final Extension

72

10 min

35

Hold

The products were visualised using gel electrophoresis. Briefly, an 8-well agarose gel
(1%

Agarose,

LE,

Analytical

Grade

(Promega)

in

1x

tris-acetate-

ethylenediaminetetraacetic acid (EDTA) buffer (Thermo Scientific) with 0.3 µg/mL
ethidium bromide (Bio-Rad)) was prepared. Samples diluted at 1:5 with Gel Loading Dye
(ThermoFisher Scientific) were allocated into each well at a volume of 15 µL. Direct
Load™ PCR 100 bp Low Ladder (Sigma-Aldrich) was used as the marker. The samples
were run on the Mini-Sub® Cell GT Cell electrophoresis system (Bio-Rad) at 96 V for
30 mins. Upon completion, the gel was imaged with Amersham Imager 680 Series (GE
Lifesciences).
3.2.5

Pup brain dissection, tissue processing and primary cell culture

Pups were sacrificed by decapitation, then the brain was exposed, collected from the skull,
and transferred into a sterile petri dish filled with cold dissecting solution (DS; Table 3.3).
The meninges and superficial blood vessels were removed from the brain, then the
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prefrontal cortex regions were dissected from both hemispheres and cut into
approximately 1 mm pieces. The pieces were dissolved in filtered enzyme solution (DS
containing 1.6 mg L-cysteine (Sigma-Aldrich), 1000 units papain (Sigma-Aldrich), 5 mM
DL-2-amino-5-phosphonopentanoic acid (APV; Sigma-Aldrich) and 0.1N sodium
hydroxide (NaOH)), then incubated at 37oC in a humidified 5% CO2 incubator for 30
mins. The cells were digested and washed in DS containing trypsin inhibitor from chicken
egg white (Sigma-Aldrich) and APV. For dissociation, the cortical cells were triturated
several times in warm Neurobasal Medium (NBM; Life Technologies) using a 1 mL
pipette tip within 5 mins, then filtered with a 40 µM cell strainer into a new 50 mL tube
containing warm NBGG (NBM containing 5% B27 (Life Technologies), 200 mM
glutamine (Life Technologies), 1% penicillin/streptomycin (Life Technologies), 18
mg/mL-NBM D-(+)-glucose (Sigma-Aldrich), 1:1000 5-fluoro-2’-deoxyuridine (SigmaAldrich)). The cells were seeded at a density of 5 x 105 cells/cm2 on PDL (SigmaAldrich)-coated Ppy chambers or TCP and maintained at 37oC in a humidified 5% CO2
incubator. The medium was replaced on day 3 (D3) or D4 of culture and maintained until
D6 or D8. The study design is outlined in Table 3.4.
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Table 3.3: Preparation of the dissecting solution (DS). The stock solution of Solution A
and Solution B were autoclaved then stored at 4oC until used for DS preparation. pH of
DS was adjusted to 7.4.
Solution A

DS

NaCl

80 g

Solution A

25 mL

KCl

4.0 g

Solution B

14 mL

Na2HPO4

0.2 g

D-(+)-glucose

3.0 g

KH2PO4

0.3 g

Sucrose

7.5 g

dH2O

To a final volume of

dH2O

To a final volume of 500

500 mL

mL

Solution B
HEPES

21 g

dH2O

To a final volume of
250 mL

NaCl, sodium chloride, KCl, potassium chloride, Na2HPO4, sodium phosphate dibasic, KH2PO4,
monopotassium phosphate, HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid),
dH2O, distilled water.

Table 3.4: Experimental setup for the culture of PFC neurons.
Assay

Cell Source
WT

Platform
Ppy/DBS vs Ppy/PSS vs Ppy/pTS

Immunocytochemistry DISC1-LI

qRT-PCR

Ppy/DBS vs Ppy/PSS vs Ppy/pTS

NRG1-KO

Ppy/DBS vs Ppy/PSS vs Ppy/pTS

WT vs DISC1-LI

TCP

WT vs NRG1-KO

TCP

WT vs DISC1-LI

Ppy/DBS

WT vs NRG1-KO

Ppy/DBS

WT

Ppy/DBS: Control vs ES

DISC1-LI

Ppy/DBS: Control vs ES

NRG1-KO

Ppy/DBS: Control vs ES

WT, wild-type, DISC1-LI, discrupted-in-schizophrenia-1 locus-impaired, NRG1-KO,
neuregulin 1 knockout, Ppy/DBS, polypyrrole doped with dodecylbenzenesulfonic acid,
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Ppy/PSS, polypyrrole doped with poly(sodium 4-styrene sulfonate), Ppy/pTS, polypyrrole
doped with toluene-4-sulfonic acid, TCP, tissue culture plastic, ES, electrical stimulation, qRTPCR, quantitative real-time polymerase chain reaction.

3.2.6

Electrical stimulation

For electrical stimulation (ES), the plastic lid on the chamber was replaced with a lid
incorporating platinum mesh electrodes for each well, then placed at 37oC in a humidified
5% CO2 incubator and connected to a DS8000 8-Channel Digital Simulator (World
Precision Instruments). ES was conducted through a two-electrode setup with an auxiliary
platinum mesh electrode contacting the medium and the gold-coated mylar coated with
Ppy/DBS as the working electrode. Based on established stimulation protocols [184, 186,
245-247], the cells were stimulated using biphasic current at a current density of 1
mA/cm2, 100 μs pulses with 20 μs interphase open circuit potential gap, and 3.78 ms short
circuit (250 Hz) for 8 hrs/day on D3, D4 and D5 of culture. Cells were fixed or collected
for experiments on D6. Images of the stimulation module were presented in Chapter 2,
Figure 2.4.
3.2.7

Immunocytochemistry

Cells were fixed in 3.7% paraformaldehyde (PFA, Fluka) in PBS at RT for 20 mins then
blocked and permeabilised with Blocking Buffer (BB: 5% goat serum (Sigma-Aldrich)
and 0.3% Triton-x-100 (Sigma-Aldrich) in PBS) at RT for 1 hr. The cells were then
incubated with rabbit anti-MAP2 (Cell Signalling Technology) diluted at 1:200 in 5%
goat serum/PBS overnight at 4oC. After incubation, cells were washed 3 times for 5 mins
with Washing Buffer (WB: 0.1% Triton-x-100 in PBS), then incubated with AlexaFluor®
goat 488 anti-rabbit (Invitrogen) and nuclear stain DAPI (ThermoFisher Scientific),
diluted at 1:1000; in BB for 2 hrs at RT. The wash step was repeated, then the polymer
films were carefully peeled off the chamber and cut into approximately 1x1 cm2 squares.
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Each square was mounted onto glass slides with ProLong® Gold antifade reagent
(Invitrogen). Imaging was performed with an AxioImager fluorescence microscope (Carl
Zeiss).
Image analysis was conducted with the Simple Neurite Tracer (FIJI) plugin in ImageJ
1.52d (NIH, USA). Figure 3.1 shows an example of the neurite traces performed on an
image of WT PFC neurons on Ppy/DBS. The Hessian-based analysis feature was enabled
to improve accuracy and efficiency of path-finding. Due to the complex nature of the
neurite outgrowths in the culture, only neurites with defined endpoints were traced.
Averages from 22 to 25 traces were then used for analysis.

Figure 3.1: Example of neurite length measurements of WT prefrontal cortical neurons
on Ppy/DBS, using FIJI Simple Neurite Tracer. Purple lines signified the paths traced
using Simple Neurite Tracer plugin on a MAP2-immunostained 8-bit image.

3.2.8

Quantitative real-time polymerase chain reaction (qRT-PCR)

3.2.8.1 RNA isolation
Cells were collected for RNA isolation using PureLink® RNA Mini Kit (Life
Technologies) on D6 or D8. The cells in culture plates or chambers were collected into
1.5 mL RNase-free tubes using a Lysis Buffer (Life Technologies) containing 1% 2mercaptoethanol (Bio-Rad). Each lysate was passed through a 21-gauge needle attached
to a 1 mL syringe, 5-10 times. 70% EtOH was added to each cell homogenate at 1:1, then
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vortexed to disperse any precipitates. The samples were transferred to separate spin
cartridges attached to collection tubes, then centrifuged at 12,000 x g for 15 secs at RT.
The flow-through was discarded and 700 µL Wash Buffer I (Life Technologies) was
added to each spin cartridge before centrifuging at 12,000 x g for 15 secs at RT. The flowthrough was discarded, then 500 µL Wash Buffer II (Life Technologies) diluted with
EtOH was added to each spin cartridge and the centrifugation step was repeated. The
wash with Wash Buffer II was repeated once more, then an additional spin at 12,000 x g
for 2 mins at RT was executed to dry the membranes with attached RNA. The spin
cartridge was inserted into a recovery tube, then 15-30 µL of RNase-free water was added
to the centre of each spin cartridge and incubated for 1 min at RT. To elute the RNA from
each membrane, the spin cartridges were centrifuged at 12,000 x g for 2 mins at RT.
The isolated RNA was treated with RQ1 RNase-free DNase (Promega). Briefly, each
RNA sample was mixed with the Reaction Buffer (Promega) and RQ1 RNase-free DNase
(Promega) diluted in nuclease-free water, in a 20 µL reaction. The mixture was incubated
at 37oC for 30 mins, then 1 µL of RQ1 DNase Stop Solution (Promega) was added to
terminate the reaction. Finally, the samples were incubated at 65oC in a C1000 Touch
Thermal Cycler (Bio-Rad) for 10 mins to inactivate the DNase.
3.2.8.2 Complementary DNA (cDNA) synthesis
The RNA concentration was measured using Thermo Scientific™ NanoDrop 2000
spectrophotometer (ThermoFisher Scientific), then 0.2 to 1 μg of RNA was used to
synthesise cDNA using Tetro™ cDNA Synthesis Kit (Bioline) in a 20 μL reaction.
Briefly, the priming premix consisting of random hexamers (40 µM), 10 mM
deoxynucleotide (dNTP) mix, 5x Reaction Buffer (Bioline), RiboSafe RNase inhibitor
(Bioline), and Tetro reverse transcriptase (Bioline), was prepared on ice. Then the premix
was mixed with each sample in an 8-strip tube (ThermoFisher Scientific), then incubated
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in a C1000 Touch Thermal Cycler at 25oC for 10 mins, 45oC for 30 mins, and 85oC for 5
mins.
3.2.8.3 RT-PCR
The cDNA samples were diluted to 5 ng/2 μL volume with autoclaved distilled water.
Primer mix was prepared by mixing SYBR® Select master mix for CFX (Life
Technologies) with primers to obtain a final primer concentration of 400 nM. Primers
listed in Table 3.5 were obtained from Sigma-Aldrich. 2 μL of diluted cDNA was
aliquoted into each well of 96-well plate then 18 μL of primer mix was added to respective
wells in triplicates or quadruplets. The plate was run on a CFX96™ Real-Time PCR
Detection System (Bio-Rad) with the conditions listed in Table 3.6. The melting curve
(65oC to 95oC with 0.5oC increment for 5 secs) was incorporated at the end of the cycle.
Experiments were run three times unless otherwise stated. For analysis, 2-ΔΔCq formula
was used [250]. Briefly, the quantification cycles (Cq) values from each sample were
normalised to their respective GAPDH levels. The samples were then normalised to the
control for each experiment to determine the relative expression.
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Table 3.5: List of primer sequences used in qRT-PCR for WT, NRG1-KO and DISC-LI
samples. The Sz candidate markers selected for investigation were glutamic acid
decarboxylase 67 (GAD67), gamma-aminobutyric acid type A (GABAA) receptor β2
subunit (GABRB2), Erb subunit β4 (ErbB4), nicotinic acetylcholine receptor subunit α7
(nAChR7), N-methyl-D-aspartate receptor (NMDAR) subunit 1 (NR1), glutamate
receptor 1 (GluR1), dopamine receptor D2 (DRD2) and tyrosine hydroxylase (TH).
Forward (5’ to 3’)

Name
GAD67

Reverse (5’ to 3’)

CATGGCGGCTCGGTACAAAGTA

AACAGTCGTGCCTGCGGTTGC

GABRB2 CAGCTGCCTGCATGATGGAC

CCGTGACTGCATTGTCATCG

ErbB4

CCCAGCGCTTCTCAGTCAGT

TGCGCAAGGCTCGGTACT

nAChR7

AACCATGCGCCGTAGGACA

CTCAGCCACAAGCAGCATGAA

NR1

AGACTCCAAGAGGGCTGA

GTACAAGGTTGGGTGAGTGA

GluR1

CCACAGCCAAACCCTATT

AGCCAACTGCCATGCTAT

DRD2

CAATGTGCTGGTGTGCATGG

CCACGGCATTACCAGTGTGG

TH

TGTTGGCTGACCGCACAT

GCCCCCAGAGATGCAAGTC

MAP2

GAAGAAACAGCTAATCTGCC

CTCTTGCTTATTCCATCAGTG

Dlg4

ATTGGAAAGGGGTAACTCAG

CTTGGTGATAAAGATGGATGG

GAPDH

GGCAAGTTCAACGGCACAGTC

TGGTGGTGAAGACGCCAGTAG

Table 3.6: The thermal cycling conditions used for PFC neurons quantitative real-time
polymerase chain reaction (qRT-PCR).
Step

Temperature (oC)

Duration

Cycles

UDG activation

50

2 min

Hold

AmpliTaq® DNA

95

2 min

Hold

95

15 sec

Anneal

58-60

15 sec

Extend

72

1 min

polymerase activation
Denature

UDG, Uracil-DNA-glycosylase.
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3.2.9

Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistics version 23. All values are
presented as mean ± standard error of the mean (SEM). The mean differences of neurite
lengths cultured on Ppy/DBS vs Ppy/PSS films were analysed using Student’s t-test.
Similarly, Student’s t-test was used to analyse mean differences of mRNA expression
between Ppy/DBS vs Ppy/PSS for WT, DISC1-LI, and NRG1-KO samples; WT vs
DISC1-LI samples; WT vs NRG1-KO samples; and electrically stimulated WT, DISC1LI, and NRG1-KO samples vs their respective non-electrically stimulated counterparts.
Levene’s test was used to test for homogeneity of variance and when significant (p<0.05),
the output derived from calculations with “equal variances not assumed” was selected for
the report.

3.3 Results
3.3.1

Characterisation of polymer films

3.3.1.1 AFM analysis
The surface topography of Ppy doped with DBS, PSS, or pTS films were characterised
using AFM. The mean roughness (Ra) and root mean square (RMS) roughness (Rq) were
calculated from height images of the films (Figure 3.2). It may be deduced that Ppy/DBS
films were generally smoother than Ppy/PSS and Ppy/pTS films, with Ppy/pTS being the
roughest surface (Figure 3.2; Table 3.7).
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Figure 3.2: Characterisation of polymer films by atomic force microscopy. Images show
surface topography of (A) Ppy/DBS, (B) Ppy/PSS and (C) Ppy/pTS films. Scale bars
represent 4 µm.
Table 3.7: The average mean roughness and root mean square (RMS) roughness of
Ppy/DBS, Ppy/PSS and Ppy/pTS.
Films

Mean Roughness (Ra, nm)

RMS roughness (Rq, nm)

Ppy/DBS

3.72

6.17

Ppy/PSS

6.36

8.12

Ppy/pTS

6.98

9.40

3.3.1.2 Compatibility of prefrontal cortical neurons with polymer films
Prefrontal cortical (PFC) neurons isolated from WT, DISC1-LI, and NRG1-KO mouse
pups were cultured on Ppy/DBS, Ppy/PSS, and Ppy/PTS films. Immunostaining on
cultures fixed at D8 showed considerable growth of WT, DISC-LI and NRG1-KO PFC
neurons on Ppy/DBS and Ppy/PSS (Figure 3.3). PFC neurons showed negligible growths
on Ppy/pTS when observed under the microscope; immunostaining of DISC1-LI PFC
neurons on Ppy/pTS showed no MAP2 staining (Appendix 2). Thus, WT and NRG1-KO
PFC neurons on Ppy/pTS were not immunostained. Due to the scarcity of cells on
Ppy/pTS,

only Ppy/DBS

and

Ppy/PSS
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were

chosen

for

further

analysis.

Figure 3.3: Immunocytochemistry of prefrontal cortical (PFC) neurons cultured on
Ppy/DBS and Ppy/PSS films. (A) WT, (B) DISC1-LI, and (C) NRG1-KO PFC neurons
were co-stained with DAPI (blue) and MAP2 (green). Scale bars represent 50 µm.

The neurite length of PFC neurons cultured on Ppy/DBS and Ppy/PSS were analysed with
Simple Neurite Tracer (FIJI) ImageJ 1.52d plugin (NIH Software). Student’s t-test
analyses showed greater neurite lengths (p<0.01) for WT and DISC1-LI PFC neurons
when cultured on Ppy/DBS (297±13.9 and 381±22.1 µm, respectively; Figure 3.4)
compared to Ppy/PSS (204±16.9 and 286±27.1 µm, respectively; Figure 3.4). There was
no significant difference (p>0.05) between the neurite lengths of NRG1-KO PFC neurons
cultured on Ppy/DBS or Ppy/PSS (188±11.7 or 191±15.3 µm, respectively; Figure 3.4).
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Figure 3.4: Neurite length analysis of prefrontal cortical neurons cultured on Ppy/DBS
and Ppy/PSS. Neurite lengths were measured with Simple Neurite Tracer (FIJI) using
MAP2-stained WT, DISC1-LI, and NRG1-KO images. Values are presented as the
mean of neurite lengths (µm) ± SEM (n = 22-25). **p<0.01, *** p<0.001 vs DBS; by
Student’s t-test.

The greater mean neurite length of DISC1-LI PFC neurons compared to WT may suggest
a reversal of the deficit by the polymer substrates. A similar observation has been reported
in another study, whereby NRG1-KO PFC neurons showed greater neurite outgrowths
than WT PFC neurons when cultured on Ppy/DBS or Ppy/PSS [188]. Nevertheless, since
another study investigating DISC-LI and NRG1-KO PFC neurons on Ppy/DBS did not
recapitulate this effect [183], and the effect was not observed in NRG1-KO PFC neurons
in the present study; the observation may not be a reproducible effect. Furthermore, the
technical limitations discussed in section 3.4.5 in this study hindered a matched
comparison between WT vs DISC1-LI or NRG1-KO in this experiment.
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3.3.1.3 MAP2 and Dlg4 mRNA expression
The mRNA from each sample was collected on D8 and analysed via qRT-PCR. MAP2
mRNA expression of WT and DISC1-LI PFC neurons were lower (p<0.01) when cultured
on Ppy/PSS films (0.040±0.023 and 0.624±0.034, respectively) in comparison with
Ppy/DBS films (Figure 3.5A, B). There was no statistically significant difference
(p>0.05) in MAP2 mRNA expression between NRG1-KO PFC neurons cultured on
Ppy/PSS (1.11±0.077) and those cultured on Ppy/DBS (Figure 3.5C).
The mRNA expression of Dlg4 (PSD-95), a post-synaptic marker; was additionally
analysed since the analyses of MAP2 mRNA expression and the neurite length of MAP2stained NRG1-KO PFC neurons on Ppy/DBS and Ppy/PSS films showed no difference,
in contrast to the observations in WT and DISC1-LI PFC neurons. The mRNA expression
of Dlg4 was generally lower in WT (0.648±0.028, p<0.01), DISC1-LI (0.774±0.232,
p>0.05) and NRG1-KO (0.790±0.063, p>0.05) PFC neurons cultured on Ppy/PSS films
compared to the PFC neurons cultured on Ppy/DBS films (Figure 3.5).
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Figure 3.5: MAP2 and Dlg4 mRNA expression in prefrontal cortical (PFC) neurons
cultured on Ppy/DBS and Ppy/PSS. MAP2 and Dlg4 mRNA expression in (A) WT, (B)
DISC1-LI, and (C) NRG1-KO PFC neurons were analysed with quantitative real-time
polymerase chain reaction. Values of Ppy/PSS are presented relative to Ppy/DBS (dashed
horizontal line) ± SEM (n= 3). **p<0.01, ***p<0.001 vs DBS; by Student’s t-test.

Although the mean neurite length of NRG1-KO PFC neurons cultured on Ppy/PSS films
was similar to those on Ppy/DBS, observations of NRG1-KO, WT, and DISC1-LI PFC
neuronal cultures under the microscope highlighted a more even distribution of neurons
on Ppy/DBS films, whereas Ppy/PSS films consisted of areas with dense cell distribution
and areas absent of cells, as illustrated in Figure 3.2.
Since ES is known to elicit different properties of the polymer films, the PFC neurons on
Ppy/DBS, Ppy/PSS, and Ppy/pTS were also electrically stimulated on D3, D4, and D5 for
8 hrs/day. By D6 however, the PFC neurons cultured on Ppy/PSS and Ppy/pTS had lifted
off the films. Taken together the current results, along with previous studies opting for
Ppy/DBS as the preferred substrate (referred to in Discussion section 3.4.1), DBS was
chosen as dopant for subsequent experiments in this chapter.
3.3.2

mRNA expression of Sz candidate markers in DISC1-LI PFC neurons

DISC1-LI PFC neurons were cultured on TCP or Ppy/DBS until D6 after reaching ~90%
confluency, then mRNA samples were collected for qRT-PCR analysis. A range of
markers associated with Sz were selected to investigate any change in expression in
DISC1-LI PFC neurons. The markers were first investigated in cells cultured on TCP to
test for alterations in a culture vessel absent of polymer substrate influences.
GluR1, GAD67, and DRD2 were not amplified in the qRT-PCR cycles, which may
indicate a design error of the primer sequences, whereby the primers may not target the
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specific transcript variants of the genes in the PFC neurons used in this study. mRNA
expression of ErbB4 (0.173±0.005), nAChR7 (0.386±0.057), GABRB2 (0.206±0.003),
and TH (0.061±0.022) were significantly reduced (p<0.01) in DISC1-LI compared to
those expressed in WT PFC neurons cultured on TCP (Figure 3.6A). Interestingly, the
mRNA expression of NR1 was significantly increased (p<0.001) in DISC1-LI
(1.71±0.012) compared to WT PFC neurons on TCP (Figure 3.6A).
The markers were then tested in PFC neurons cultured on Ppy/DBS films to investigate
the influence of polymer substrates on the downregulation of markers. The reduction
(p<0.05) of ErbB4 (0.710±0.021), nAChR7 (0.782±0.028), GABRB2 (0.669±0.020), and
TH (0.126±0.002) mRNA expression in DISC1-LI PFC neurons, compared to WT; were
generally maintained on Ppy/DBS (Figure 3.6B). In accordance with the results on TCP,
the mRNA expression of NR1 was also increased in DISC1-LI (2.01±0.060, p<0.001)
compared to WT (Figure 3.6B).
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Figure 3.6: Quantitative real-time polymerase chain reaction analysis of ErbB4,
nAChR7, GABRB2, TH and NR1 in DISC1-LI vs WT PFC neurons. PFC neurons were
cultured on (A) tissue culture plastic (TCP) or (B) Ppy/DBS films until D6. Expression
levels of markers in DISC1-LI samples are presented relative to WT (dashed horizontal
line) and presented as the means ± SEM (n = 4). *p<0.05, **p<0.01, ***p<0.001 vs
WT; by Student’s t-test.
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3.3.3

mRNA expression of Sz candidate markers in NRG1-KO PFC neurons

The experiment described in section 3.3.2 was repeated in NRG1-KO vs WT PFC
neurons. The qRT-PCR analyses of NRG1-KO vs WT PFC neurons cultured on TCP
demonstrated downregulation of ErbB4 (0.647±0.107, p<0.05) and nAChR7
(0.622±0.034, p<0.05) in NRG1-KO PFC neurons (Figure 3.7A). The mRNA expression
of GABRB2 (1.08±0.004), TH (1.10±0.060), and NR1 (0.967±0.064) in NRG1-KO were
comparable (p>0.05) to that of WT PFC neurons (Figure 3.7A).
Due to limited samples and time constraints, the analyses for NRG1-KO PFC neurons on
Ppy/DBS were narrowed to markers that were reduced on the TCP platform, which were
ErbB4 and nAChR7. The reduction of ErbB4 (0.749±0.021, p<0.01) and nAChR7
(0.591±0.022, p<0.01) in NRG1-KO vs WT PFC neurons was maintained in the Ppy/DBS
culture (Figure 3.7B).
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Figure 3.7: Quantitative real-time polymerase chain reaction analysis of ErbB4,
nAChR7, GABRB2, TH and NR1 in NRG1-KO vs WT PFC neurons. PFC neurons
were cultured on (A) tissue culture plastic (TCP) or (B) Ppy/DBS films until D6.
Expression of markers in NRG1-KO samples are presented relative to WT (dashed
horizontal line) and presented as the means ± SEM (n = 3). *p<0.05, **p<0.01 vs WT;
by Student’s t-test.
3.3.4

The effects of electrical stimulation on the levels of mRNA in DISC1-LI,
NRG1-KO and WT prefrontal cortical neurons

To investigate whether ES could reverse the downregulation of markers in DISC1-LI and
NRG1-KO PFC neurons, the samples were electrically stimulated for 8 hrs/day over a 3day period, then mRNA was extracted on D6 for qRT-PCR analyses. ES increased the
mRNA expression of nAChR7 (2.12±0.110, p<0.01), TH (1.49±0.046, p<0.05), and NR1
(5.98±0.331, p<0.001) in DISC1-LI PFC neurons vs their non-electrically stimulated
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controls (Figure 3.8A). In contrast, the mRNA expression of ErbB4 (0.574±0.069,
p<0.05) was reduced and negligible effect was observed on mRNA expression of
GABRB2 (0.968±0.092, p>0.05) in DISC1-LI ES PFC neurons when compared to
DISC1-LI non-electrically stimulated control (Figure 3.8A).
In NRG1-KO PFC neurons, ES increased the mRNA expression of nAChR7 (1.39±0.009,
p<0.01); however, no significant change was observed in the mRNA expression of ErbB4
(1.08±0.046, p>0.05; Figure 3.8B).

Figure 3.8: Quantitative real-time polymerase chain reaction analysis of the effects of
electrical stimulation (ES) in DISC1-LI and NRG1-KO PFC neurons. (A) Level of
ErbB4, nAChR7, GABRB2, TH, and NR1 in DISC1-LI ES are expressed relative to
DISC1-LI unstimulated control (dashed horizontal line) and presented as means ± SEM
(n = 3). (B) Levels of ErbB4 and nAChR7 in NRG1-KO ES are expressed relative to
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NRG1-KO unstimulated control (dashed horizontal line) and presented as means±SEM
(n = 3). *P<0.05, **P<0.01, ***<0.001 vs DISC1-LI or NRG1-KO control, by Student’s
t-test.

As a control, the effect of ES on the same markers was tested in WT PFC neurons. ES
increased the mRNA expression of nAChR7 (2.17±0.015, p<0.01), NR1 (8.25±0.172,
p<0.01) and GABRB2 (2.66±0.221, p<0.01) in WT PFC neurons (Figure 3.9). The
mRNA expression of TH (0.067±0.025, p<0.01) was significantly reduced, whereas no
significant effect was observed in ErbB4 (1.20±0.062, p>0.05) mRNA expression in
electrically stimulated WT PFC neurons when compared to WT unstimulated control
(Figure 3.9).

Figure 3.9: Quantitative real-time polymerase chain reaction analysis of the effects of
electrical stimulation (ES) on WT PFC neurons. Expression levels of ErbB4, nAChR7,
GABRB2, TH, and NR1 in WT ES are presented relative to WT unstimulated control
(dashed horizontal line) as means ± SEM (n = 3). **p<0.01 vs WT, by Student’s t-test.
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3.4 Discussion
This chapter was developed from a previous study conducted within the group whereby
the effect of Ppy/DBS-mediated ES was investigated in WT, DISC1-LI and NRG1-KO
PFC neurons through the assessment of neuronal markers. This study aimed to explore
Ppy dopants other than DBS and to examine the influence of ES on some of the common
Sz candidate genes in DISC1-LI and NRG1-KO PFC neurons.
3.4.1

Compatibility of prefrontal cortical neurons with polymer films

The tests that are often used to characterise polymer substrates include cyclic
voltammetry for electrochemical characterisation, contact angle measurement for film
hydrophobicity, and scanning electron microscopy or atomic force microscopy (AFM) to
observe the polymer film topography [186, 188, 308, 318]. To compare pTS and PSS
against DBS in this study, the surface roughness and cytocompatibility of each film were
investigated.
The AFM analyses of the film topographies showed Ppy/pTS had the roughest surface
compared to Ppy/DBS and Ppy/PSS, similar to findings in previous studies [186, 308]. In
contrast, other studies have found the surface of Ppy/PSS smoother than Ppy/DBS [188,
308]. The variation between these studies may be due to different synthesis parameters
used during electrochemical polymerisation. These parameters include the current
density, synthesis duration, and the concentration of dopant and monomer - factors known
to affect the roughness of the resultant polymers [309]. It could be expected that Ppy/DBS
may have shown the highest cell compatibility due to its smoother surface compared to
other substrates in this study. However, other studies have either shown positive
correlation or did not show a clear correlation between the roughness and
cytocompatibility of the films, which suggests surface roughness alone does not
determine the degree of cytocompatibility of the substrates [188, 308, 309]. An extensive
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film characterisation was not conducted in this study since it was mainly focused on
selecting the film with the best cytocompatibility with PFC neurons. For future studies,
further film characterisations could be performed to elucidate the factors that influence
the cytocompatibility of Ppy/DBS.
The superiority of Ppy/DBS over the other polymer films demonstrated in the present
study, is supported by other studies. Ppy/DBS was previously found to promote longer
neurite outgrowth of NRG1-KO and WT PFC neurons on Ppy/DBS compared to Ppy/PSS
[188]. Another study determined that Ppy/DBS provided better support for MAP2positive neurons in human neural stem cells compared to Ppy/pTS [186]. In primary
auditory neural explants, Ppy/DBS showed the highest average number of neurites per
explant compared to Ppy/pTS and Ppy/PSS [308]. Albeit a different cell type, human
primary osteoblasts were also shown to be more compatible with Ppy/DBS compared to
Ppy/pTS, with improved cell adhesion, morphology, cell number, and bone-specific gene
expression [309].
In the current work, attempts were made to investigate the cytocompatibility of each film
with the application of ES. The PFC neurons on substrates other than Ppy/DBS however,
did not survive when electrically stimulated. Williams and Doherty [175] have
demonstrated toxicity in L929 mouse fibroblast and neuro-2a neuroblastoma cell lines
when 1 mA ES was applied via Ppy for 96 hrs, suggesting certain ES conditions could be
toxic to certain type of cells. For future experiments, different ES parameters could be
employed such as lower current density or shorter ES duration to further investigate other
polymer substrates.
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3.4.2

mRNA expression of Sz candidate markers in DISC1-LI prefrontal cortical
neurons

A significant reduction of ErbB4, nAChr7, GABRB2, and TH was observed in DISC1LI PFC neurons when cultured on TCP and Ppy/DBS, compared to WT PFC neurons.
Orchestration of NRG1- ErbB4 signalling in vitro and in vivo by DISC1 has been reported
in two studies [296, 319]. The results however, are contradictory, in that Seshadri et al.
[296] showed increased NRG1-ErbB4 activation and upregulation of ErbB4 protein in a
DISC1-mutant, whereas Unda at al. [319] indicated a positive correlation between DISC1
and ErbB4 signalling. Unda et al. [319] proposed age as one of the sources for the
contradiction as Seshadri et al. [296] had used mature cortex whereas Unda et al. [319]
had used mouse embryonic brains. As this study used PFC neurons isolated from mouse
pups (PN0-3), it coincides with the findings from Unda et al. [319]. The downregulation
of nAChR7 is supported by another study which found a lower protein expression of
nAChR7 in the cortex of mutant DISC1 mice [320]. It is noted that there is a lack of
literature linking nAChR7 to DISC1 in Sz models.
The finding on GABRB2 expression is in accordance with another study that has
demonstrated the reduction of GABRB2 surface protein expression in DISC1-KD mouse
postnatal cortical neurons, an effect that was reversed with the rescue of DISC1 [321]. A
DISC1-KD rat PFC also showed a downregulation of gamma-aminobutyric acid type A
receptor (GABAAR) surface and synaptic cluster expression, which was increased with
an overexpression of DISC1 [322].
The downregulation of TH in this study also correlates with other studies. Western blot
and immunoreactivity showed a reduction of TH in the prefrontal cortex of DISC1-KD
mice compared to control mice [323]. The level of TH expression in the frontal cortex
was also decreased in transgenic mouse models with dominant-negative DISC1 compared
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to WT [324].
In contrast to other markers, NR1 was increased in DISC1-LI PFC neurons in the present
study. The findings of decreased NR1 levels in Sz patients have led to the emergence of
NR1 mutant Sz models [325-327]. However, overexpression of NR1 has recently been
reported in the prefrontal cortex of Sz patients [328]. Several studies have investigated
the relationship between DISC1 and N-methyl-D-aspartate receptor (NMDAR)
hypofunction in Sz models [329]. For instance, a study has found DISC1-KD significantly
increased NMDAR current density and NMDAR subunit expression in pyramidal
neurons in rat frontal cortex [330]. Dracheva et al. [328] suggested that NMDAR
hypofunction may have resulted from an altered NMDAR gene expression, thereby the
overexpression of NR1 observed in this study may be an abnormal expression that could
have led to a dysregulation of NMDAR transmission.
3.4.3

mRNA expression of sz candidate markers in NRG1-KO prefrontal cortical
neurons

Downregulation of ErbB4 and nAChr7 mRNA expression in NRG1-KO PFC neurons
were observed in the present study. Since ErbB4 is a receptor of NRG1, the reduction of
ErbB4 expression was expected in a NRG1-KO model. Furthermore, NRG1-ErbB4
signalling has been implicated as one of the Sz risk factors [331, 332]. The decrease in
nAChR7 correlates with a study that has demonstrated a downregulation of nAChR7
mRNA expression in a model with single-nucleotide polymorphisms in the 5’ region of
the NRG1 gene [333].
The changes in expression of GABRB2, TH, and NR1 in this study were not as
anticipated. An increase in GABRB2 mRNA and protein expression; mediated by NRG1ErbB4 activation; has been reported in rat cerebellar granule neurons [334, 335].
Furthermore, NRG1-ErbB4 enhanced depolarisation-induced GABA release in rat
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primary cortical neurons [336]. Therefore, the level of GABRB2 was expected to be
lowered in a NRG1-KO model, which was not observed in this study.
This study showed an increased level of TH mRNA expression in a downregulated NRG1
model. This is in accordance with a study demonstrating similar negative correlation,
where an overexpression of NRG1 in mouse frontal cortex significantly lowered the level
of TH protein [337]. Another study however, revealed that neonatal NRG1 treatment had
increased the protein level and enzyme activity of TH in developing frontal cortex
dopaminergic neurons; suggesting other factors may be involved in the NRG1-mediated
regulation of TH expression and activity [338].
There was no significant difference observed in the mRNA level of NR1 between WT
and NRG1-KO PFC neurons. Previous literature has shown a reduction of functional NR1
in NRG1-KO mice [317]. In contrast, another study showed NRG1 treatment may have
increased NR1 internalisation, leading to reduced whole-cell NMDA receptor currents in
pyramidal neurons of prefrontal cortex [339].
3.4.4

The effects of electrical stimulation on Sz candidate markers in DISC1-LI
and NRG1-KO prefrontal cortical neurons

The most consistent effect of ES across the different types of PFC neurons observed in
this study was the upregulation of nAChR7 and NR1. These two receptors could be linked
to the calcium (Ca2+) signalling pathways [340]. nAChR7 and NMDAR are both ligandgated Ca2+ ion channels, with high permeability to Ca2+. Neuronal function, development,
and survival rely on the levels of cytosolic Ca2+, where the optimum Ca2+ concentration
conveys neuroprotective effects, whereas an imbalance results in cell death. For instance,
over-activation of NMDAR mediated by Ca2+ can lead to neurotoxicity [340]. Induction
of Ca2+ signalling by ES has been reported in various cells [341-343], although to the
author’s knowledge, this has not been thoroughly investigated in mouse PFC neurons. A
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study has linked ES to NR1 and Ca2+ by observing an ES-mediated increase in NR1
mRNA expression in a mouse fibroblast cell line via Ca2+ signalling [344]. ES has also
been shown to modulate its effects via phosphoinositide-3-kinase (PI3K)/Akt signalling
pathways [345, 346], and both nAChR7 and NMDAR have been reported to modulate
neuroprotective effects via Ca2+-PI3K/Akt pathways [340]. This further supports the
association of these receptors with the ES mechanism of action. Figure 3.10 illustrates
possible Ca2+-PI3K/Akt pathways induced by ES through NMDAR and nAChR7.

Figure 3.10: Proposed electrical (ES) stimulation effect via calcium (Ca2+)-induced
pathways. ES may convey neuroprotective effects by inducing Ca2+/phosphoinositide 3kinase (PI3K)/Akt signalling pathways through N-methyl-D-aspartate (NMDA) and
nicotinic acetylcholine α7 (nAChR7) receptors.
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Another ES mechanism of action may involve the dopamine signalling pathways (Figure
3.11). ES of the prefrontal cortex has been reported to increase the level of dopamine in
nucleus accumbens [347, 348]. This increase in dopamine release may be modulated
through TH, an enzyme involved in dopamine synthesis; as the present study showed an
upregulation of TH mRNA expression in DISC1-LI PFC neurons when electrically
stimulated. Furthermore, a study of ventral medial prefrontal cortex deep brain
stimulation has shown an increase in the protein expression of TH [349]. It is worth
nothing that in the present study, ES significantly reduced the level of TH in WT PFC
neurons, suggesting a complex regulation of the TH level modulated by ES. Another
mechanism involved in dopamine release may be via nAChR7, as studies have shown a
modulation of dopamine release via nAChR7 in rat prefrontal cortex and in studies
investigating other species [350-352].

Figure 3.11: Proposed mechanisms of dopamine release induced by electrical stimulation
(ES). Increased dopamine release may be induced by ES through (i) an increase in
nicotinic acetylcholine α7 receptor (nAChR7), and/or (ii) an increase in tyrosine
hydroxylase (TH), an enzyme that catalyses the conversion of L-tyrosine to Ldihydroxyphenylalanine (L-DOPA), which is then converted into dopamine. Chemical
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structures were obtained from ChemSpider (CS) with the following CSIDs: L-tyrosine:
5833, L-DOPA: 18555822, and dopamine: 661[237].
3.4.5

Technical limitations

The study design in this chapter was limited by the inconsistent supply of cells. Initially,
the aim was to compare DISC-LI and NRG1-KO to WT in each experiment; however,
the experimental setup outlined in Table 3.4 was employed instead due to the following
reasons: i) genotyping and isolating cells from the mouse pups was labour intensive when
performed by only one person; thus, limiting the number of mouse pups that could be
used at one time, consequently reducing the number of cells available and the number of
experiments that could be performed in parallel; ii) the number of cells available for each
experiment was unpredictable due to variations in the number of pups and the genotype
ratio available, where in some cases, no pups were available 3 weeks after mating either
due to infertility or stillborn pups. Although the ideal ratio of the pups’ genotype was 1:2
(ie. 4 WT pups and 4 DISC-LI or NRG1-KO pups), there were cases of a batch of pups
with 1:8 genotype ratio, therefore experiments comparing WT vs DISC1-LI or NRG1KO were not always possible due to the disproportionate number of cells available; iii)
observation of the PFC neuron cell culture showed cells isolated on PN1 had different
growth profiles compared to cells isolated on PN3. Since the pups’ birthdates were
inconsistent, it was challenging to isolate on the same PN each time, hence the window
of isolation was set to PN0-3. Comparing WT PFC neurons PN1 on Ppy/DBS to mutant
PFC neurons PN3 on Ppy/DBS may not be an equal comparison. Due to these reasons,
the study was designed to allow matched comparisons and to limit variations.
Another limitation was the heterogeneity of the sample populations. Note that not all
literature cited in this chapter focused on the prefrontal cortex and that the findings in one
brain region may not always translate to other brain regions, as each region consists of
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different population of neurons and neurotransmitters. Although this study narrowed the
area of interest to PFC neurons, this is still a heterogeneous population of cells which may
consist of GABAergic, dopaminergic, cholinergic, and glutamatergic neurons. The
proportion of these neurons in each cell population isolated from the prefrontal cortex of
the mouse pups may differ from one another and these variations in populations may
ultimately have an influence on the data.
3.4.6

Conclusions and future directions

Sz candidate genes nAChR7 and ErbB4 were both reduced in DISC1-LI and NRG1-KO
PFC neurons compared to the WT PFC neurons. In addition, the mRNA expression of
GABRB2 and TH were reduced, whereas NR1 was increased in DISC1-LI PFC neurons
compared to WT. ES consistently elevated the mRNA expression of nAChR7 and NR1
across the different samples, which may be associated with the induction of Ca2+-PI3KAkt signalling pathways; warranting further investigation into the association between ES
and Ca2+-PI3K-Akt signalling pathways. TH and nAChR7 may also be involved in ESmediated dopamine release in the brain.
Due to its capacity and ease in analysing a variety of targets at one time, qRT-PCR was
utilised in this study to narrow down the signalling pathways to be explored further. As
such, future studies could investigate the effects of ES on the protein expression of
nAChR7, NMDAR, TH, and the levels of dopamine. Another analysis that could be
studied using these in vitro models is migration assays; cell migration deficits have been
associated with DISC1 and NRG1 mutant cells, and ES has been shown to induce cell
migration [302, 353, 354].
As low levels of nAChR7 and NR1 have been implicated in Sz pathophysiology, the
upregulation of these receptors by ES may support the use of ES as a treatment. In a model
with NR1 overexpression however, such as the DISC1-LI model demonstrated in this
114

study, the question arises as to whether ES application conveys neuroprotective or
neurotoxic effects in the long run. Therefore, it would be worthwhile to further explore
the role of ES in nAChR7 and NR1 activation through the regulation of Ca2+ in PFC
neurons over longer time periods.
It has been postulated that dopamine transmission is hyperactive in the mesolimbic brain
areas and hypoactive in the prefrontal cortex of Sz patients [355]. In this case, the
elevation of dopamine level in the PFC neurons by ES may counteract the hypoactive
dopamine transmission in Sz patients. The involvement of nAChR7 and TH in the
dopamine transmission associated with ES, could also be further elucidated in future
studies.
The mouse model has shown its value as a disease model in revealing potential pathways
and networks involved in a mechanism of action; however, a model that provides better
access to a homogenous cell population may be more effective in elucidating the specific
role of each type of neuron in disease pathophysiology and consequently, the effects of
treatments on each subset of neurons and neurotransmitters.
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Chapter 4: Proof-of-concept culture, neural induction and
electrical stimulation of induced pluripotent stem cells for
patient-specific cell-based modelling of schizophrenia

4.1 Introduction
As demonstrated in Chapters 2 and 3, different cell models have their own advantages
and limitations. The aim of the present chapter is to show proof-of-concept of using
human induced pluripotent stem cells (iPSC) to model schizophrenia (Sz) towards
improving on, and complementing models described in preceding chapters.
iPSC from patients offer a new and unprecedented opportunity to determine the effects
of genetic risk factors on the cellular phenotype including insight to cellular etiopathology
and developmental origins of Sz and related disorders [356]. The iPSC can also
complement and improve in vivo mouse modelling where transplanted iPSC-derived
neural cells may reveal relevant cellular phenotypes through their interaction with other
systems within an intact organism for a better representation of the disease. Studying the
effects of drugs such as PCP on cells with Sz genetic background would indubitably yield
a relevant and significant outcome. In addition, the self-renewal capacity of iPSC can
overcome the limited lifespan of primary mouse neurons during culture as described in
Chapter 3. Moreover, the pluripotency of iPSC will allow the study of different specific
brain regions and neural cell-types from a single source. An overview of iPSC disease
modelling is provided in Figure 4.1.
Pluripotency is commonly defined by a cell’s capability to differentiate into three germ
layers in vitro or in vivo and is supported (but not proven) by expression of stem cell
markers such as OCT4, NANOG, Tra-1-60, Tra-1-81 and SSEA4 [357]. Mouse or human
fibroblast feeders (MEFs or HFFs respectively) are conventionally co-cultured with iPSC
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and are believed to secrete factors that are essential for iPSC maintenance. Importantly,
the feeder cells are irradiated or treated with mitomycin C (MMC) so that they can no
longer divide and outgrow the stem cells. As the field is advancing towards human clinical
application however, feeder-free and xeno-free systems of cell culture are preferential
since animal products carry the risk of immune response induction in humans and the
transfer of animal pathogens [358]. In addition, multicellular systems pose greater
difficulty for regulatory approval. Although HFFs are used in place of MEFs, they are
laborious and costly to prepare in addition to yielding variable efficiencies across
different batches [359]. Recent innovations have led to the use of various coating
substrates to replace feeders such as Matrigel™, poly-D-lysine, and poly-Lornithine/laminin or vitronectin [359].

Figure 4.1: Patient-specific iPSC derivation and differentiation for disease modelling.
iPSC derived from a patients’ keratinocyte, fibroblast or blood cells are differentiated
into intermediate neural progenitor cells and mature neurons for a “systems” approach
to investigate candidate genes, disease progression in in vitro or in vivo, and gene x
environment (ie. drugs) interaction.
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iPSC can develop into various cell types through spontaneous or directed
differentiation. Conventional approaches to neural differentiation relevant to Sz have
therefore involved manipulating cell culture media to either select out cells of interest or
induce iPSC to mixed or subtype specific neural cells. Furthermore, cells are often
differentiated firstly into a heterogeneous population of neural progenitor cells (NPC)
followed by further induction to end-stage neural cells [125, 133, 360].
More recently, other features of stem cell culture have been identified as important to
differentiation, bolstering efforts to develop more controllable and better-defined
systems. For instance, there are various reports of enhanced neural differentiation and
proliferation of neural stem cells and iPSC-derived NPC through the application of
biomaterial-based scaffolds [361-364]. Furthermore, chemical, biological, mechanical
and electrical properties of these materials are currently being investigated to create an
environment optimal for stem cell proliferation, differentiation and function [365].
As described in Chapter 1, modelling Sz with iPSC is advancing at a rapid pace with
studies investigating the effects of electrical stimulation (ES) on stem cell differentiation.
However, to the author’s knowledge, electroactive Sz iPSC-based modelling has not yet
been reported. This chapter describes the processes involved in establishing and
optimising iPSC culture including the transition of iPSC from HFF to simplified feederfree culture conditions, iPSC differentiation to NPC, characterisation of iPSC and neural
derivatives, and a preliminary ES experiment to show compatibility and test for effects
on the survival and differentiation of iPSC-NPC. Importantly, iPSC culture and
differentiation studies involved the use of two biologically independent cell lines, namely
JMC1i-SS9 (a healthy donor cell line) and JMC3i-SZ1 (a Sz patient donor cell line).
However, due to time constraints, ES studies were limited to JMCli-SS9. Also, the
principle aim of ES studies was to test the priori hypothesis that ES will increase survival
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and advance the differentiation of iPSC-NPC to fully differentiated neuronal cell cultures
as a potential platform for future modelling; being relevant to neurodevelopment and
applicable to neurodevelopmental disorders such as Sz. Finally, JMC3i-SZ1 iPSC line
was included for the purpose of initiating characterisation of the line for future in vitro
disease modelling. Although such modelling was planned for the present project,
unfortunately due to time constraints work did not progress as far, but nevertheless
provided important baseline data needed to qualify cells for modelling.

4.2 Materials and methods
4.2.1

Human fibroblast feeder (HFF) culture and mitotic inactivation by gamma
irradiation

Human fibroblasts used as feeder cells (HFF-1) were obtained from American Type
Culture Collection ATCC® (SCRC-1041™). The cells were cultured in human fibroblast
feeder (HFF) medium (11% foetal bovine serum (FBS; Life Technologies) in low glucose
Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies)) and expanded in T175
flasks until confluent. The medium was replaced every other day. For irradiation, 10 x
T175 flasks were prepared at a time. After reaching ~90% confluency, the cells were
dissociated using TrypLE™ Select (Life Technologies), then collected in 2 x 50 mL
Falcon tubes (5 x T175 flasks pooled into 1 x 50 mL tube), followed by centrifugation at
300 x g for 5 mins. Supernatant was removed and the cells in each tube were resuspended
in 45 mL of fresh HFF medium. The 50 mL tubes were contained in a resealable plastic
bag and placed in an ice-filled esky for transportation to the irradiation facility. An aliquot
of the cells was set aside as a non-irradiated HFF control for BrdU analysis.
The cells were gamma(γ)-irradiated at 2500 rad (25 Gy) at approximately 340 rads/minute
using the irradiation facility at Australian Nuclear Science and Technology Organisation
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(ANSTO), New South Wales. Aliquots of the γ-irradiated cells were used for BrdU
analysis and the remaining cells were then stored at -80oC until further use.
4.2.2

5-bromo-2′-deoxyuridine (BrdU) analysis of human fibroblast feeders

After γ-irradiation, 7 x 103 of γ-irradiated and non-irradiated fibroblast cells were seeded
into each well of a 96-well plate (100 µL/well) in triplicates and left overnight at 37 °C
in a humidified 5% CO2 incubator for 5-bromo-2′-deoxyuridine (BrdU) analysis to
confirm mitotic inactivation of the γ-irradiated cells. The assay was performed on the
following day using a Cell Proliferation ELISA BrdU colorimetric kit (Roche
Diagnostics) in accordance with the manufacturer’s protocol. Briefly, 10 µL of BrdU
labelling solution (BrdU labelling reagent (Roche Diagnostics) diluted at 1:100 in HFF
culture medium) was added to each well followed by a 2-hr incubation at 37 °C in a
humidified 5% CO2 incubator. The labelling was removed by tapping off the solution,
then each sample was incubated with 200 µL/well of FixDenat (Roche Diagnostics) at
RT for 30 mins. After removing the FixDenat, 100 µL/well of anti-BrdU-POD working
solution (Roche Diagnostics) was added to each well for a 90-min incubation at RT. The
wells were rinsed three times with 300 µL/well of the Washing solution (Roche
Diagnostics), then 100 µL/well of the Substrate solution (Roche Diagnostics) were added
to the plate, followed by 5-30 min incubation at RT. The absorbance of the samples was
measured using the FLUOstar Omega Microplate Reader (BMG Labtech) with 370 nm
filter and reference wavelength of 492 nm.
4.2.3

iPSC culture

iPSC lines JMC1i-SS9 and JMC3i-SZ1, previously derived in the laboratory of Associate
Professor Jeremy Crook (Intelligent Polymer Research Institute, University of
Wollongong); were employed for the present project. Both lines were approved for use
by the University of Wollongong’s Human Research Ethics Committee (HE14/049).
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4.2.3.1 Feeder-based iPSC culture
γ-irradiated HFF were seeded at a density of 2.5 x 105 cells/well in 6-well plates followed
by incubation overnight at 37 °C in a humidified 5% CO2 incubator. The following day,
iPSC were seeded onto the HFF and maintained in iPSC culture medium comprising 78%
knockout DMEM (KO-DMEM; Life Technologies) supplemented with 20% KO-serum
replacement (Life Technologies), 1% L-glutamine (Life Technologies), 1 % minimum
essential medium (MEM) non-essential amino acids (NEAA; Life Technologies) and 50
ng/mL basic fibroblast growth factor (bFGF; Invitrogen). The medium was changed every
other day with washes using DMEM:F12 (50% DMEM + 50% Ham’s F12 (Invitrogen)).
Mechanical passaging was performed using a Stem Cell Cutting Tool (Vitrolife) for early
passages through to bulk enzymatic passaging using 1 mg/mL collagenase type IV (Life
Technologies).
4.2.3.2 Feeder-independent iPSC culture
Six-well culture plates were coated with Poly-L-Ornithin (PLO; Sigma-Aldrich)/laminin
(Life Technologies) or Matrigel™ (In Vitro Technologies) and then stored under sterile
conditions at 4oC overnight or at RT for at least 1 hr. iPSC seeding and culture, including
passaging were performed as described for feeder-based iPSC culture. In addition, 0.5
mM ethylenediaminetetraacetic acid (EDTA; Ajax Finechem) was evaluated for
enzymatic passaging.
4.2.4

iPSC differentiation to neural progenitor cell (NPC) cultures

iPSC were seeded as single cells (after passaging with TrypLE™ Select in a 6-well plate,
coated with Matrigel™ or poly-L-ornithine (PLO)/laminin (Life Technologies)), at 1.5 x
105 cells/well (~1.6x104 cells/cm2). The cells were seeded in STEMdiff™ Neural
Induction Medium (NIM; STEMCELL Technologies) with the addition of 10 µM Rhoassociated Coil Kinase inhibitor (Y-27632; STEMCELL Technologies) on day 0 of each
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passage. The cells were maintained for 3-4 passages using NIM with medium changes
every other day for initial neural induction before advancing to STEMdiff™ Neural
Progenitor Medium (STEMCELL Technologies) to support proliferation and
maintenance of progenitors. Cells were collected or fixed at various time points during
differentiation for characterisation by quantitative(q)RT-PCR, immunocytochemistry and
flow cytometry.
4.2.5

Preparation of conductive polymer films

Polymer films for the ES of stem cells were prepared as described by Stewart et al. [186].
Briefly, galvanostatic polymerisation of aqueous pyrrole solution (0.2 M) was performed
using an eDAQ EA161 potentiostat at a current density of 0.10 mA/cm2 for 10 mins with
dodecylbenzene sulfonic acid (DBS; 0.05 M) as the dopant. Pyrrole and DBS were
obtained from Merck Millipore and Sigma-Aldrich, respectively. All pyrrole and dopant
solutions were prepared with Milli-Q water. The deposition of polymer onto gold-coated
mylar (Solutia Performance Films) was performed in a standard three-electrode
electrochemical cell with gold-coated mylar as the working electrode, platinum wire mesh
as the counter electrode, and Ag/AgCl as the reference electrode. After polymerisation,
the films were rinsed with dH2O then dried with N2.
4.2.6

iPSC-NPC culture and differentiation with electrical stimulation

Custom cell culture chamber and stimulation module (presented in Chapter 2: Figures 2.3
and 2.4) were prepared by gluing clear bottomless polystyrene chambers onto Ppy/DBS
films using silicon adhesive followed by overnight curing at RT. The Ppy/DBS-based
chambers were sterilised with 70% ethanol (EtOH) for 20 mins and air-dried in a
Biosafety Cabinet (BSC). To reduce toxicity from the glue and for sterility testing, 1
mL/well of cell culture medium was added to the chambers, which were then covered
with a plastic lid. The chambers were contained within a deep petri dish (25 x 100 mm)
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and left overnight at 37oC in a humidified 5% CO2 incubator. Prior to coating, the medium
was removed from the chambers, followed by rinsing with sterile phosphate buffered
solution (PBS). The Ppy/DBS films within the chambers were subsequently coated with
Matrigel™ onto which iPSC were seeded and incubated overnight in NIM + Y-27632 at
37oC in a humidified 5% CO2. For ES, the plastic lid on the chamber was replaced with a
lid incorporating platinum mesh electrodes for each well, then connected to a DS8000 8Channel Digital Simulator (World Precision Instruments) and placed at 37oC in a
humidified 5% CO2 incubator. Following 2 days of differentiation, ES was conducted
with a pulsed biphasic current at a current density of 1 mA/cm2, 100 µs pulses with 20 µs
interphase open circuit potential gap, and 3.78 ms short circuit (250 Hz) based on
established stimulation protocols [184, 186, 245-247]. After ES, the cells were fixed for
further analysis.
4.2.7

Immunocytochemistry

Cells were fixed in 3.7% paraformaldehyde (PFA, Fluka) in PBS at RT for 20 mins then
blocked and permeabilised with Blocking Buffer (BB: 5% goat serum and 0.3% Tritonx-100 (Sigma-Aldrich) in PBS) at RT for 1 hr. The cells were then incubated with primary
antibodies diluted in 5% goat serum/PBS overnight at 4oC. After incubation, cells were
washed 3 times for 5 mins with Washing Buffer (WB: 0.1% Triton-x-100 in PBS)
followed by incubation with secondary antibodies diluted in BB for 2 hrs at RT. For
visualization, cells were stained with 1:3000 Hoechst33342 (Life Technologies) and
mounted with ProLong® Gold Antifade reagent (Life Technologies). Imaging was
performed using a Leica TCS SP5 II Confocal microscope (Leica Microsystems). The
antibodies with dilutions used are outlined in Table 4.1.
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Table 4.1: List of primary and secondary antibodies used for immunocytochemistry of
pluripotent and differentiating iPSC.

4.2.8

Antibody

Dilution Source

Mouse anti-OCT4

1:200

STEMCELL Technologies

Mouse anti-Tra-1-60

1:200

Millipore

Mouse anti-Tra-1-81

1:200

Millipore

Mouse anti-SSEA4

1:100

STEMCELL Technologies

Mouse anti-human Nestin

1:200

STEMCELL Technologies

Rabbit anti-Pax6

1:200

Sigma-Aldrich

Rabbit anti-Sox2

1:200

Millipore

Mouse anti-BIII-tubulin, Tuj1

1:1000

Covance

Rabbit anti-GFAP

1:1000

Millipore

Chicken anti-Vimentin

1:1000

Millipore

AlexaFluor® goat 488 or 594 anti-mouse

1:1000

Invitrogen

AlexaFluor® goat 488 or 594 anti-rabbit

1:1000

Invitrogen

AlexaFluor® goat 488 anti-chicken

1:1000

Invitrogen

AlexaFluor® donkey 488 anti-rabbit

1:1000

Invitrogen

AlexaFluor® donkey 594 anti-mouse

1:1000

Invitrogen

Flow cytometry

Cells were dissociated using TrypLE™ Select (Life Technologies) for 5 mins, washed in
DMEM:F12 and centrifuged at 300 x g for 5 mins before removing the supernatant and
fixing with 3.7% PFA in PBS on ice for 10 mins. Cells were washed with WB followed
by centrifugation at 300 x g for 5 mins. The cells were then blocked and permeabilized
with BB for 30 mins on ice followed by incubation with primary antibodies diluted in 5%
goat serum/PBS for 30 mins on ice. After a second wash, cells were incubated in
secondary antibodies in the dark for 30 mins on ice. For conjugated antibodies, only one
antibody incubation step was required. The wash protocol was repeated and cells were
resuspended in 2% FBS:PBS before analysing the samples through a BD Accuri™ C6
Flow Cytometer (Becton Dickinson (BD) Biosciences). The antibodies and dilutions used
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are outlined in Table 4.2.

Table 4.2: List of primary and secondary antibodies used for flow cytometry of
pluripotent and differentiating iPSC.
Antibody

Dilution Source

Mouse anti-OCT4

1:1000

STEMCELL Technologies

Mouse anti-Tra-1-60

1:100

Millipore

Mouse anti-Tra-1-81

1:100

Millipore

Mouse anti-SSEA4

1:1000

STEMCELL Technologies

Alexa Fluor® 488 mouse anti-GFAP conjugated

1:20

BD Biosciences

Alexa Fluor® 647 mouse anti-Nestin conjugated

1:20

BD Biosciences

1:20

BD Biosciences

conjugated

1:20

BD Biosciences

Alexa Fluor® 488 mouse anti-IgG2b

1:20

BD Biosciences

Alexa Fluor® 488 mouse anti-IgG1K

1:20

BD Biosciences

Alexa Fluor® 647 mouse anti-IgG1K

1:20

BD Biosciences

Alexa Fluor® 488 goat anti-mouse

1:1000

Invitrogen

Alexa Fluor® 647 mouse anti-βIII-tubulin
conjugated
Alexa Fluor® 488 mouse anti-sox2 (Millipore)

4.2.9

Quantitative real-time polymerase chain reaction (qRT-PCR)

Differentiating cells were seeded at 6 x 104 cells/well in 6-well culture plate for cell
collection at various time points. Cells were passaged using TrypLE™ Select (Life
Technologies) and then centrifuged at 190 x g for 3 mins. Supernatant was removed, and
the cell pellet was resuspended in 0.5 mL or 1 mL TRIzol (ThermoFisher Scientific),
depending on cell density. Approximately, 1 mL TRIzol was used for ≥1x106 cells. The
cells were immediately stored at -80oC until further use.
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4.2.9.1 RNA Isolation
Cells were fluxed by pipetting up and down several times. Lysate was centrifuged at
12,000 x g for 10 mins at 4oC and the supernatant was transferred to fresh tubes. The
samples were incubated at RT for 5 mins to allow complete dissociation of the
nucleoprotein complex, then 0.2 mL chloroform/mL of TRIzol-used was added to each
sample. Samples were vortexed for ~15 seconds and then incubated at RT for ~15 mins
before centrifugation at 12,000 x g for 15 mins at 4oC. The colourless upper aqueous
phase (RNA) was transferred to fresh tubes and 0.5 mL 2-propranol (Sigma-Aldrich)/ml
of TRIzol-used was added to each sample and incubated at RT for 10 mins. The samples
were centrifuged at 12,000 x g for 10 mins at 4oC. Supernatant was removed, and the
RNA pellet washed with 75% EtOH (1 mL/mL of TRIzol-used). Samples were vortexed
then centrifuged at 7,500 x g for 5 mins at 5oC. The wash was discarded, and the RNA
pellet was air-dried for ~30 mins at RT. RNA was then resuspended in 30 µL RNAsefree, nuclease-free water. For purification with DNAse, DNase I Amplification Grade
(Sigma-Aldrich) was used according to the manufacturer’s instructions. RNA
concentration was measured using a NanoDrop 2000 Spectrophotometer (Thermo
Scientific).
4.2.9.2 cDNA synthesis and RT-PCR
GoTaq® 2-Step RT-qPCR kit (Promega) was used for cDNA synthesis and RT-PCR.
Briefly, RNA samples were mixed with reverse transcription primers, then incubated at
70oC for 5 mins, followed by an incubation at 4oC while GoScript™ reaction mix was
being prepared for each sample. The GoScript™ reaction mix and RNA reverse
transcription mix were then added to an 8-strip tube then ran on C1000 Touch Thermal
Cycler (Bio-Rad) at 25oC for 5 mins, 42oC for 1 hr, then 72oC for 15 mins. GoTaq® qPCR
reaction mix was prepared with GoTaq® qPCR master mix and respective primers (Table
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4.3). The GoTaq® qPCR reaction mix was then added to synthesised cDNA (5-10 ng/20
µL reaction) in a 96-well microplate and ran on CFX96™ Real-Time PCR detection
system (Bio-Rad) with the conditions listed in Table 4.4. The melting curve (65oC to 95oC
with 0.5oC increment for 5 secs) was incorporated at the end of the cycle.
Experiments were run three times unless otherwise stated. For analysis, 2-ΔΔCq formula
was used [250]. Briefly, the quantification cycle (Cq) values from each sample were
normalised to their respective GAPDH, a reference gene. The samples were then
normalised to the control of each experiment for a relative expression.

Table 4.3: List of primers used for quantitative polymerase chain reaction (qRT-PCR)
of differentiating iPSC.
Name

Forward (5’ to 3’)

Reverse (5’ to 3’)

OCT4

CAA TTT GCC AAG CTC CTG A

CAA TTT GCC AAG CTC CTG A

PAX6

CCG AGA GTA GCG ACT CCA G

CTT CCG GTC TGC CCG TTC

βIII Tubulin

GCG GAT CAG CGT CTA CTA CA ATG TCC AAA GGC CCC TGA G

Nestin

GCC CTG ACC ACT CCA GTT TA

GGA GTC CTG GAT TTC CTT CC

GAPDH

TGC ACC ACC AAC TGC TTA GC

GGC ATG GAC TGT GGT CAT GAG

Table 4.4: The thermal cycling conditions used for differentiating iPSC quantitative
real-time polymerase chain reaction (qRT-PCR).

Step

Temperature
(oC)

Duration Cycles

GoTaq® Hot Start
Polymerase
Activation
Denaturation
Annealing/Extension

1
95

2 min

95

15 sec

60

1 min
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4.2.10 Statistical Analysis
All values are presented as mean ± standard error of the mean (SEM), unless otherwise
specified. Statistical analyses were performed using IBM SPSS Statistics version 23.
Specifically, the mean difference between BrdU incorporation of γ-irradiated cells and
non-irradiated cells was analysed using Student’s t-test. Levene’s test was used to test for
homogeneity of variance. The time point differences of the differentiating mRNA in NPC
JMC1I-SS9 was assessed by one-way ANOVA with Tukey Honest Significance
Difference (HSD) post-hoc test. When Levene’s test was significant (p<0.05), Welch and
Brown-Forsythe tests were additionally performed to confirm the statistical significance.

4.3 Results
4.3.1

Mitotic inactivation of human fibroblast feeders (HFF)

BrdU-based analysis of the effect of γ-irradiation on HFFs demonstrated statistically
significant (p<0.001) suppression of cell mitotic activity (0.028±0.004 BrdU
incorporation)

compared

to

non-irradiated

HFF

control

(0.405±0.022

BrdU

incorporation; Figure 4.2). Moreover, qualitative assessment by bright-field microscopy
also showed non-proliferating HFF cell cultures (Figure 4.3). Irradiated cells were
subsequently employed for feeder-based iPSC culture.
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Figure 4.2: BrdU analysis of γ-irradiated human fibroblast feeders (HFF) and nonirradiated HFF controls. Mitotic activity of γ-irradiated HFF was reduced by >90%
compared to non-irradiated control. Values are represented as the mean absorbance
(A370 nm – A492 nm) of BrdU incorporation ± SEM (n=3). *** p<0.001 by Student’s ttest.

Figure 4.3: Bright field image of γ-irradiated human fibroblast feeders (HFFs). The
HFFs were exposed to γ-irradiation at 25 Gy, then seeded onto 6-well tissue culture
plates.
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4.3.2

Optimisation of iPSC (JMC1i-SS9 and JMC3i-SZ1 lines) culture

Working stocks of iPSC were prepared from quality-controlled master stocks stored in
liquid nitrogen. Frozen vials of cells were thawed and initially seeded onto HFF in 6-well
culture plates. The cell cultures were monitored daily by bright field microscopy for
evidence of spontaneous differentiation. Any differentiated material was carefully
removed to avoid widespread differentiation and ensure high-quality undifferentiated
iPSC cultures. To increase the efficiency of locating and removing differentiated cells,
the under surface of each well of a 6-well plate was divided into eight sections with a
marker pen as shown in Figure 4.4. The differentiated areas were located and again
indicated by pen.

Figure 4.4:

Schematic of a 6-well tissue culture plate marked for identifying

spontaneously differentiated iPSC. The under surface of each well was divided into 8
sections (blue lines) using a marker pen ahead of similarly marking zones of differentiated
cells.

Removal of differentiated cells was initially performed by using a pipette tip on a pipette
to scrape and aspirate the colonies. However, a more optimal method involved the use of
a glass pipette attached to a vacuum aspiration/filtration system (Millipore) where the
differentiated colonies were removed from the culture in a single step. This method was
found to be more time-efficient and ensured complete removal of the differentiated
colonies.
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For mechanical passaging during the initial phase of establishing an iPSC culture, a Stem
Cell Cutting Tool (Vitrolife) was used to ensure high quality iPSC colonies. Once
established, bulk passaging methods were employed, including enzymatic or nonenzymatic passaging techniques. Upon reaching a stable proliferation rate and
maintenance of pluripotency for at least 4-5 passages on HFF (Figure 4.5), the iPSC were
transitioned to feeder-free Matrigel™-coated 6-well plates in mTESR medium. Passaging
of feeder-free cultures with 0.5 mM EDTA produced less spontaneously differentiated
colonies compared to using collagenase type IV (Figure 4.5 & Figure 4.6).

Figure 4.5: Bright field images of JMC1i-SS9 and JMC3i-SZ1 iPSC under optimised
culture conditions. Images show (A) JMC1i-SS9 and (B) FB3JMC3i-SZ1 colonies under
feeder-dependent culture (top panel) and feeder-independent culture (bottom panel).
Passaging was performed with 0.5 mM EDTA. Scale bars represent 200 µm.
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Figure 4.6: Bright field images of spontaneous differentiation of JMC1i-SS9 iPSC. The
images show widespread spontaneous differentiation of cultures on Matrigel. Passaging
was performed with collagenase type IV. Scale bars represent 200 µm.
4.3.3

Characterisation of iPSC JMC1i-SS9 and JMC3i-SZ1 culture and
differentiation

Confirmation of iPSC status was performed by immunocytochemistry and flow
cytometry of a panel of stem cell markers. Immunocytochemistry showed high expression
of iPSC markers OCT4, SSEA4, Tra-1-60 and Tra-1-81 by feeder-based or feeder-free
JMC1i-SS9 (Figure 4.7). Moreover, flow cytometry of feeder-independent iPSC showed
>90% cells expressing the same markers (Figure 4.8). These results confirmed the ability
to maintain undifferentiated iPSC using the feeder-independent system. As such, all
subsequent work performed for the purpose of this chapter and described below was
limited to the use of feeder-independent iPSC culture.
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Figure 4.7: Immunocytochemistry of feeder-dependent (left column) and -independent
(right panel) JMC1i-SS9 iPSC. Images show the expression of (A) OCT4, (B) SSEA4,
(C) Tra-1-60 and (D) Tra-1-81. Scale bars represent 250 µm.
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Figure 4.8: Flow cytometry analysis of JMC1i-SS9 iPSC. Negative controls are
represented by the red peaks and the black peaks designate the (A) OCT4-, (B) SSEA4-,
(C) Tra-1-60- and (D) Tra-1-81-stained sample.

iPSC were differentiated using STEMDiff™ Neural Induction Medium (NIM) and
STEMDiff™ Neural Progenitor Medium (STEMCELL Technologies) over the course of
at least 3 weeks. The iPSC-derived NPC were passaged at day 6 (referred to as Passage 1
(P1), day 12 (referred to as P2), day 18 (referred to as P3) and day 24 (referred to as P4).
Immunocytochemistry showed expression of NPC markers Pax6, Nestin, and Vimentin,
as well as early neuronal marker Tuj1 by day 4 (D4), continuing through to P3 (Figure
4.9 - Figure 4.12). Expression of OCT4 was negligible by D4 (Figure 4.13). Glial marker,
glial fibrillary acidic protein (GFAP) was also expressed by P2 (Figure 4.11C, 4.12C).
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Figure 4.9: Immunocytochemistry of JMC1i-SS9 iPSC-derived neural progenitor cells
(NPC) at day 4 of differentiation. The NPC expressed (A) Pax6, (B) Nestin, and (C)
Tuj1. Scale bars represent 100 µm.

Figure 4.10: Immunocytochemistry of JMC1i-SS9 iPSC-derived NPC at Passage 1 of
differentiation. Images show expression of (A) Pax6/Tuj1 and (B) Nestin. Scale bars
represent 100 µm.
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Figure 4.11: Immunocytochemistry of JMC1i-SS9 iPSC-derived NPC at Passage 2 of
differentiation. Images show expression of (A) Vimentin/Tuj1, (B) Pax6/Tuj1, and (C)
GFAP/Nestin. Scale bars represent 100 µm.

Figure 4.12: Immunocytochemistry of JMC1i-SS9 iPSC-derived NPC at Passage 3 of
differentiation. Images show expression of (A) Vimentin/Tuj1, (B) Pax6/Nestin and (C)
GFAP/ Tuj1. Scale bars represent 100 µm.
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Figure 4.13: Immunocytochemistry of OCT4 expression in JMCli-SS9 iPSC-derived
NPC. Images show expression of OCT4 at (A) day 2 and (B) day 4 of differentiation.
Scale bars represent 100 µm.

The expression of Sox2, a regulator of pluripotency and differentiation, was also analysed
in a separate trial of differentiation. Sox2 was barely detectable by P2 of differentiation
(Figure 4.14), alluding to a reduction of Sox2 expression.

Figure 4.14: Immunocytochemistry of Sox2 at passage 2 of differentiating JMC1I-SS9
iPSC. Scale bars represent 50 µm.
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The expression of differentiation markers was quantified using flow cytometry at P1 of
differentiation. A large majority of cells expressed Nestin (92.6%), with around half the
population expressing Tuj1 (51.3%) and relatively fewer cells expressed GFAP (35.2%)
(Figure 4.15A). Comparative analysis of iPSC cultures and neural cell derivatives
expressing Sox2 was also performed. Interestingly, a reduction of Sox2-expressing cells
was observed (from 97.1% to 69.6%) with neural differentiation of iPSC (Figure
4.15A(ii) & Figure 4.15B).

Figure 4.15: Flow cytometry of JMC1i-SS9 iPSC and derivative NPC. (A) iPSC
derivative NPC expressing: i) Tuj1, (ii) Sox2, (iii) Nestin, and (iv) GFAP at P1 of
differentiation. (B) iPSC expressing Sox2. Negative controls are represented by the red
peaks

and

the

black

peaks

designate
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the

stained

samples.

Samples were collected for mRNA extraction from iPSC-NPC at D0, D2, D4, P1 and P2
for qRT-PCR analysis. One-way ANOVA analysis with Post-hoc Tukey HSD test
showed a rapid and significant reduction of OCT4 from D0 to D2 (0.195 ± 0.006,
p<0.001), with an ongoing but more gradual decline thereafter until P2 (Figure 4.16A).
The mRNA expression of Pax6 peaked at D4 before being significantly downregulated at
P1 (0.434±0.015, p<0.001) and P2 (0.306±0.035, p<0.001; Figure 4.16B). Interestingly,
while initially the levels of Tuj1 expression were relatively low, ie. there was an initial
decrease from D0 (0.672±0.025) to D2 (0.417±0.017, p<0.001), it plateaued until P1 after
which there was a rapid and significant increase by P2 (Figure 4.16C). Similar to Pax6,
the expression of Nestin was highest at D4 however, Nestin was significantly
downregulated by P1 (0.089±0.005) returning to higher levels by P2 (Figure 4.16D). In
general, differentiation markers Nestin, Pax6 and Tuj1 were significantly increased
(p<0.001) by P2 compared to D0 and the iPSC marker OCT4 significantly decreased
(p<0.001) from D0.

139

Figure 4.16: Time course (day 0 (D0) to passage 2 (P2)) of mRNA expression for
differentiating NPC derived from JMC1i-SS9 iPSC. mRNA samples from differentiating
NPC were collected at D0, D2, D4, P1 and P2 and analysed via quantitative real-time
polymerase chain reaction (qRT-PCR) for the expression of (A) OCT4, (B) Pax6, (C)
Tuj1, and (D) Nestin. Values are presented as the mean of mRNA expression relative to
the time point with the highest expression (ie. mRNA expression of (A) is relative to
expression at D0 and (B) relative to expression at D4) ± SEM (n = 4). ***p<0.001 vs D0,
###p< 0.001 vs time point with highest expression (D4 or P2); by one-way ANOVA
analysis with post-hoc Tukey HSD analysis.

Notably, the number of NPC gradually declined with each passage, resulting in the
termination and re-initiation of differentiation trials with different batches of iPSC. In
addition, the phenotype of iPSC-derived NPC varied between experiments, impacting the
reproducibility of findings from one experiment to another. In one instance, despite the
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protocol being for intermediate NPC formation, differentiation yielded cells with clear
neuronal morphology by P3 and extended neurites with branching by P4, indicative of
premature terminal differentiation (Figure 4.17 & Figure 4.18). Notwithstanding,
achievement of neural cell cultures from the iPSC was attained, paving the way for trials
involving electrical stimulation (ES).

Figure 4.17: Immunocytochemistry of Pax6 and Tuj1 of differentiating JMC1i-SS9
iPSC-derived neural cells. Photomicrographs show clear albeit immature neuronal
morphology at P3. Scale bars represents 100 µm.
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Figure 4.18: Immunocytochemistry of Tuj1 of differentiating JMC1i-SS9 iPSC-derived
neural cells. Photomicrographs show cells with neurite extensions with branching at P4.
Scale bars represent 100 µm.

Alongside iPSC JMC1li-SS9 (a healthy control), iPSC JMC3i-SZ1 which was
reprogrammed from a Sz patient was also cultured. The long-term goal is to compare a
family cohort of healthy and Sz iPSC. Due to the limited time available for this thesis
however, iPSC JMC3i-SZ1 was thawed and cultured for initial characterisations and to
ensure the reprogramming conducted was successful. Comparison of healthy and Sz iPSC
may be discussed, though not the primary focus of this thesis.
The iPSC JMC3i-SZ1 cells were successfully transitioned to a feeder-independent system
from the feeder-based system and the pluripotency was established via expression of
OCT4, SSEA4, Tra-1-60 and Tra-1-81 (Figure 4.19). Flow cytometry analysis also
showed high expression (>84%) of the pluripotency markers in iPSC JMC3i-SZ1 (Figure
4.20), albeit at a slightly lower expression than iPSC JMC1li-SS9 (Figure 4.8) for OCT4
(96.2% vs 85.5%), Tra-1-60 (94.1% vs 92.1%) and Tra-1-81 (93.5% vs 89.4%)
expression.
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Figure 4.19: Immunocytochemistry of iPSC JMC3i-SZ1 on a feeder-independent
system. The cells expressed (A) OCT4, (B) SSEA4, (C) Tra-1-60 and (D) Tra-1-81.
Scale bars represent 250 µm.

Figure 4.20: Flow cytometry analysis iPSC JMC3i-SZ1. Negative controls are
represented by the red peaks and the black peaks designate the (A) OCT4-, (B) SSEA4-,
(C) Tra-1-60- and (D) Tra-1-81-stained sample.
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Differentiation of iPSC JMC3i-SZ1 was initiated using a similar protocol as described for
iPSC JMC1i-SS9. Expressions of Pax6, Nestin, Tuj1, Vimentin, GFAP and Sox2 were
observed in differentiating NPC JMC3i-SZ1 at D4 and P1 (Figure 4.21 &Figure 4.22).
Figure 4.22C suggested a downregulation of Sox2 expression when compared to the
expression at D4 (Figure 4.21C).

Figure 4.21: Immunocytochemistry of differentiating JMC3i-SZ1 iPSC-derived NPC at
day 4. Images show expression of (A) Pax6/Nestin, (B) GFAP/Tuj1, and (C)
Vimentin/Sox2. Scale bars represent 100 µm.

Figure 4.22: Immunocytochemistry of differentiating JMC3i-SZ1 iPSC-derived NPC at
passage 1. Images show expression of (A) Pax6/Nestin, (B) GFAP/Tuj1, and (C)
Vimentin/Sox2. Scale bars represent 100 µm.
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Flow cytometry analysis of differentiating JMC3i-SZ1 NPC at P1 yielded high Sox2- and
Nestin-expressing cell populations (95.9% and 83.9%, respectively) (Figure 4.23B & C)
with a lower expression of Tuj1 (30.1%) and GFAP (27.8%) (Figure 4.23A & D).

Figure 4.23: Flow cytometry analysis of JMC3i-SZ1 iPSC-derived NPC at passage 1 of
differentiation. Images show expression of (A) Tuj1, (B) Nestin, (C) Sox2 and (D)
GFAP.
4.3.4

Electrical stimulation of JMC1i-SS9 iPSC-derived NPC

ES was applied to cell cultures following initial induction of iPSC to NPC towards
determining an effect on NPC survival and state. To reiterate from the Introduction
(section 4.1), the principle aim was to test the priori hypothesis that ES will increase
survival and advance the differentiation of iPSC-NPC to fully differentiated neuronal cell
cultures as a potential platform for future modelling; being relevant to neurodevelopment
and applicable to neurodevelopmental disorders such as Sz. iPSC were passaged into ES
modules with NIM + Y-27632 and incubated overnight at 37oC in a humidified 5% CO2.
Based on the above described findings of iPSC differentiation studies (Figure 4.9,Figure
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4.16), whereby neural induction had occurred by D4 with NPC markers increasing to peak
levels between D2 and D4, and early neuronal marker Tuj1 expressed with neurites by
D4, ES was initiated on D2 of differentiation. Although the standard protocol in the
laboratory involved 8 hrs of ES over a 3-day period, it resulted in cell death of the
differentiating iPSC. As such, the 24-hr-ES was performed in one day instead of over 3
days. As illustrated by Figure 4.24, qualitative assessment of immunolabelled cultures
following 24 hrs of stimulation showed evidence of increased Tuj1, Pax6 and Nestin
expression for ES cultures compared to non-ES cultures. However, vimentin appeared to
be more highly expressed by non-ES compared to ES cultures, and there were no clear
morphological differences between ES and non-ES cell cultures.
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Figure 4.24: Immunocytochemistry of ES and non-ES JMC1i-SS9 iPSC-derived NPC.
(A) Comparison of Vimentin and Tuj1 expression in ES-NPC (left panel) and non-ES
NPC (right panel). Scale bars represent 100 µm. (B) Comparison of Pax6 and Nestin
expression in ES-NPC (left panel) and non-ES NPC (right panel). Scale bars represent
200 µm.
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4.4 Discussion
This chapter has demonstrated a successful transition of iPSC cultures from a feederdependent system to a feeder-independent system, iPSC differentiation to neural cell
cultures, and finally, proof-of-concept of ES of iPSC-NPC. Taken together, the results set
the stage for future research involving iPSC-based modelling for studies of patientspecific neural cells which could incorporate ES to either improve or accelerate neural
induction and/or better model in vivo tissue function
4.4.1

Gamma irradiation of human fibroblast feeders (HFF)

HFF are rendered non-replicative to allow for the expansion of iPSC; while at the same
time maintaining the metabolic activity of HFF to act as a source of cytokines and growth
factors that are essential for the growth of iPSC in their undifferentiated state [366]. The
most common methods used to achieve mitotic inactivation are through gamma(γ)irradiation exposure or mitomycin-C (MMC) treatment.
This study has shown that γ-irradiation of HFF at 25 Gy suppressed their mitotic activity
by over 90% and that the inactivated feeders were able to support iPSC cultures. Studies
have shown superiority of γ-irradiation over MMC treatment where γ-irradiated feeders
showed higher metabolic activity retainment, higher cytokines secretion and less
differentiated embryonic stem cells colonies in the culture [367, 368]. Nevertheless, both
methods have similar efficiency at arresting cell growth [366].
Ultimately, the choice of mitotic inactivation method depends on the accessibility and
cost of a γ-irradiation source, with mitomycin-C reagent being more cost-efficient and
readily available.
4.4.2

Optimisation of iPSC culture

Maintenance of quality iPSC is largely dependent on cell culture conditions and operator
technique, with the former varying at different stages of the cell culture [369]. Manual
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microdissection with a Stem Cell Cutting Tool (Vitrolife) was used for early iPSC
passaging, and in particular for preparing cryostocks of iPSC. This is to minimise the risk
of introducing chromosomal abnormalities potentially caused by enzymatic or nonenzymatic dissociation buffers. A study has shown that a normal karyotype could be
maintained up to 105 passages through mechanical passaging, while the cells could be
genetically compromised with 15-25 passages by enzymatic or non-enzymatic processing
[370]. In this study, enzymatic and non-enzymatic bulk passaging methods were reserved
for experiments to allow sufficient sample collection, since manual microdissection is
labour-intensive.
Collagenase type IV is commonly used for passaging feeder-dependent iPSC; however,
enzyme-based solutions may eventually lead to cell damage through digestion of cell
surface proteins [369, 371]. Consistent with the present observations, EDTA-based
passaging has been shown to support greater iPSC survival and batch consistency, with
less impact on extracellular matrix or membrane proteins [369].
Finally, the removal of spontaneously differentiated colonies was facilitated by using the
Millipore vacuum aspiration system, being more effective than scraping with pipette tips,
ultimately enabling the generation of a higher quality iPSC cultures. This may be
explained in part by more rapid removal of unwanted material resulting in less time out
of the 37oC incubator during the removal process.
4.4.3

iPSC pluripotency characterisation and differentiation

In addition to alkaline phosphatase live stains, some of the commonly assayed markers
by immunocytochemistry for iPSC characterisation are nuclear transcription factors,
OCT4, NANOG and SOX2; glycolipid antigens, SSEA3 and SSEA4; and keratan sulfate
antigens, Tra-1-60 and Tra-1-81 [372]. The expression of OCT4, SSEA4, Tra-1-60 and
Tra-1-81 were achieved in JMC1li-SS9 and JMC3i-SZ1 iPSC. In addition, flow
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cytometry analyses in this study have also demonstrated over 80% expression of these
markers by JMC1li-SS9 and JMC3i-SZ1 iPSC cultures, consistent with other reports
confirming stem cell state [373, 374].
Further to immunocytochemistry, flow cytometry, and visual inspection under the
microscope, iPSC characterisation includes, but is not limited to; embryoid body
differentiation into three germ layers (ectoderm, mesoderm and endoderm), RT-PCR of
stem cell and pluripotency markers, karyotype analysis, and whole genome sequencing
[372, 375]. For this study, a basic characterisation is sufficient, although more
comprehensive characterisation would be required for future research and translational
applications [375-380].
It is worth noting that iPSC JMC1li-SS9 and JMC3i-SZ1 were cultured in parallel and, in
spite of employing off-the-shelf commercially available neural induction media, their
differentiation required some optimisation. Nonetheless, differentiation for both cell lines
was achieved, with a standard panel of markers employed as indicators of differentiation.
Some analyses such as qRT-PCR were not performed on JMC3i-SZ1-based cultures due
to time restriction.
Immunocytochemistry showed the iPSC-derived NPC expressed neural progenitor
markers, Nestin, PAX6 and Vimentin, and early neuronal marker Tuj1. These markers
are commonly used for characterising NPC and neuronal cell cultures [381-383]. Tuj1 is
a neural lineage marker commonly used for detecting early post-mitotic neurons,
differentiated neurons and in some cases, mitotically active NPC [384]. Nevertheless, the
marker has also been detected at D0 of neural differentiation [385], as recapitulated in
this study. The reduction of Tuj1 mRNA level observed in this study may have been due
to the upregulation of proliferative genes such as Pax6 and Nestin during the proliferating
phase, and the re-upregulation of Tuj1 coincides with the post-mitotic phase.
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Flow cytometry analyses of JMC1li-SS9 and JMC3i-SZ1 iPSC-derived NPC at P1
showed a higher proportion of Tuj-1-expressing NPC compared to NPC expressing the
glial marker, GFAP, suggesting a differentiation propensity towards the neuronal lineage,
rather than the glial lineage, by downregulating GFAP and upregulating Tuj1. Note that
the difference between the Tuj-1- and GFAP-expressing NPC in JMC3i-SZ1 were not as
large as in JMC1li-SS9. It could be inferred that the rate of differentiation towards the
neuronal lineage was higher in JMC1li-SS9 compared to JMC3i-SZ1. It may be that at
P1, the JMC3i-SZ1 NPC were still in the proliferation phase; thus, have not fully
committed to the neuronal lineage.
The proliferation phase of the NPC may further be signified by the high expression of
Sox2 in JMC3i-SZ1 iPSC-derived NPC. Sox2 regulates pluripotency and neural
differentiation in iPSC [386]. Sox2 interacts with OCT4 to maintain pluripotency whereas
in neural induction and differentiation, Sox2 maintains a high expression in proliferating
NPC and is downregulated when exiting the cell cycle and differentiating into postmitotic neurons or glia [387]. In differentiating iPSC JMC1li-SS9, flow cytometry
showed a reduction of Sox2-expressing cells from 97.1% in the pluripotent iPSC to 69.6%
in the differentiating NPC, as the cells progressed towards terminal differentiation. In
NPC JMC3i-SZ1, Sox2-expressing cells were still high (95.9%) at P1 suggesting most of
the NPC were still proliferating.
Similarly, a study has shown that Pax6 is required for neural induction and the expression
is lowered for post-mitotic differentiation whereby maintenance of high expression of
Pax6 would interfere with differentiation [388]. This may explain the decline in Pax6
mRNA expression after reaching a peak at D4 in differentiating NPC JMC1li-SS9. Nestin
is expressed in uncommitted NPC before being replaced by neuronal or glial markers
after differentiation [389]. The expression of Nestin mRNA in differentiating NPC
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JMC1li-SS9 followed a similar pattern observed in another study conducted by Zimmer
et al. [390] where the mRNA decreased after reaching a peak followed by a resurge. The
reasoning behind this phenomenon however, was not explained and further investigation
into this trend is beyond the scope of this thesis. Overall, the differentiation of iPSC to
NPC in this study coincides with the literature; evidence of a successful differentiation to
NPC.
4.4.4

Differentiation of iPSC with electrical stimulation

The results in section 4.3.4 confirmed the compatibility of the electrical stimulation (ES)
system with iPSC and iPSC-derived NPC. Although there was limited evidence for more
advanced neural differentiation following ES, with ES neural cells clearly expressing
higher levels of Pax6, Nestin and early neuronal maker Tuj1, the finding was somewhat
confounded by higher vimentin expression for non-ES cell cultures. Additionally, there
were no clear morphological differences between ES-NPC and non-ES-NPC. As such, no
definitive conclusions can be made based on the current results. However,
notwithstanding the need for further and quantitative studies, including replication of the
current experiment and experiments with a modified ES regimen, the data minimally
provides proof-of-concept for employing the Ppy/DBS platform for ES of iPSC-NPC. It
may be that ES has no phenotypic impact early in the differentiation, with possible
changes coming into effect after D3 of stimulation (ie. D5 culture).
4.4.5

Technical limitations

One of the issues arising from the differentiation protocols was the reduction in NPC after
each passage, providing limited number of cells available for experiments and for
maintaining the culture. An alternative is to switch to STEMdiff™ Neural Progenitor
Medium (STEMCELL Technologies) earlier on after neural induction instead of
maintaining NPC in STEMdiff™ NIM up to the third passage (Day 18-21) as per the
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manufacturer’s recommendation. This may ensure continuous proliferation and
expansion of NPC.
The iPSC-derived NPC phenotype varied in different trial rounds of differentiation
conducted in this study. Some NPC terminally differentiated by P3 demonstrating
extended neurites. A contributing factor may be the varying qualities of iPSC at the time
of neural induction. In this study, it was observed that iPSC with a number of
spontaneously differentiated colonies greatly impacted NPC morphology, reaching
terminal differentiation prematurely. It is critical to initiate differentiation with high
quality iPSC with no or minimal signs of spontaneous differentiation [391, 392]. Another
contributing factor in these variations may be the passage number of the iPSC. A study
has indicated that iPSC at later passages had increased efficiency of neural differentiation,
as extended passaging stabilised the pluripotency of iPSC [393].
It is worth noting that a recurring experience for a 3-day stimulation encountered with the
ES system presently employed was contamination. As iPSC and NPC require a more
regular media replenishment compared to other types of cells previously used in this
thesis, the frequent assembling/disassembling of the electrode lids had increased the risks
of introducing contaminations. It would be beneficial to develop an ES system in the
future where the media can be replaced without compromising the sterility of the set-up.
4.4.6

Conclusions and future directions

The effort in this chapter has yielded an optimised iPSC culture, whereby the optimum
removal of differentiated iPSC and passaging techniques in maintaining iPSC
pluripotency were established. iPSC-derived NPC expressing neural progenitor, neuronal
and glial markers were also achieved in this study. Future work would include optimising
the differentiation protocol and a robust characterisation (ie. time course flow cytometry)
to ensure consistent and reproducible output.
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The ES of differentiating iPSC has shown survival and hint of effect on the differentiation.
Future experiments should consider an ES regimen that more closely reflects clinicallyrelevant physiology. Different levels, duration, and time of initiation of ES during
differentiation should be investigated. It is important to note that the function of
incorporating ES in developing (rather than treating) a disease model should not
necessarily be to enhance differentiation but perhaps should solely be to recreate the in
vivo condition (ie. in the brain). While studies will be necessary to clarify the application
of ES for modelling, it may be that neural differentiation enhanced by ES masks the
pathophysiology of the disease and therefore interferes with comparative analysis
between diseased and healthy models.
Due to time limitations, actual studies of possible cellular and molecular defects of Sz
patient-derived iPSC were not feasible, although learned iPSC culture and induction to
neural lineage for future neural cell-based modelling is demonstrated. Therefore, while
beyond the scope of the present project, it is envisaged that future studies using the
described methods of culturing, differentiating and characterising iPSC with putative risk
genes for Sz (ie. patient specific iPSC modelling) would reasonably be expected to better
determine disease pathophysiology compared to phencyclidine (PCP)-induced Sz cell
line models and Sz mutant mouse models.
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Chapter 5: Overall discussion and conclusions
5.1 Development of schizophrenia models for electrical stimulation
studies
The development of a pharmacological model via phencyclidine (PCP) treatment of a
mouse hypothalamus neuronal cell line (mHypoA-59) was described in Chapter 2. While
PCP-treated mHypoA-59 cells cultured on tissue culture plastic (TCP) demonstrated a
reduction of MAP2 mRNA level, a recapitulation of a Sz molecular feature; the deficit
was reversed when the cells were treated with PCP within a custom Ppy/DBS electrical
stimulation (ES) module. To elucidate this observation, additional experiments including
studying the adsorption of PCP onto the polymer, assessing changes in PCP chemical
structure after incubation with Ppy/DBS substrates, and treating the cells with PCP within
a 3D collagen gel culture were conducted. However, complex interactions of the PCP
molecules with the polymer, cells and proteins from the culture medium have not yielded
a conclusive answer. As such, the development of a PCP-induced Sz model compatible
with the custom ES module was not achieved in this study, and the effects of ES on the
model did not progress further.
The development of iPSC isolated from a healthy control (JMCli-SS9) and a Sz patient
(JMC3i-SZ1) in this study have generated iPSC cultures with optimised passaging
techniques and high maintenance of pluripotency. Basic characterisation of JMCli-SS9
and JMC3i-SZ1 were also performed, confirming the cells’ pluripotency state. Moreover,
differentiation of iPSC into NPC expressing neural progenitor, neuronal and glial markers
were also achieved; comparable to results reported in the literature. While beyond the
scope of the present project, it is expected that the cell lines will be used for future
research, including other PhD projects relating to 2D and 3D cell and tissue modelling of
155

Sz etiopathology.

5.2 The effects of electrical stimulation on Sz models
ES of mHypoA-59 showed enhanced neurite outgrowth, along with increased MAP2
mRNA level and the number of cells expressing MAP2. While a PCP-induced Sz model
was not developed with the ES platform, this is the first report on mHypoA-59 cells’
responsiveness towards an electrical stimulus; justifying further investigation into the
effects of ES on a hypothalamus Sz model. Future studies could investigate the influence
of ES on markers more relevant to the function of hypothalamus such as appetite
regulation and energy homeostasis (ie. neuropeptide Y). Since obesity and metabolic
syndrome are prevalent in Sz patients, the findings from the study could contribute to the
use of hypothalamic-ES as part of Sz treatment.
In ES studies employing prefrontal cortical (PFC) neurons isolated from wild-type (WT),
disrupted-in-schizophrenia 1-locus impaired (DISC1-LI) and neuregulin 1-knockout
(NRG1-KO) mice, the induction of calcium (Ca2+)- phosphoinositide-3-kinase
(PI3K)/Akt signalling pathways via nicotinic acetylcholine receptor subunit 7 (nAChR7)
and N-methyl-D-aspartate receptor (NMDAR) have been proposed as one of the ES
mechanisms of action. Dopamine signalling pathways potentially mediated by nAChR7
and tyrosine hydroxylase (TH) have also been implicated in the modulation of ES effects.
The implication of ES in NMDAR and dopamine signalling could further support the
utilisation of ES therapy for Sz patients as they relate to the glutamate and dopamine
hypotheses of Sz.
A proof-of-concept was established with the ES of iPSC-derived NPC. While significant
enhancement cannot be deduced from the preliminary ES study, the study has shown that
the PPy/DBS-mediated ES supported the cell survival and differentiation. Notably, the
application of ES in developing a disease model is not necessarily to treat the deficits but
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to mimic the microenvironment in humans, potentially leading to a model that could
better represent the disease.

5.3 Advantages and challenges of each Sz model
The immortalised hypothalamic cell line mHypoA-59 was easy to obtain, culture and
expand, compared to the primary mouse neurons and iPSC cell lines. Each passage could
yield a large number of cells, providing an unlimited supply of cells. Furthermore, ethical
concerns surrounding the use of immortalised cell lines are minimal, compared to
working with cells from human or animal tissues [394]. Its ease of use makes it suitable
for preliminary studies; however, the processes involved in the immortalisation of cell
lines such as genetic manipulations, could potentially alter the cells’ phenotype, native
function and responsiveness to stimuli [394]. Therefore, the cells may not carry all the
genetic materials of the original primary cells. As the manufacturer of the mHypoA-59
cell line has not provided a comprehensive genetic screening profile, it is difficult to
identify whether the lack of expression of a certain mRNA, ie. common PCP receptors
such as NR1; were due to the primer design or simply because the cells did not express
the receptors; questioning its response towards PCP treatment. While additional
phenotypic and genetic variations could also occur after extended passages of cell lines,
this could be overcome by cryobanking cells in the early passages and thawing fresh batch
of cells after a certain passage. In this study, thawed mHypoA-59 cells were propagated
up to 25 passages, when a decreased cell proliferation rate was noticeable; before thawing
a new batch of frozen cells.
Cells obtained from primary mouse models on the other hand, should contain all the
genetic makeup of the mouse, providing an insight into a more complete system. The
challenges in using pups from genetic models in this study include unpredictable supply
of cells, as the proportion of mutant and WT pups were not always equal, making
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experimental design with matched controls difficult. Dams giving birth to stillborn pups
also resulted in limited availability of cells on the day. Moreover, the source of the
samples is finite (the mice could be mated for a limited period of time before replacing
with a different batch of mice) and the cultured neurons have a short half-life. These
variations in sources and sample populations may have an influence on the data.
While the culture and expansion of iPSC were laborious, it holds a great potential as it
retains the genetic background of donors, could be propagated for an extended time, and
could be differentiated into cell type of interest. The main challenge in using iPSC is
establishing a defined culture and ensuring the original genotype is not altered by
mechanical handling, chemicals used, and other processes involved in the study.

5.4 Conclusions and future directions
The studies conducted herein have demonstrated that iPSC and its derivatives have the
greatest potential in modelling diseases; potentially providing insights at various stages
of the disease, which is crucial in neurodevelopmental disorders such as Sz. JMC3i-SZ1
and JMCli-SS9 iPSC and their derivatives will be used to study the genotypic and
phenotypic differences in a Sz model compared to the healthy control cell line. The
models could also be enhanced through a 3D biomaterial scaffold and the incorporation
of electrical stimuli to better mimic human microenvironment.
To further elucidate the mechanism of action of ES, protein assays investigating the levels
of nAChR7, NMDAR, PI3K/Akt and dopamine signalling pathways could also be
conducted in conjunction with calcium assays. An optimisation study of the ES
parameters for the iPSC-NPC culture, in progressing towards a more clinically relevant
condition, would also be worthwhile.
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Appendices
Appendix 1
3D electrical stimulation platform

Ppy/DBS-coated interdigitated electrodes for a 3-dimensional electrical stimulation
system. Image obtained from Zhang et al. 2018 [184].
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Appendix 2
Immunocytochemistry of DISC-LI on Ppy/pTS

Immunocytochemistry of DISC-LI prefrontal cortical neurons cultured on Ppy/pTS
film. PFC neurons were co-stained with MAP2 and DAPI. Scale bars represent 50 µm.
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